Compounds as thyroid hormone beta receptor agonists and their uses

Abstract

Provided are compounds as thyroid hormone beta receptor agonists, and uses thereof, further including pharmaceutical compositions comprising the compounds. The compounds and pharmaceutical compositions may be used for the preparation of a medicament for preventing, treating, or ameliorating diseases mediated by agonist thyroid hormone beta receptors, particularly for the preparation of a medicament for treating non-alcoholic fatty liver disease.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of Chinese Patent Applications Nos. 201910901997.0, 202010164947.1, and 202010231242.7, filed with the State Intellectual Property Office of China on September 24, 2019, March 11, 2020, and March 27, 2020, respectively, which are incorporated by reference herein in their entireties.

[0002] The present invention belongs to the field of medicine, particularly to compounds and their uses as thyroid hormone beta receptor agonists, and further to pharmaceutical compositions comprising the compounds.The present invention further relates to the use of the compounds and pharmaceutical compositions in the manufacture of medicaments for preventing, treating or alleviating diseases mediated by activated thyroid hormone beta receptors, particularly in the manufacture of medicaments for treating non-alcoholic fatty liver disease. [Background technology]

[0003] Thyroid hormones (TH) play vital roles in growth, differentiation, development and maintaining metabolic balance. Thyroid hormones are synthesized by the thyroid gland and secreted into the circulation in two major forms, triiodothyronine (T3) and tetraiodothyronine (T4). T4 is the major form secreted by the thyroid gland, while T3 is the more physiologically active form. T4 is converted to T3 by tissue-specific deiodinases, which are present in all tissues but mainly in the liver and kidney.

[0004] The physiological functions of TH are mainly carried out by the thyroid hormone receptor (TR). TR belongs to the nuclear receptor superfamily and is a transcription factor induced by the ligand T3. TR is central to mediating the role of the ligand T3. TR is mainly located in the nucleus, forms heterodimers with the retinoid X receptor (RXR) and other nuclear receptors, binds to the thyroid hormone response element (TRE) in the promoter region of the target genes, thereby regulating gene transcription. There are two subtypes of TR: TRα and TRβ. TRα can be divided into TRα1 and TRα2, and TRβ can be divided into TRβ1 and TRβ2. Among these, only TRα1, TRβ1 and TRβ2 can bind to the ligand T3. TRα mainly regulates the heart rate, while TRβ plays an important role in controlling cholesterol metabolism in the liver and inhibiting the release of thyroid stimulating hormone (TSH), which may be related to the increased expression of TBβ in the liver and pituitary gland.

[0005] Thyroid hormones exert certain therapeutic benefits if side effects can be minimized or eliminated (Paul M. Yen et al., Physiological Reviews, 81(3): 1097-1126 (2001); Paul Webb et al., Expert Opin. Investig. Drugs, 13(5): 489-500 (2004)). For example, thyroid hormones can increase metabolic rate, oxygen consumption, and heat production, thereby reducing body weight. Weight loss can improve obesity-associated comorbidities, beneficially affecting obese patients, and may also beneficially affect glycemic control in obese patients with type 2 diabetes.

[0006] Thyroid hormone can also reduce serum low-density lipoprotein (LDL) (Eugene Morkin et al., Journal of Molecular and Cellular Cardiology, 37:1137-1146 (2004)). Hyperthyroidism has been found to be associated with a reduction in total serum cholesterol, which is due to the fact that thyroid hormone increases LDL receptor expression in the liver and stimulates the metabolism of cholesterol to bile acids (JJ. Abrams et al., J. Lipid Res., 22:323-38 (1981)). Hypothyroidism is associated with hypercholesterolemia, and there are reports that thyroid hormone replacement therapy reduces total cholesterol (M. Aviram et al., Clin. Biochem., 15:62-66 (1982); JJ. Abrams et al., J. Lipid Res., 22:323-38 (1981)). In animal models, thyroid hormone has been shown to have beneficial effects in increasing HDL cholesterol and increasing the rate of conversion of LDL to HDL by increasing the expression of apoA-1, one of the major apolipoproteins of HDL (Gene C. Ness et al., Biochemical Pharmacology, vol. 56: 121-129 (1998); GJ. Grover et al., Endocrinology, vol. 145: 1656-1661 (2004); GJ. Grover et al., Proc. Natl. Acad. Sci. USA, vol. 100: 10067-10072 (2003)). The incidence of atherosclerotic vascular disease is directly related to LDL cholesterol levels. By regulating LDL and HDL, thyroid hormone may also reduce the risk of atherosclerosis and other cardiovascular diseases.Furthermore, there is evidence that thyroid hormones may reduce lipoprotein(a), which is a risk factor for atherosclerosis and is increased in patients with atherosclerosis (Paul Webb et al., Expert Opin. Investig. Drugs, 13(5):489-500 (2004); de Bruin et al., J. Clin. Endo. Metab., 76:121-126 (1993)).

[0007] In addition, non-alcoholic fatty liver disease (NAFLD) is also closely related to thyroid hormones. On the one hand, NAFLD can affect the conversion and inactivation of thyroid hormones in patients, which can lead to a decrease in serum thyroid hormone levels. On the other hand, the decrease in thyroid hormone levels can further cause the disorder of lipid metabolism and glucose metabolism, which is involved in the development of NAFLD. Studies have shown that a choline-methionine deficient diet induces the formation of fatty liver in rats, and the recovery of fatty liver can be observed after the supply of T3 (Perra A et al., Faseb, 2008, 22 (8): 2981).

[0008] However, endogenous thyroid hormones are non-selective and have side effects such as hyperthyroidism, especially those related to cardiovascular toxicity. Thus, the development of thyroid hormone analogs (such as thyroid hormone beta receptor agonists) that avoid the deleterious effects of hyperthyroidism while maintaining the beneficial effects of thyroid hormones would open up new ways to treat patients with the following diseases: obesity, hyperlipidemia, hypercholesterolemia, diabetes, hepatic steatosis, non-alcoholic fatty liver disease, atherosclerosis, cardiovascular disease, hypothyroidism, thyroid cancer, thyroid disease, and related conditions and diseases. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] Chinese Patent Application No. 201910901997.0 [Patent Document 2] Chinese Patent Application No. 202010164947.1 [Patent Document 3] Chinese Patent Application No. 202010231242.7 [Non-patent literature]

[0010] [Non-Patent Document 1] Paul M. Yen et al., Physiological Reviews, 81(3):1097-1126 (2001) [Non-Patent Document 2] Paul Webb et al., Expert Opin. Investig. Drugs, 13(5):489-500 (2004) [Non-Patent Document 3] Eugene Morkin et al., Journal of Molecular and Cellular Cardiology, 37:1137-1146 (2004) [Non-Patent Document 4] J. J. Abrams et al., J. Lipid Res., 22: 323-38 (1981) [Non-Patent Document 5] M. Aviram et al., Clin. Biochem., 15: 62-66 (1982) [Non-Patent Document 6] Gene C. Ness et al., Biochemical Pharmacology, 56:121-129 (1998) [Non-Patent Document 7] GJ Grover et al., Endocrinology, 145:1656-1661 (2004) [Non-Patent Document 8] GJ. Grover et al., Proc. Natl. Acad. Sci. USA, 100:10067-10072 (2003). [Non-Patent Document 9] de Bruin et al., J. Clin. Endo. Metab., 76: 121-126 (1993). [Non-Patent Document 10] Perra Aら, Faseb, 2008, 22(8):2981

Non-licensed Document 11

Non-licensed Document 12

Non-licensed Document 13

Non-licensed Document 14

Non-licensed Document 15

Non-licensed Document 16

Non-licensed Document 17

Non-licensed Document 18

Non-licensed Document 19

Non-licensed Document 20

[0011] The present invention provides a class of compounds with good agonist activity for thyroid hormone beta receptors.Such compounds and compositions thereof can be used in the manufacture of medicaments for preventing, treating or alleviating non-alcoholic fatty liver disease, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes, metabolic disorders, glycogen storage disease type 1A, hypothyroidism, or thyroid cancer in a subject.

[0012] In one aspect, the present invention relates to a compound having formula (I) or a stereoisomer, geometric isomer, tautomer, N-oxide, solvate, metabolite, pharma- ceutically acceptable salt, or prodrug thereof:

[0013] [ka]

[0014] (In the formula, Y is -O-, -S-, -NR c -, -CR a R b -, -S(=O)2-, -S(=O)- or -C(=O)-; L is absent, -O-, -S-, -NR c -, -CR d R e -, -S(=O)2-, -S(=O)- or -C(=O)-; R a , R b , R c , R d and R e are independently H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl or C 1~6 is haloalkoxy; R 3a , R 3b , R 3c and R 3d are independently H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylthio, C 1~6 Alkylamino, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, Hydroxy C 1~6 Alkyl, Amino C 1~6 Alkyl or cyano C 1~6 is alkyl, M is -C(=O)-, -C(=S)-, -S(=O)2- or -S(=O)-; E1 is N, CH or CR z and R z are deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -NH2, -SH, C 1~6 Alkyl, C 1~6Haloalkyl, C 1~6 Haloalkoxy, C 1~6 Alkoxy, C 2~6 Alkenyl, C 2~6 Alkynyl, Hydroxy C 1~6 Alkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkyl C 1~6 Alkyl, 3-8 membered heterocyclyl, (3-8 membered heterocyclyl)C 1~6 Alkyl, C 6~10 Aryl, C 6~10 Aryl C 1~6 Alkyl, 5-10 membered heteroaryl or (5-10 membered heteroaryl)C 1~6 is alkyl, E2 is CR 2 and E3 is N or CR 3 and R 2 and R 3 are independently H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -NH2, -SH, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, C 1~6 Alkoxy, C 2~6 Alkenyl, C 2~6 Alkynyl, Hydroxy C 1~6 Alkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkyl C 1~6 Alkyl, 3-8 membered heterocyclyl, (3-8 membered heterocyclyl)C 1~6 Alkyl, C 6~10 Aryl, C 6~10 Aryl C 1~6 Alkyl, 5-10 membered heteroaryl or (5-10 membered heteroaryl)C 1~6 is alkyl, R 1 are H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -C(=O)NH2, -S(=O)2NH2, -OH, -NH2, -SH, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6Haloalkyl, C 1~6 Haloalkoxy, -C(=O)-C 1~6 Alkoxy, -C(=O)-C 1~6 Alkylamino, -C(=O)-C 1~6 Alkyl, -S(=O)2-C 1~6 Alkyl, -S(=O)2-C 1~6 Alkylamino, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 5-8 membered heterocyclyl, C 6~10 aryl or 5-8 membered heteroaryl, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, -C(=O)-C 1~6 Alkoxy, -C(=O)-C 1~6 Alkylamino, -C(=O)-C 1~6 Alkyl, -S(=O)2-C 1~6 Alkyl, -S(=O)2-C 1~6 Alkylamino, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 5-8 membered heterocyclyl, C 6~10 Each of the aryl and 5-8 membered heteroaryl is independently unsubstituted or substituted with deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -C(=O)NH2, -S(=O)2NH2, -SH, -OH, -NH2, =O, -C(=O)-C 1~6 Alkyl, -C(=O)-C 1~6 Alkoxy, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl or C 1~6 substituted by 1, 2 or 3 substituents selected from haloalkoxy; W is -OCH2COOH, -NHC(=O)COOH, -NHCH2COOH,

[0015] [ka]

[0016] and R 4 are H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, -C(=O)-C 1~6 Alkoxy, -C(=O)-C 1~6 Alkyl, -C(=O)-C 1~6 Alkylamino, -C(=O)NH2, -S(=O)2-C 1~6 Alkyl, -S(=O)2-C 1~6 Alkylamino, C 1~6 Alkylamino, C 1~6 Alkoxy, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, Hydroxy C 1~6 Alkyl, Amino C 1~6 Alkyl, Carboxy C 1~6 Alkyl or cyano C 1~6 Alkyl, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, -C(=O)-C 1~6 Alkoxy, -C(=O)-C 1~6 Alkyl, -C(=O)-C 1~6 Alkylamino, -C(=O)NH2, -S(=O)2-C 1~6 Alkyl, -S(=O)2-C 1~6 Alkylamino, C 1~6 Alkylamino, C 1~6 Alkoxy, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, Hydroxy C 1~6 Alkyl, Amino C 1~6 Alkyl, Carboxy C 1~6 Alkyl and Cyano C 1~6 Each alkyl is independently unsubstituted or substituted with deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, C 1~6 Alkyl, C 2~6 Alkenyl or C2~6 alkynyl; R 5 H, deuterium, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~6 Cycloalkyl, 5-6 membered heterocyclyl, C 6~10 aryl or 5-6 membered heteroaryl).

[0017] In some embodiments, R 3a , R 3b , R 3c , and R 3d each is independently H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, NH2, -SH, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, methylthio, methylamino, -CF3, -CHF2, -CH2F, -CH2CF3, trifluoromethoxy, difluoromethoxy, hydroxymethyl, aminomethyl, or cyanomethyl.

[0018] In some embodiments, R a , R b , R c , R d and R e each is independently H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, NH2, -SH, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, -CF3, -CHF2, -CH2F, -CH2CF3, or trifluoromethoxy.

[0019] In some embodiments, R z is deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -NH2, -SH, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, trifluoromethyl, difluoromethyl, trifluoromethoxy, difluoromethoxy, methoxy, ethoxy, n-propoxy, isopropoxy, C 2~4 Alkenyl, C 2~4Alkynyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, C 3~6 Cycloalkyl, C 3~6 Cycloalkyl C 1~3 Alkyl, 5-6 membered heterocyclyl, (5-6 membered heterocyclyl)C 1~3 alkyl, phenyl, phenylmethyl, phenylethyl, pyridyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyridylmethyl, pyridylethyl or pyrimidinylmethyl; R 2 and R 3 each independently represents H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -NH2, -SH, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, trifluoromethyl, difluoromethyl, trifluoromethoxy, difluoromethoxy, methoxy, ethoxy, n-propoxy, isopropoxy, C 2~4 Alkenyl, C 2~4 Alkynyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, C 3~6 Cycloalkyl, C 3~6 Cycloalkyl C 1~3 Alkyl, 5-6 membered heterocyclyl, (5-6 membered heterocyclyl)C 1~3 It is alkyl, phenyl, phenylmethyl, phenylethyl, pyridyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyridylmethyl, pyridylethyl or pyrimidinylmethyl.

[0020] In some embodiments, R 1 are H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -C(=O)NH2, -S(=O)2NH2, -OH, -NH2, -SH, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, -C(=O)-C 1~4 Alkoxy, -C(=O)-C 1~4 Alkylamino, -C(=O)-C 1~4 Alkyl, -S(=O)2-C 1~4 Alkyl, -S(=O)2-C 1~4Alkylamino, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 Cycloalkyl, 5-6 membered heterocyclyl, C 6~10 aryl or 5-6 membered heterocyclyl, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, -C(=O)-C 1~4 Alkoxy, -C(=O)-C 1~4 Alkylamino, -C(=O)-C 1~4 Alkyl, -S(=O)2-C 1~4 Alkyl, -S(=O)2-C 1~4 Alkylamino, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 Cycloalkyl, 5-6 membered heterocyclyl, C 6~10 Each of the aryl and 5- to 6-membered heterocyclyl is independently unsubstituted or substituted with deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -C(=O)NH2, -S(=O)2NH2, -SH, -OH, -NH2, =O, -C(=O)-C 1~4 Alkyl, -C(=O)-C 1~4 Alkoxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl or C 1~4 Substituted with 1, 2 or 3 substituents selected from haloalkoxy.

[0021] In some embodiments, R 1are H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -C(=O)NH2, -S(=O)2NH2, -OH, -NH2, -SH, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, -CF3, -CHF2, -CH2F, -CH2CF3, trifluoromethoxy, difluoromethoxy, -C(=O)-OCH3, -C(=O)-OCH2CH3, -C(=O)-OCH(CH3)2, -C(=O)-OCH2CH2C H3, -C(=O)-O(CH2)3CH3, -C(=O)-OCH2CH(CH3)2, -C(=O)-NHCH3, -C(=O)-N(CH3)2, -C(=O)-CH3, -C(=O)-CH2CH3, -S(=O)2-CH3, -S(=O)2-CH2CH3, -S(=O)2-CH2CH2CH3, -S(=O)2-NHCH3, -S(=O)2-N(CH3)2, -CH=CH2, -CH2CH=CH2, -CH=CHCH3, -C≡CH, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl , imidazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydropyrrolyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydropyrazinyl, tetrahydropyridazinyl, dihydropyrrolyl, dihydrofuranyl, dihydropyranyl, dihydrothienyl, dihydropyridyl, dihydropyrimidinyl, dihydropyrazinyl, dihydropyridazinyl, phenyl, naphthyl, furyl, thienyl, imidazolyl, pyrazolyl, pyrimidinyl , pyridyl, pyrrolyl, pyrazinyl, pyridazinyl, thiazolyl, tetrazolyl, triazolyl, isoxazolyl, isothiazolyl, oxadiazolyl or oxazolyl, and is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, -CHF2, -CH2F, -CH2CF3, difluoromethoxy, -C(=O)-OCH3, -C(=O)-OCH2CH3, -C(=O)-OCH(CH3)2, -C(=O)-OCH2CH2CH3,-C(=O)-O(CH2)3CH3, -C(=O)-OCH2CH(CH3)2, -C(=O)-NHCH3, -C(=O)-N(CH3)2, -C(=O)-CH3, -C(=O)-CH2CH3, -S(=O)2-CH, 3、 -S(=O)2-CH2CH3, -S(=O)2-CH2CH2CH3, -S(=O)2-NHCH3, -S(=O)2-N(CH3)2, -CH=CH2, -CH2CH=CH2, -CH=CHCH3, -C≡CH, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydropyrrolyl, tetrahydrofuranyl, Tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydropyrazinyl, tetrahydropyridazinyl, dihydropyrrolyl, dihydrofuranyl, dihydropyranyl, dihydrothienyl, dihydropyridyl, dihydropyrimidinyl, dihydropyrazinyl, dihydropyridazinyl, phenyl, naphthyl, furyl, thienyl, imidazolyl, pyrazolyl, pyrimidinyl, pyridyl, pyrrolyl, pyrazinyl, pyri Each of dazinyl, thiazolyl, tetrazolyl, triazolyl, isoxazolyl, isothiazolyl, oxadiazolyl and oxazolyl is independently unsubstituted or substituted with deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -C(=O)NH2, -S(=O)2NH2, -SH, -OH, -NH2, =O, -C(=O)-CH3, -C(=O)-CH2CH3, -C(=O)-OCH3, -C(=O)-OCH2CH3, -C(=O)-OC Substituted by 1, 2 or 3 substituents selected from H(CH3)2, -C(=O)-OCH2CH2CH3, -C(=O)-O(CH2)3CH3, -C(=O)-OCH2CH(CH3)2, -C(=O)-CH3, -C(=O)-CH2CH3, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, -CF3, -CHF2, -CH2CF3, trifluoromethoxy or difluoromethoxy.

[0022] In some embodiments, R 4are H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, methyl, ethyl, n-propyl, isopropyl, -CH=CH2, -CH2CH=CH2, -CH=CHCH3, -C≡CH, -C(=O)-OCH3, -C(=O)-OCH2CH3, -C(=O)-OCH(CH3)2, -C(=O)-OCH2CH2CH3, -C(=O)-O(CH2) 3CH3, -C(=O)-OCH2CH(CH3)2, -C(=O)-CH3, -C(=O)-CH2CH3, -C(=O)-NHCH3, -C(=O)-N(CH3)2, -C(=O)NH2, -S(=O)2-CH3, -S(=O)2-CH2CH3, -S(=O)2-NHCH3, methylamino, ethylamino, methoxy, ethoxy, -CF3, -CHF2, -CH2F, -CH2CF3 , -CH2CHF2, trifluoromethoxy, difluoromethoxy, hydroxymethyl, aminomethyl, carboxymethyl or cyanomethyl; and methyl, ethyl, n-propyl, isopropyl, -CH=CH2, -CH2CH=CH2, -CH=CHCH3, -C≡CH, -C(=O)-OCH3, -C(=O)-OCH2CH3, -C(=O)-OCH(CH3)2, -C(=O)-OC H2CH2CH3, -C(=O)-O(CH2)3CH3, -C(=O)-OCH2CH(CH3)2, -C(=O)-CH3, -C(=O)-CH2CH3, -C(=O)-NHCH3, -C(=O)-N(CH3)2, -C(=O)NH2, S(=O)2-CH3, -S(=O)2-CH2CH3, -S(=O)2-NHCH3, methylamino, ethylamino, methoxy, ethoxy, -CF 3、 Each of -CHF2, -CH2F, -CH2CF3, -CH2CHF2, difluoromethoxy, hydroxymethyl, aminomethyl, carboxymethyl and cyanomethyl is independently unsubstituted or deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, C 1~6 Alkyl, C 2~6 Alkenyl or C 2~6 alkynyl is substituted with 1, 2 or 3 substituents selected from alkynyl.

[0023] In some embodiments, R5 is H, deuterium, methyl, ethyl, n-propyl, isopropyl, tert-butyl, -CH=CH2, -CH2CH=CH2, -CH=CHCH3, -C≡CH, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 5- to 6-membered heterocyclyl, phenyl, naphthyl, or 5- to 6-membered heteroaryl.

[0024] In another aspect, the present invention relates to a pharmaceutical composition comprising a compound of the present invention and optionally further comprising any one or combination of a pharma- ceutically acceptable carrier, excipient, adjuvant, vehicle.

[0025] In another aspect, the invention relates to the use of a compound or pharmaceutical composition of the invention in the manufacture of a medicament for agonizing a thyroid hormone receptor or for preventing, treating or ameliorating a disease mediated by an agonist thyroid hormone receptor in a subject.

[0026] In some embodiments, the thyroid hormone receptor of the present invention is a thyroid hormone beta receptor.

[0027] In some embodiments, the disease mediated by the agonist thyroid hormone receptor of the present invention is non-alcoholic fatty liver disease, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes, metabolic disorders, glycogen storage disease type 1A, hypothyroidism, or thyroid cancer.

[0028] In some embodiments, the non-alcoholic fatty liver disease of the present invention is non-alcoholic simple fatty liver, non-alcoholic steatohepatitis, cryptogenic cirrhosis or primary liver cancer.

[0029] In some embodiments, the metabolic disorder of the present invention is a lipid metabolism disorder or a glucose metabolism disorder.

[0030] The above is merely a summary of certain aspects disclosed herein and is not intended to be limiting in nature. These aspects, as well as other aspects and embodiments, are described in more detail below. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] The present invention provides a class of compounds with good agonist activity against thyroid hormone β receptor, a preparation method, a pharmaceutical composition containing the compound and its use.Those skilled in the art can learn from this paper how to properly improve the process parameters for carrying out the preparation method.It is particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in the present invention.

[0032] Definitions and General Terms Reference will now be made in detail to certain embodiments of the present invention, examples of which are illustrated in the accompanying structures and formulas. The present invention is intended to encompass all alternatives, modifications, and equivalents that may fall within the scope of the present invention. Those skilled in the art will recognize numerous methods and materials similar or equivalent to those described herein that can be used to practice the present invention. The present invention is in no way limited to the methods and materials described herein. In the event that one or more of the incorporated literature, patents, and similar materials differ or conflict with this application, including but not limited to defined terms, use of terms, techniques described, etc., this application shall control.

[0033] It is further understood that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

[0034] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications referenced herein are incorporated by reference in their entirety.

[0035] As used herein, the following definitions apply unless otherwise indicated: For purposes of this invention, the chemical elements are identified according to the Periodic Table of the Elements, CAS edition, and the Handbook of Chemistry and Physics, 75th Edition, 1994. Furthermore, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and Smith et al., "March's Advanced Organic Chemistry", John Wiley & Sons, New York: 2007, the entire contents of which are incorporated herein by reference.

[0036] As used herein, the grammatical articles "a," "an," and "the" are intended to include "at least one" or "one or more," unless otherwise indicated herein or clearly contradicted by context. Thus, an article as used herein refers to one or to more than one (i.e., at least one) of the grammatical object of the article. By way of example, "a component" means one or more components, and thus, perhaps more than one component is contemplated and may be utilized or used in the practice of the described embodiments.

[0037] Unless otherwise stated, terms used in the present specification and claims have the following definitions.

[0038] The term "comprising" is an open-ended term, meaning inclusive of the subjects disclosed herein, but not exclusive of other subjects.

[0039] As described herein, the compounds disclosed herein may be optionally substituted with one or more substituents, such as those generally exemplified below or those exemplified by the specific classes, subclasses and species of the present invention. The phrase "optionally substituted" is understood to be used interchangeably with the phrase "substituted or unsubstituted". The term "optionally" or "optionally" means that the event or condition described thereafter may, but does not necessarily, occur, and the description includes cases where the event or condition occurs and cases where the event or condition does not occur. In general, unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group. When more than one position of a given structure is substitutable with more than one substituent selected from a particular group, the substituents may be the same or different at each position. Substituents described herein include, but are not limited to, H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -C(=O)NH2, -S(=O)2NH2, -OH, =O, -NH2, -SH, -OCH2COOH, -NHC(=O)COOH, -NHCH2COOH,

[0040] [ka]

[0041] , -C(=O)-alkoxy, -C(=O)-alkyl, -C(=O)-alkylamino, -S(=O)2-alkyl, -S(=O)2-C 1~6 alkylamino, alkyl, alkoxy, alkylthio, alkylamino, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, cyanoalkyl, carboxyalkyl, alkenyl, alkynyl, cycloalkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, etc., wherein R 4 and R 5 has the definition set forth herein.

[0042] Furthermore, it should be explained that the phrases "each independently" and "and each independently" should be understood broadly unless otherwise stated, which may mean that particular options represented by the same symbol are independent of each other in different groups, or that particular options represented by the same symbol are independent of each other in the same group.

[0043] At various points in the specification, alternatives of the compounds disclosed herein are disclosed in groups or ranges. Specifically, the invention is intended to include any and all individual subcombinations of the members of such groups and ranges. For example, "C 1~6 The term "alkyl" specifically refers to C alkyl (methyl), C alkyl (ethyl), C alkyl, C alkyl, C alkyl, C alkyl, and C alkyl, each of which is disclosed independently, and includes "C 3~8 "Cycloalkyl" specifically refers to the independently disclosed C3 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, C7 cycloalkyl, and C8 cycloalkyl, and "5- to 8-membered heteroaryl" refers to heteroaryl of 5 ring atoms, heteroaryl of 6 ring atoms, heteroaryl of 7 ring atoms, and heteroaryl of 8 ring atoms.

[0044] In various places in this specification, linking substituents are described. When a linking group is clearly required by the structure, it is understood that the Markush group variable listed for that group is the linking group. For example, when a linking group is required by the structure and "alkyl" or "aryl" is listed in the Markush group definition for that variable, it is understood that "alkyl" or "aryl" represents a linking alkylene group or arylene group, respectively.

[0045] The terms "alkyl" or "alkyl group" refer to a saturated straight or branched chain monovalent hydrocarbon group of 1 to 20 carbon atoms, where the alkyl group is optionally substituted with one or more substituents described herein. In some embodiments, an alkyl group contains 1 to 10 carbon atoms, i.e., C 1~10In some embodiments, the alkyl group contains 1 to 8 carbon atoms, i.e., C 1~8 In another embodiment, the alkyl group contains 1 to 6 carbon atoms, i.e., C 1~6 In another embodiment, the alkyl group contains 1 to 4 carbon atoms, i.e., C 1~4 In yet other embodiments, the alkyl group contains 1 to 3 carbon atoms, i.e., C 1~3 In yet another embodiment, the alkyl group contains 1 to 2 carbon atoms, i.e., C 1~2 It is an alkyl.

[0046] Some non-limiting examples of alkyl groups are methyl (Me, -CH3), ethyl (Et, -CH2CH3), n-propyl (n-Pr, -CH2CH2CH3), isopropyl (i-Pr, -CH(CH3)2), n-butyl (n-Bu, -CH2CH2CH2CH3), isobutyl (i-Bu, -CH2CH(CH3)2), sec-butyl (s-Bu, -CH(CH3)CH2CH3), tert ... (t-Bu, -C(CH3)3), n-pentyl (-CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-l-butyl (-CH2CH2CH(CH3)2), 2-methyl- l-Butyl (-CH2CH(CH3)CH2CH3), n-Hexyl (-CH2CH2CH2CH2CH2CH2CH3), 2-Hexyl (-CH(CH3)CH2CH2CH2CH2CH3), 3-Hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-Methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-Methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), These include 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3, n-heptyl, and n-octyl.

[0047] The term "alkenyl" refers to an alkyl group having at least one site of unsaturation, i.e., carbon-carbon, sp 2 "Alkenyl" refers to a straight or branched chain monovalent hydrocarbon radical of 2 to 12 carbon atoms having a double bond, where the alkenyl radical may be optionally substituted with one or more substituents described herein, and includes radicals having "cis" and "trans" orientations, or alternatively, "E" and "Z" orientations. In some embodiments, alkenyl contains 2 to 8 carbon atoms, i.e., C 2~8In another embodiment, the alkenyl contains 2 to 6 carbon atoms, i.e., C 2~6 In yet another embodiment, the alkenyl contains 2 to 4 carbon atoms, i.e., C 2~4 It is alkenyl.

[0048] Some non-limiting examples of alkenyl groups include vinyl (-CH=CH2), allyl (-CH2CH=CH2), propenyl (-CH=CHCH3), butenyl (-CH=CHCH2CH3, -CH2CH=CHCH3, -CH2CH2CH=CH2, -CH=C(CH3)2, -CH=C(CH3)2, -CH2C(CH3)=CH2), pentenyl (-CH2CH2CH2CH=CH2, -CH2CH2CH=CHCH3, -CH2CH2CH=CHCH3, -CH2CH2CH=CHCH3, -CH2CH=CHCH2CH3, -CH2CH2CH2CH3, -CH2CH2C(CH3)=CH2, -CH2CH=C(CH3)2, -CH=CHCH(CH3)2, -C(CH2CH3)=CHCH3, -CH(CH2CH3)CH=CH2), and the like.

[0049] The term "alkynyl" refers to a linear or branched monovalent hydrocarbon group of 2 to 12 carbon atoms having at least one site of unsaturation, i.e., a carbon-carbon, sp triple bond, where the alkynyl group may be optionally substituted with one or more substituents described herein. In some embodiments, alkynyl contains 2 to 8 carbon atoms, i.e., C 2~8 In another embodiment, the alkynyl group contains 2 to 6 carbon atoms, i.e., C 2~6 In yet another embodiment, the alkynyl contains 2 to 4 carbon atoms, i.e., C 2~4 Some non-limiting examples of alkynyl groups include ethynyl (-C≡CH), 1-propynyl (-C≡CH-CH), propargyl (-CHC≡CH), 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1-butynyl, 1-hexynyl, 1-heptynyl, 1-octynyl, and the like.

[0050] The term "alkoxy" refers to an alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom, i.e., -O-alkyl, where the alkoxy group may be optionally substituted with one or more substituents as described herein. In some embodiments, the alkoxy group contains 1 to 8 carbon atoms, i.e., C 1~8 In another embodiment, the alkoxy group contains 1 to 6 carbon atoms, i.e., C 1~6 In another embodiment, the alkoxy group contains 1 to 4 carbon atoms, i.e., C 1~4 In yet another embodiment, the alkoxy group contains 1 to 3 carbon atoms, i.e., C 1~3 In yet another embodiment, the alkoxy group contains 1 to 2 carbon atoms, i.e., C 1~2 It is an alkoxy.

[0051] Some non-limiting examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH3), ethoxy (EtO, -OCH2CH3), n-propyloxy (n-PrO, n-propoxy, -OCH2CH2CH3), isopropyloxy (i-PrO, i-propoxy, -OCH(CH3)2), 1-butoxy (n-BuO, n-butoxy, -OCH2CH2CH2CH3), 2-methyl-l-propoxy (i-BuO, i-butoxy, -OCH2CH(CH3)2), 2-butoxy (s-BuO, s-butoxy, -OCH(CH3)CH2CH3), 2 -Methyl-isopropyloxy (t-BuO, t-butoxy, -OC(CH3)3), 1-pentoxy (n-pentoxy, -OCH2CH2CH2CH2CH3), 2-pentoxy (-OCH(CH3)CH2CH2CH3), 3-pentoxy (-OCH(CH2CH3)2), 2-methyl-2-butoxy (-OC(CH3)2CH2CH3), 3-methyl-2-butoxy (-OCH(CH3)CH(CH3)2), 3-methyl-l-butoxy (-OCH2CH2CH(CH3)2), 2-methyl-l-butoxy (-OCH2CH(CH3)CH2CH3), and the like.

[0052] The term "alkylamino" encompasses "N-alkylamino" and "N,N-dialkylamino", i.e., an amino group independently substituted with one or two alkyl groups, where the alkyl groups are as defined herein, and where the alkyl groups may be optionally substituted with one or more substituents disclosed herein. In some embodiments, an alkylamino group comprises one or two C alkyl groups bonded to a nitrogen atom. 1~6 Alkyl groups, i.e. C 1~6 In some embodiments, the alkylamino group is an alkyl group having one or two C alkyl groups bonded to a nitrogen atom. 1~4 Alkyl groups, i.e. C 1~4 In some embodiments, the alkylamino group is an alkyl group having one or two C alkyl groups bonded to a nitrogen atom. 1~2 Alkyl groups, i.e. C 1~2 Examples of alkylamino groups include, but are not limited to, methylamino (N-methylamino), ethylamino (N-ethylamino), dimethylamino (N,N-dimethylamino), diethylamino (N,N-diethylamino), n-propylamino (Nn-propylamino), isopropylamino (N-isopropylamino), tert-butylamino (N-tert-butylamino), and the like.

[0053] The term "alkylthio" refers to an alkyl group, as previously defined, attached to the parent molecular moiety through a sulfur atom, i.e., -S-alkyl, where the alkylthio group may be optionally substituted with one or more substituents described herein. In some embodiments, the alkylthio group contains 1 to 8 carbon atoms, i.e., C 1~8 In another embodiment, the alkylthio group contains 1 to 6 carbon atoms, i.e., C 1~ In another embodiment, the alkylthio group contains 1 to 4 carbon atoms, i.e., C 1~4 In yet other embodiments, the alkylthio group contains 1 to 3 carbon atoms, i.e., C 1~3In yet another embodiment, the alkylthio group contains 1 to 2 carbon atoms, i.e., C 1~2 Examples of alkylthio groups include, but are not limited to, methylthio (-SCH3), ethylthio (-SCH2CH3), and the like.

[0054] The term "haloalkyl" refers to an alkyl group having one or more halogen substituents, which may be optionally substituted with one or more substituents disclosed herein. In some embodiments, a haloalkyl group contains 1 to 10 carbon atoms, i.e., C 1~10 In some embodiments, the haloalkyl group contains 1 to 8 carbon atoms, i.e., C 1~8 In another embodiment, the haloalkyl group contains 1 to 6 carbon atoms, i.e., C 1~6 In another embodiment, the haloalkyl group contains 1 to 4 carbon atoms, i.e., C 1~4 In yet other embodiments, the haloalkyl group contains 1 to 3 carbon atoms, i.e., C 1~3 In yet other embodiments, the haloalkyl group contains 1 to 2 carbon atoms, i.e., C 1~2 Examples of haloalkyl groups include, but are not limited to, fluoromethyl (-CHF), difluoromethyl (-CHF), trifluoromethyl (-CF), fluoroethyl (-CHFCH, -CHCHF), difluoroethyl (-CFCH, -CFHCFH, -CHCHF), perfluoroethyl, fluoropropyl (-CHFCHCH, -CHCHFCH, -CHCHCHF), difluoropropyl (-CFCHCH, -CFHCFHCH, -CHCHCHF, -CHCFCH, -CHCHFCHF), trifluoropropyl (-CHCHCF), 1,1-dichloroethyl, 1,2-dichloropropyl, and the like.

[0055] The term "haloalkoxy" refers to an alkoxy group having one or more halogen substituents, which may be optionally substituted with one or more substituents disclosed herein. In some embodiments, a haloalkoxy group contains 1 to 10 carbon atoms, i.e., C 1~ In some embodiments, the haloalkoxy group contains 1 to 8 carbon atoms, i.e., C 1~8 In another embodiment, the haloalkoxy group contains 1 to 6 carbon atoms, i.e., C 1~6 In another embodiment, the haloalkoxy group contains 1 to 4 carbon atoms, i.e., C 1~4 In yet other embodiments, the haloalkoxy group contains 1 to 3 carbon atoms, i.e., C 1~3 In yet another embodiment, the haloalkoxy group contains 1 to 2 carbon atoms, i.e., C 1~2 Some non-limiting examples of haloalkoxy groups include trifluoromethoxy (-OCF3), difluoromethoxy (-OCHF2), and the like.

[0056] The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups (-OH), where alkyl is as defined herein, and where the hydroxyalkyl group may be optionally substituted with one or more substituents disclosed herein. In some embodiments, the hydroxyalkyl groups of the present invention include a C substituted with one or more hydroxy groups (-OH). 1~6 Alkyl, i.e., hydroxy C 1~6 In some embodiments, a hydroxyalkyl group refers to a C alkyl group substituted with one or more hydroxy groups (-OH). 1~4 Alkyl, i.e., hydroxy C 1~4 In some embodiments, a hydroxyalkyl group refers to a C alkyl group substituted with one or more hydroxy groups (-OH). 1~2 Alkyl, i.e., hydroxy C 1~2Examples of hydroxyalkyl groups include, but are not limited to, hydroxymethyl (e.g., -CHOH), hydroxyethyl (e.g., 2-hydroxyethyl), hydroxy-n-propyl (e.g., -CHCHCHOH), and the like.

[0057] The term "aminoalkyl" refers to an alkyl group substituted with one or more amino groups (-NH), where the alkyl group is as defined herein, and where the aminoalkyl group may be optionally substituted with one or more substituents disclosed herein. In some embodiments, the aminoalkyl group of the present invention is a C substituted with one or more amino groups (-NH). 1~6 Alkyl, i.e., amino C 1~6 In some embodiments, an aminoalkyl group refers to a C alkyl group substituted with one or more amino groups (-NH). 1~4 Alkyl, i.e., amino C 1~4 In some embodiments, an aminoalkyl group refers to a C alkyl group substituted with one or more amino groups (-NH). 1~2 Alkyl, i.e., amino C 1~2 Examples of aminoalkyl groups include, but are not limited to, aminomethyl (-CH-NH), diaminomethyl (-CH(NH)), aminoethyl (e.g., 2-aminoethyl), amino-n-propyl (e.g., -CHCHCHNH), and the like.

[0058] The term "cyanoalkyl" refers to an alkyl group substituted with one or more cyano groups (-CN), where alkyl is as defined herein, and where the cyanoalkyl group may be optionally substituted with one or more substituents disclosed herein. In some embodiments, the cyanoalkyl groups of the present invention include a C substituted with one or more cyano groups (-CN). 1~6 Alkyl, i.e., cyano C 1~6 In some embodiments, a cyanoalkyl group refers to a C alkyl group substituted with one or more cyano groups (-CN). 1~4 Alkyl, i.e., cyano C 1~4In some embodiments, a cyanoalkyl group refers to a C alkyl group substituted with one or more cyano groups (-CN). 1~2 Alkyl, i.e., cyano C 1~2 Examples of cyanoalkyl groups include, but are not limited to, cyanomethyl (e.g., —CHCN), cyanoethyl (e.g., 2-cyanoethyl), and the like.

[0059] The term "carboxyalkyl" refers to an alkyl group substituted with one or more carboxy groups (-COOH), where alkyl is as defined herein, and where the carboxyalkyl group may be optionally substituted with one or more substituents disclosed herein. In some embodiments, the carboxyalkyl group of the present invention is a C substituted with one or more carboxy groups (-COOH). 1~6 Alkyl, i.e., carboxy C 1~6 In some embodiments, a carboxyalkyl group refers to a C alkyl group substituted with one or more carboxy groups (-COOH). 1~4 Alkyl, i.e., carboxy C 1~4 In some embodiments, a carboxyalkyl group refers to a C alkyl group substituted with one or more carboxy groups (-COOH). 1~2 Alkyl, i.e., carboxy C 1~2 Examples of carboxyalkyl groups include, but are not limited to, carboxymethyl, carboxyethyl (e.g., 2-carboxyethyl), and the like.

[0060] The term "cycloalkyl" refers to a monovalent or polyvalent non-aromatic saturated ring having 3 to 12 carbon atoms as a monocyclic, bicyclic, or tricyclic ring system, where the cycloalkyl group is optionally substituted with the substituents described herein. In some embodiments, cycloalkyl refers to a ring system containing 3 to 10 ring carbon atoms, i.e., C 3~10 In yet another embodiment, cycloalkyl is a ring system containing 3 to 8 ring carbon atoms, i.e., C 3~8In yet another embodiment, cycloalkyl is a ring system containing 3 to 6 ring carbon atoms, i.e., C 3~6 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.

[0061] The term "carbocycle" or "carbocyclyl" refers to a mono- or polyvalent non-aromatic saturated or partially unsaturated ring having 3 to 14 ring carbon atoms as a monocyclic, bicyclic, or tricyclic ring system. The terms "carbon ring", "carbocyclyl" or "carbocyclic" may be used interchangeably herein. In some embodiments, a carbocyclyl has 3 to 12 ring carbon atoms, i.e., C 3~12 In another embodiment, the carbocyclyl has 3 to 10 ring carbon atoms, i.e., C 3~10 In another embodiment, the carbocyclyl has 3 to 8 ring carbon atoms, i.e., C 3~8 In another embodiment, the carbocyclyl has 3 to 6 ring carbon atoms, i.e., C 3~6 In another embodiment, the carbocyclyl has 5 to 6 ring carbon atoms, i.e., C 5~6 In another embodiment, the carbocyclyl has 5 to 8 ring carbon atoms, i.e., C 5~8 In another embodiment, the carbocyclyl has 6 to 8 ring carbon atoms, i.e., C 6~8Some non-limiting examples of carbocyclyl groups include cycloalkyl, cycloalkenyl, and cycloalkynyl. Further examples of carbocyclyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-l-enyl, l-cyclopent-2-enyl, l-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-l-enyl, l-cyclohex-2-enyl, l-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, bicyclo[2.2.2]octyl, bicyclo[2.2.1]heptyl, bicyclo[3.3.1]nonyl, bicyclo[3.2.3]nonyl, and the like.

[0062] The term "heterocyclyl" refers to a saturated or partially unsaturated non-aromatic ring having 3-12 ring atoms as a monocyclic, bicyclic, or tricyclic ring system, where at least one ring member is selected from heteroatoms such as nitrogen, sulfur, oxygen, and phosphorus. Here, the heterocyclic group is non-aromatic and does not contain an aromatic ring, and the rings of the heterocyclic group may be optionally substituted with one or more substituents as described in the present invention. The term "heterocyclyl" includes monocyclic, bicyclic, or polycyclic fused, spiro, or bridged heterocyclic ring systems. Bicyclic heterocyclic groups include bridged bicyclic heterocyclyls, fused bicyclic heterocyclyls, and spiro bicyclic heterocyclyls. The terms "heterocyclyl", "heterocyclic group", and "heterocycle" are used interchangeably herein. Unless otherwise specified, a heterocyclyl group may be carbon- or nitrogen-linked, and the -CH2- group may be optionally replaced by a -C(=O)- group. Here, sulfur may be optionally oxidized to an S-oxide, nitrogen may be optionally oxidized to an N-oxide, and phosphorus may be optionally oxidized to a P-oxide. In some embodiments, the heterocyclyl is a ring system consisting of 3 to 10 ring atoms, i.e., a 3- to 10-membered heterocyclyl. In some embodiments, the heterocyclyl is a ring system consisting of 5 to 10 ring atoms, i.e., a 5- to 10-membered heterocyclyl. In some embodiments, the heterocyclyl is a ring system consisting of 5 to 8 ring atoms, i.e., a 5- to 8-membered heterocyclyl. In some embodiments, the heterocyclyl is a ring system consisting of 6 to 8 ring atoms, i.e., a 6- to 8-membered heterocyclyl. In some embodiments, the heterocyclyl is a ring system consisting of 5 to 6 ring atoms, i.e., a 5- to 6-membered heterocyclyl. In other embodiments, the heterocyclyl is a ring system consisting of 3 to 6 ring atoms, i.e., a 3- to 6-membered heterocyclyl. In another embodiment, the heterocyclyl is a ring system consisting of 3 ring atoms. In another embodiment, the heterocyclyl is a ring system consisting of 4 ring atoms. In another embodiment, the heterocyclyl is a ring system consisting of 5 ring atoms. In another embodiment, the heterocyclyl is a ring system consisting of 6 ring atoms.

[0063] Examples of heterocyclyl groups include, but are not limited to, oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydropyrrolyl, dihydropyrrolyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothienyl, dihydrothienyl, tetrahydropyridyl, dihydropyridyl (e.g., 1,2-dihydropyridyl). , 1,4-dihydropyridyl), tetrahydropyrimidinyl, dihydropyrimidinyl, tetrahydropyrazinyl, dihydropyrazinyl, tetrahydropyridazinyl, dihydropyridazinyl, 1,3-dioxopentyl, dithiocyclopentyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thiazinyl, homopiperazinyl, homopiperidinyl, oxepanyl, thiepanyl, etc. Some non-limiting examples of heterocyclyl groups in which a -CH2- group is replaced by a -C(=O)- moiety include 2-oxopyrrolidinyl, oxo-1,3-thiazolidinyl, 2-piperidinonyl, and 3,5-dioxopiperidinyl. Non-limiting examples of heterocyclyl groups in which the ring sulfur atom is oxidized include sulfonyl and 1,1-dioxo-thiomorpholinyl. Bridged heterocyclyl groups include, but are not limited to, 2-oxabicyclo[2.2.2]octyl, 1-azabicyclo[2.2.2]octyl, 3-azabicyclo[3.2.1]octyl, and the like.

[0064] The term "m-membered", where m is an integer, typically describes the number of atoms forming the ring of the moiety where m is the number of atoms forming the ring. For example, piperidinyl is an example of a 6-membered heterocyclyl group, and furanyl is an example of a 5-membered heteroaryl group. As another example, "5-8 membered heteroaryl" refers to a heteroaryl group consisting of 5, 6, 7, or 8 atoms.

[0065] The term "aryl" refers to monocyclic, bicyclic, and tricyclic aromatic carbocyclic ring systems having 6 to 14 ring atoms, where each ring of the system contains 3 to 7 ring atoms. In some embodiments, aryl groups are carbocyclic ring systems having 6 to 12 ring atoms, i.e., C 6~12 In some embodiments, the aryl group is a carbocyclic ring system having 6 to 10 ring atoms, i.e., C 6~10 Aryl, where the aryl may be optionally substituted with one or more substituents disclosed herein. The term "aryl" may be used interchangeably with the terms "aryl ring" or "aromatic ring". Some non-limiting examples of aryl groups include phenyl, indenyl, naphthyl, and anthracenyl.

[0066] The term "heteroaryl" refers to a mono- or polyvalent monocyclic, bicyclic, or tricyclic aromatic system having 5-14 ring atoms, where at least one ring member is selected from a heteroatom, each ring of the system contains 5-7 ring members, and at least one ring of the system is aromatic. Herein, the heteroaryl may be optionally substituted with one or more substituents disclosed herein. Unless otherwise stated, the heteroaryl group may be connected to the remainder of the molecule (such as the parent structure in the general formula) through any reasonable position (which may be C in CH, or N in NH). If a -CH2- group is present in the heteroaryl group, the -CH2- group may be optionally replaced by a -C(=O)- group. The terms "heteroaryl" and "heteroaromatic ring" or "heteroaromatic compound" may be used interchangeably herein. In some embodiments, the heteroaryl is a heteroaryl group of 5-8 ring atoms containing 1, 2, 3, or 4 heteroatoms independently selected from O, S, P, and N. In another embodiment, heteroaryl is a heteroaryl group of 5-7 ring atoms containing 1, 2, 3 or 4 heteroatoms independently selected from O, S, P and N. In another embodiment, heteroaryl is a heteroaryl group of 5-6 ring atoms containing 1, 2, 3 or 4 heteroatoms independently selected from O, S, P and N. In another embodiment, heteroaryl is a heteroaryl group of 5 ring atoms containing 1, 2, 3 or 4 heteroatoms independently selected from O, S, P and N. In another embodiment, heteroaryl is a heteroaryl group of 6 ring atoms containing 1, 2, 3 or 4 heteroatoms independently selected from O, S, P and N.

[0067] Some non-limiting examples of heteroaryl include the following monocyclic groups: furyl (2-furanyl, 3-furanyl), imidazolyl (N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), isoxazolyl (3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), pyrrolyl (N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), pyridyl (2-pyridyl, 3-pyridyl), , 4-pyridyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyridazinyl (e.g., 3-pyridazinyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), tetrazolyl (e.g., 5H-tetrazolyl, 2H-tetrazolyl), triazolyl (e.g., 2-triazolyl, 5-triazolyl, 4H-1,2,4-triazolyl, 1H-1,2,4-triazolyl, 1,2,3-triazolyl), thienyl (2-thienyl, 3- thienyl), pyrazolyl (e.g., 2-pyrazolyl and 3-pyrazolyl), isothiazolyl, oxadiazolyl (e.g., 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl), 1,2,3-thiodiazolyl, 1,3,4-thiodiazolyl, 1,2,5-thiodiazolyl, pyrazinyl, 1,3,5-triazinyl, pyridine-2(1H)-keto, pyridine-4(1H)-keto, and the following bicyclic or tricyclic rings: Groups of the formula: indolinyl, 1,2,3,4-tetrahydroisoquinolinyl, benzimidazolyl, benzofuryl, benzothiophenyl, indolyl (e.g., 2-indolyl), purinyl, quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl or 4-isoquinolinyl), phenoxothiyl, dibenzimidazolyl, dibenzofuranyl, dibenzothienyl.

[0068] The terms "cycloalkylalkyl", "heterocyclylalkyl", "arylalkyl" and "heteroarylalkyl" refer to cycloalkyl, heterocyclyl, aryl and heteroaryl, respectively, independently connected to the remainder of the molecule by an alkyl group. Cycloalkyl, heterocyclyl, aryl, heteroaryl and alkyl have the meanings described herein. Examples of such include, but are not limited to, cyclopropylmethyl, morpholinylmethyl, piperidinylmethyl, tetrahydrofuranylmethyl, phenylmethyl (i.e., benzyl), phenylethyl, pyridylmethyl, pyridylethyl or pyrimidinylmethyl, and the like.

[0069] The term "heteroatom" refers to any oxidized form of nitrogen, sulfur, or phosphorus, the quaternized form of any basic nitrogen, or a substitutable nitrogen of a heterocyclic ring, such as N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR T (In the case of N-substituted pyrrolidinyl, R T is a substituent for N).

[0070] The term "halogen" refers to fluoro (F), chloro (Cl), bromo (Br) or iodo (I).

[0071] The term "nitro" refers to --NO.

[0072] The term "mercapto" refers to --SH.

[0073] The term "hydroxy" refers to --OH.

[0074] The term "amino" refers to --NH.sub.2.

[0075] The term "cyano" refers to --CN.

[0076] The term "carboxylic acid" or "carboxy" refers to -C(=O)OH or -COOH.

[0077] The term "carbonyl" refers to -(C=O)-.

[0078] The term "deuterium" refers to D, i.e. 2 Point to H.

[0079] The term "oxo" refers to =O.

[0080] The term "protecting group" or "PG" refers to a substituent that is commonly used to block or protect a particular functional group while reacting with other functional groups of a compound. For example, an "amino protecting group" is a substituent attached to an amino group that blocks or protects the amino functionality of the compound. Suitable amino protecting groups include acetyl, trifluoroacetyl, t-butoxy-carbonyl (BOC, Boc), benzyloxycarbonyl (CBZ, Cbz) and 9-fluorenylmethyleneoxy-carbonyl (Fmoc). Similarly, a "hydroxy protecting group" refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable protecting groups include, but are not limited to, acetyl, benzoyl, p-methoxybenzyl, silyl, and the like. A "carboxy protecting group" refers to a substituent of a carboxy group that blocks or protects the carboxy functionality. Suitable carboxy protecting groups include -CH2CH2SO2Ph, cyanoethyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxy-methyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfonyl)-ethyl, 2-(diphenylphosphino)-ethyl, nitroethyl, etc. For a general description of protecting groups and their use, see TW Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991; and PJ Kocienski, Protecting Groups, Thieme, Stuttgart, 2005.

[0081] The term "leaving group" or "LG" refers to an atom or functional group that leaves a larger molecule in a chemical reaction and is a term used in nucleophilic substitution and elimination reactions. In a nucleophilic substitution reaction, the reactant that is attacked by the nucleophile is called the substrate, and the atom or group of atoms that dissociates from the substrate molecule along with an electron pair is called the leaving group. Common leaving groups are, for example, but not limited to, halogen atoms, ester groups, sulfonate groups, nitro groups, azide groups, or hydroxy groups.

[0082] The phrase "pharmacologically acceptable" refers to the fact that a substance or composition must be chemically and / or toxicologically compatible with the other ingredients that make up the formulation and / or with the mammal being treated therewith. Preferably, as used herein, the term "pharmacologically acceptable" means approved by a federal or state government regulatory agency for use in animals, more particularly humans, or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias.

[0083] The term "carrier" includes any solvent, dispersion medium, coating agent, surfactant, antioxidant, preservative (e.g., antibacterial, antifungal), isotonic agent, salt, drug stabilizer, binder, excipient, dispersing agent, lubricant, sweetener, flavoring agent, coloring agent, or combinations thereof, all of which are well known to those skilled in the art (e.g., Remington's Pharmaceutical Sciences, 18th Edition, Mack Printing Company, 1990, pages 1289-1329, all of which are incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient, a pharma- ceutically acceptable carrier is usefully used in the treatment or pharmaceutical composition.

[0084] The term "pharmaceutical composition" refers to a combination of one or more of the compounds described herein, or physiologically / pharmaceutical acceptable salts or prodrugs thereof, with other chemical components, such as physiologically / pharmaceutical acceptable carriers, excipients, diluents, binders, fillers and other additional therapeutic agents, such as antidiabetic agents, antihyperglycemic agents, antiobesity agents, antihypertensive agents, antiplatelet agents, antiatherosclerotic agents, lipid-lowering agents, etc. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

[0085] The term "prodrug" refers to a compound that is converted in vivo to a compound of formula (I). Such conversion may occur, for example, by hydrolysis of the prodrug form in blood or enzymatic conversion to the parent form in blood or tissue. Prodrugs of the compounds disclosed herein may be, for example, esters. Some common esters utilized as prodrugs are phenyl esters, aliphatic (C 1~24) esters, acyloxymethyl esters, carbonates, carbamates, and amino acid esters. For example, compounds disclosed herein that contain a hydroxy group may be acylated at this position in their prodrug forms. Other prodrug forms include phosphates, e.g., phosphate compounds derived from phosphonation of the hydroxy group of the parent compound. A detailed discussion of prodrugs is provided in Higuchi et al., Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series; Roche et al., eds., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987; Rautio et al., Prodrugs: Design and Clinical Applications, Nature Reviews Drug Discovery, 2008, 7, 255-270, and Hecker et al., Prodrugs of Phosphates and Phosphonates, J. Med. Chem., 2008, 51, 2328-2345, all of which are incorporated herein by reference in their entirety.

[0086] The term "metabolite" refers to a product produced by metabolism in the body of a particular compound or salt thereof. Metabolites of a compound may be identified using routine techniques known in the art, and their activity may be determined using tests such as those described herein. Such products may result, for example, from oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound. Thus, the present invention includes metabolic products of the compounds disclosed herein, including metabolic products produced by contacting a mammal with a compound disclosed herein for a sufficient period of time.

[0087] The term "pharmaceutically acceptable salt" refers to organic or inorganic salts of the compounds disclosed herein. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are detailed in Berge et al., J. Pharm. Sci., 1977, 66:1-19, the entire contents of which are incorporated herein by reference.

[0088] The term "solvate" refers to an association or complex of one or more solvent molecules and a compound disclosed herein. Some non-limiting examples of solvents that form solvates include water, isopropanol, ethanol, methanol, dimethylsulfoxide (DMSO), ethyl acetate, acetic acid, and ethanolamine. The term "hydrate" refers to a complex where the solvent molecule is water.

[0089] The term "N-oxide" refers to the oxidation of one or more nitrogen atoms to form N-oxides when the compound contains multiple amine functional groups. Particular examples of N-oxides are the N-oxides of the nitrogen atoms of tertiary amines or nitrogen-containing heterocycles. N-oxides may be formed by treating the corresponding amines with an oxidizing agent such as hydrogen peroxide or peracids (e.g., peroxycarboxylic acids) (see pages in Advanced Organic Chemistiy, 4th Edition, Wiley Interscience, by Jerry March). More specifically, N-oxides may be made by the procedure of LW Deady (Syn. Comm. 1977, 7, 509-514), which involves reacting an amine compound with m-chloroperbenzoic acid (MCPBA) in an inert solvent such as dichloromethane.

[0090] Any asymmetric atom (e.g., carbon, etc.) of the compounds disclosed herein may be present in a racemic or enantiomerically enriched state, such as (R), (S) or (R,S) configuration. In certain embodiments, each asymmetric atom has an enantiomeric excess of at least 50%, an enantiomeric excess of at least 60%, an enantiomeric excess of at least 70%, an enantiomeric excess of at least 80%, an enantiomeric excess of at least 90%, an enantiomeric excess of at least 95%, or an enantiomeric excess of at least 99% in the (R) or (S) configuration. Where possible, substituents of atoms having unsaturated double bonds may be present in cis-(Z)- or trans-(E)-form.

[0091] Thus, as described in the present invention, the compounds disclosed herein may exist in the form of any possible isomers, rotamers, atropisomers, tautomers, or mixtures thereof, such as substantially pure geometric (cis or trans) isomers, diastereoisomers, optical isomers (enantiomers), racemates, or mixtures thereof.

[0092] Any resulting mixture of stereoisomers can be separated on the basis of the physical chemical differences of their components, for example, by chromatography and / or fractional crystallization, into pure or substantially pure geometric or optical isomers, diastereomers, racemates.

[0093] Any resulting racemates of the final product or intermediates can be resolved into their optical antipodes by methods known to those skilled in the art, for example, by separation of their diastereomeric salts. Racemic products can also be resolved by chiral chromatography, for example, high performance liquid chromatography (HPLC) using a chiral adsorbent. Preferred enantiomers can also be prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Principles of Asymmetric Synthesis (2nd ed., Robert E. Gawley, Jeffrey Aube, Elsevier, Oxford, UK, 2012); Eliel, EL Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, SH Tables of Resolving Agents and Optical Resolutions, p. 268 (EL Eliel, ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).

[0094] The present invention also includes isotopically labeled compounds of the present invention, which are the same as described herein except that one or more atoms are replaced by an atom whose atomic mass or mass number is different from the atomic mass or mass number typically found in nature. Examples of isotopes that may be incorporated into the compounds of the present invention are: 2 H, 3 H, 13 C. 14 C. 15 N, 16 O. 17 O. 31 P, 32 P, 36 S, 18 F and 37 Each of these includes isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as Cl.

[0095] Compounds disclosed herein and pharmaceutical salts thereof that contain the aforementioned isotopes or other atomic isotopes are within the scope of the present invention. Certain isotopically labeled compounds of the present invention, e.g., 3 H or 14 Those incorporating radioactive isotopes such as C are useful in drug and / or substrate tissue distribution assays. Because of their ease of preparation and detection, tritium-labeled ones, i.e. 3 H, and carbon-14, i.e. 14 Isotopes such as C are preferred. Additionally, heavier isotopes, particularly deuterium (i.e. 2 Substitution with H or D) may provide certain therapeutic benefits resulting from increased metabolic stability, for example increased half-life in vivo or reduced dosage requirements. Thus, heavier isotopes may be preferred at any one position.

[0096] The stereochemical definitions and conventions used herein generally follow those of McGraw-Hill Dictionary of Chemical Terms (1984), edited by SP Parker, McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. The compounds disclosed herein may contain asymmetric or chiral centers and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds disclosed herein, including but not limited to diastereomers, enantiomers and atropisomers, as well as mixtures thereof, such as racemic mixtures, are part of the present invention. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule around its chiral center. The prefixes d and l, or (+) and (-), are used to designate the sign of rotation of plane polarized light by a compound, with (-) or l meaning that the compound is levorotatory. Compounds prefixed with (+) or d are dextrorotatory. For a given chemical structure, different optically active compounds are called stereoisomers, and are identical except that they are mirror images of one another. A specific stereoisomer is referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, and may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.

[0097] Depending on the selection of starting materials and procedures, the compounds may exist in one of the possible isomers depending on the number of asymmetric carbon atoms, or in mixtures thereof, such as racemic and diastereoisomeric mixtures. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds contain double bonds, the substituents may be in the E or Z configuration. When the compounds contain disubstituted cycloalkyl, the cycloalkyl substituents may have a cis or trans configuration.

[0098] Unless otherwise specified, the formulations described herein include all isomers thereof (enantiomers, diastereomers, atropisomers, and geometric (or conformational) isomers; for example, all (R)- and (S)-isomers, (Z) and (E) isomers around double bonds, and (Z) and (E) conformational isomers. Thus, single stereochemical isomers as well as enantiomeric, diastereomeric, or geometric isomeric mixtures (or conformational isomers) of the compounds of the invention are within the scope disclosed herein.

[0099] The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier. When tautomerization is possible (e.g., in solution), a chemical equilibrium of tautomers can be reached. For example, proton tautomers (also known as prototropic tautomers) include interconversions via the transfer of a proton, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions by rearrangement of some of the bond electrons. A specific example of keto-enol tautomerization is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerization is phenol-keto tautomerization. A specific example of phenol-keto tautomerization is pyridin-4-ol and pyridin-4(1H)-one tautomerization. Unless otherwise stated, all tautomeric forms of the compounds disclosed herein are within the scope of the invention.

[0100] The term "geometric isomers", also known as "cis-trans isomers", arises from the inability to freely rotate about double bonds (including olefinic double bonds, C=N double bonds and N=N double bonds) or single bonds of ring carbon atoms.

[0101] The term "subject" may be used interchangeably with "patient" in the present invention. The terms "subject" and "patient" refer to animals (e.g., birds such as chickens, quails, or turkeys, or mammals), particularly mammals including non-primates (e.g., cows, pigs, horses, sheep, rabbits, guinea pigs, rats, dogs, cats, and mice) and primates (e.g., monkeys, chimpanzees, and humans), more particularly humans. In one embodiment, the subject is a non-human animal, such as a farm animal (e.g., horses, cows, pigs, or sheep), or a pet (e.g., dog, cat, guinea pig, or rabbit). In some embodiments, "patient" refers to a human.

[0102] Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.

[0103] As used herein, the term "treat", "treating" or "treatment" of any disease or disorder refers, in one embodiment, to alleviating the disease or disorder (i.e., delaying, arresting or reducing the onset of the disease or at least one of its clinical symptoms). In another embodiment, "treat", "treating" or "treatment" refers to alleviating or ameliorating at least one physical parameter, including those that are not discernible by the patient. In yet another embodiment, "treat", "treating" or "treatment" refers to modulating the disease or disorder, either physically (e.g., stabilizing discernible symptoms), physiologically (e.g., stabilizing physical parameters), or both. In yet another embodiment, "treat", "treating" or "treatment" refers to preventing or delaying the onset or development or progression of the disease or disorder.

[0104] Description of the compounds of the present invention The present invention provides a class of compounds with good agonist activity for thyroid hormone beta receptor. Such compounds can be used in the manufacture of medicaments for treating non-alcoholic fatty liver disease, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes, metabolic disorders, glycogen storage disease type 1A, hypothyroidism, or thyroid cancer in a subject. The present invention also provides methods for preparing these compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds and compositions to prepare medicaments for the above-mentioned diseases in mammals, particularly humans. Compared with existing similar compounds, the compounds of the present invention not only have better pharmacological activity and selectivity, but also have better in vivo metabolic kinetic properties and in vivo pharmacodynamic properties. The preparation method of the compounds of the present invention is simple and easy, and the technical method is stable, making it suitable for industrial production. Therefore, the compounds provided by the present invention have better drug potential compared with existing similar compounds.

[0105] In more detail:

[0106] In one aspect, the present invention relates to a compound having formula (I) or a stereoisomer, geometric isomer, tautomer, N-oxide, solvate, metabolite, pharma- ceutically acceptable salt, or prodrug thereof:

[0107] [ka]

[0108] (In the formula, L, W, Y, M, E1, E2, E3, R 1 , R 3a , R 3b , R 3c and R 3d has the definition set forth herein).

[0109] In some embodiments, Y is -O-, -S-, -NR c -, -CR a R b -, -S(=O)2-, -S(=O)- or -C(=O)-, R a , R b and R c has the definition set forth herein.

[0110] In some embodiments, L is absent, -O-, -S-, -NR c -, -CR d R e -, -S(=O)2-, -S(=O)- or -C(=O)-, R c , R d and R e has the definition set forth herein.

[0111] In some embodiments, R a , R b , R c , R d and R e are independently H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl or C 1~6 It is haloalkoxy.

[0112] In some embodiments, R 3a , R 3b , R 3c and R 3d are independently H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Alkylthio, C 1~6 Alkylamino, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, Hydroxy C 1~6 Alkyl, Amino C 1~6 Alkyl or cyano C 1~6 It is an alkyl.

[0113] In some embodiments, M is -C(=O)-, -C(=S)-, -S(=O)2-, or -S(=O)-.

[0114] In some embodiments, E1 is N, CH, or CR z and R z has the definition set forth herein.

[0115] In some embodiments, E2 is N or CR 2 and R 2 has the definition described herein. Preferably, E2 is CR 2 and R 2 has the definition set forth herein.

[0116] In some embodiments, E3 is N or CR 3 and R 3 has the definition set forth herein.

[0117] In some embodiments, R z are deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -NH2, -SH, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, C 1~6 Alkoxy, C 2~6 Alkenyl, C 2~6 Alkynyl, Hydroxy C 1~6 Alkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkyl C 1~6 Alkyl, 3-8 membered heterocyclyl, (3-8 membered heterocyclyl)C 1~6 Alkyl, C 6~10 Aryl, C 6~10 Aryl C 1~6 Alkyl, 5-10 membered heteroaryl or (5-10 membered heteroaryl)C 1~6 It is an alkyl.

[0118] In some embodiments, R 2 and R3 are independently H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -NH2, -SH, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, C 1~6 Alkoxy, C 2~6 Alkenyl, C 2~6 Alkynyl, Hydroxy C 1~6 Alkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkyl C 1~6 Alkyl, 3-8 membered heterocyclyl, (3-8 membered heterocyclyl)C 1~6 Alkyl, C 6~10 Aryl, C 6~10 Aryl C 1~6 Alkyl, 5-10 membered heteroaryl or (5-10 membered heteroaryl)C 1~6 It is an alkyl.

[0119] In some embodiments, R 1 are H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -C(=O)NH2, -S(=O)2NH2, -OH, -NH2, -SH, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, -C(=O)-C 1~6 Alkoxy, -C(=O)-C 1~6 Alkylamino, -C(=O)-C 1~6 Alkyl, -S(=O)2-C 1~6 Alkyl, -S(=O)2-C 1~6 Alkylamino, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 5-8 membered heterocyclyl, C 6~10 aryl or 5-8 membered heteroaryl, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, -C(=O)-C 1~6 Alkoxy, -C(=O)-C1~6 Alkylamino, -C(=O)-C 1~6 Alkyl, -S(=O)2-C 1~6 Alkyl, -S(=O)2-C 1~6 Alkylamino, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~8 Cycloalkyl, 5-8 membered heterocyclyl, C 6~10 Each of the aryl and 5-8 membered heteroaryl is independently unsubstituted or substituted with deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -C(=O)NH2, -S(=O)2NH2, -SH, -OH, -NH2, =O, -C(=O)-C 1~6 Alkyl, -C(=O)-C 1~6 Alkoxy, C 1~6 Alkyl, C 1~6 Alkoxy, C 1~6 Haloalkyl or C 1~6 Substituted with 1, 2 or 3 substituents selected from haloalkoxy.

[0120] In some embodiments, W is -OCH2COOH, -NHC(=O)COOH, -NHCH2COOH,

[0121] [ka]

[0122] and R 4 and R 5 has the definition set forth herein.

[0123] In some embodiments, R 4 are H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, -C(=O)-C 1~6 Alkoxy, -C(=O)-C 1~6 Alkyl, -C(=O)-C 1~6 Alkylamino, -C(=O)NH2, -S(=O)2-C1~6 Alkyl, -S(=O)2-C 1~6 Alkylamino, C 1~6 Alkylamino, C 1~6 Alkoxy, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, Hydroxy C 1~6 Alkyl, Amino C 1~6 Alkyl, Carboxy C 1~6 Alkyl or cyano C 1~6 Alkyl, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, -C(=O)-C 1~6 Alkoxy, -C(=O)-C 1~6 Alkyl, -C(=O)-C 1~6 Alkylamino, -C(=O)NH2, -S(=O)2-C 1~6 Alkyl, -S(=O)2-C 1~6 Alkylamino, C 1~6 Alkylamino, C 1~6 Alkoxy, C 1~6 Haloalkyl, C 1~6 Haloalkoxy, Hydroxy C 1~6 Alkyl, Amino C 1~6 Alkyl, Carboxy C 1~6 Alkyl and Cyano C 1~6 Each alkyl is independently unsubstituted or substituted with deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, C 1~6 Alkyl, C 2~6 Alkenyl or C 2~6 alkynyl is substituted with 1, 2 or 3 substituents selected from alkynyl.

[0124] In some embodiments, R 5 is H, deuterium, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~6 Cycloalkyl, 5-6 membered heterocyclyl, C 6~10 It is aryl or 5- to 6-membered heteroaryl.

[0125] In some embodiments, R 3a , R 3b , R 3c and R 3d are independently H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylthio, C 1~4 Alkylamino, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, Hydroxy C 1~4 Alkyl, Amino C 1~4 Alkyl or cyano C 1~4 It is an alkyl.

[0126] In some embodiments, R 3a , R 3b , R 3c , and R 3d each is independently H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, NH2, -SH, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, methylthio, methylamino, -CF3, -CHF2, -CH2F, -CH2CF3, trifluoromethoxy, difluoromethoxy, hydroxymethyl, aminomethyl, or cyanomethyl.

[0127] In some embodiments, R a , R b , R c , R d and R e are independently H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, NH2, -SH, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl or C 1~4 It is haloalkoxy.

[0128] In some embodiments, R a , R b , R c , R d and R eeach is independently H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, NH2, -SH, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, -CF3, -CHF2, -CH2F, -CH2CF3, or trifluoromethoxy.

[0129] In some embodiments, R z are deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -NH2, -SH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkoxy, C 2~4 Alkenyl, C 2~4 Alkynyl, Hydroxy C 1~4 Alkyl, C 3~6 Cycloalkyl, C 3~6 Cycloalkyl C 1~3 Alkyl, 3-6 membered heterocyclyl, (3-6 membered heterocyclyl)C 1~3 Alkyl, C 6~10 Aryl, C 6~10 Aryl C 1~3 Alkyl, 5-6 membered heteroaryl or (5-6 membered heteroaryl)C 1~3 It is an alkyl.

[0130] In some embodiments, R z is deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -NH2, -SH, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, trifluoromethyl, difluoromethyl, trifluoromethoxy, difluoromethoxy, methoxy, ethoxy, n-propoxy, isopropoxy, C 2~4 Alkenyl, C 2~4 Alkynyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, C 3~6 Cycloalkyl, C 3~6 Cycloalkyl C 1~3 Alkyl, 5-6 membered heterocyclyl, (5-6 membered heterocyclyl)C 1~3It is alkyl, phenyl, phenylmethyl, phenylethyl, pyridyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyridylmethyl, pyridylethyl or pyrimidinylmethyl.

[0131] In some embodiments, R 2 and R 3 are independently H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -NH2, -SH, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkoxy, C 2~4 Alkenyl, C 2~4 Alkynyl, Hydroxy C 1~4 Alkyl, C 3~6 Cycloalkyl, C 3~6 Cycloalkyl C 1~3 Alkyl, 5-6 membered heterocyclyl, (5-6 membered heterocyclyl)C 1~3 Alkyl, C 6~10 Aryl, C 6~10 Aryl C 1~3 Alkyl, 5-6 membered heteroaryl or (5-6 membered heteroaryl)C 1~3 It is an alkyl.

[0132] In some embodiments, R 2 and R 3 each independently represents H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -NH2, -SH, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, trifluoromethyl, difluoromethyl, trifluoromethoxy, difluoromethoxy, methoxy, ethoxy, n-propoxy, isopropoxy, C 2~4 Alkenyl, C 2~4 Alkynyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, C 3~6 Cycloalkyl, C 3~6 Cycloalkyl C 1~3 Alkyl, 5-6 membered heterocyclyl, (5-6 membered heterocyclyl)C 1~3It is alkyl, phenyl, phenylmethyl, phenylethyl, pyridyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyridylmethyl, pyridylethyl or pyrimidinylmethyl.

[0133] In some embodiments, R 1 are H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -C(=O)NH2, -S(=O)2NH2, -OH, -NH2, -SH, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, -C(=O)-C 1~4 Alkoxy, -C(=O)-C 1~4 Alkylamino, -C(=O)-C 1~4 Alkyl, -S(=O)2-C 1~4 Alkyl, -S(=O)2-C 1~4 Alkylamino, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 Cycloalkyl, 5-6 membered heterocyclyl, C 6~10 aryl or 5-6 membered heterocyclyl, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, -C(=O)-C 1~4 Alkoxy, -C(=O)-C 1~4 Alkylamino, -C(=O)-C 1~4 Alkyl, -S(=O)2-C 1~4 Alkyl, -S(=O)2-C 1~4 Alkylamino, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 Cycloalkyl, 5-6 membered heterocyclyl, C 6~10 Each of the aryl and 5- to 6-membered heterocyclyl is independently unsubstituted or substituted with deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -C(=O)NH2, -S(=O)2NH2, -SH, -OH, -NH2, =O, -C(=O)-C 1~4 Alkyl, -C(=O)-C 1~4Alkoxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl or C 1~4 Substituted with 1, 2 or 3 substituents selected from haloalkoxy.

[0134] In some embodiments, R 1are H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -C(=O)NH2, -S(=O)2NH2, -OH, -NH2, -SH, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, -CF3, -CHF2, -CH2F, -CH2CF3, trifluoromethoxy, difluoromethoxy, -C(=O)-OCH3, -C(=O)-OCH2CH3, -C(=O)-OCH(CH3)2, -C(=O)-OCH2CH2C H3, -C(=O)-O(CH2)3CH3, -C(=O)-OCH2CH(CH3)2, -C(=O)-NHCH3, -C(=O)-N(CH3)2, -C(=O)-CH3, -C(=O)-CH2CH3, -S(=O)2-CH3, -S(=O)2-CH2CH3, -S(=O)2-CH2CH2CH3, -S(=O)2-NHCH3, -S(=O)2-N(CH3)2, -CH=CH2, -CH2CH=CH2, -CH=CHCH3, -C≡CH, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl , imidazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydropyrrolyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydropyrazinyl, tetrahydropyridazinyl, dihydropyrrolyl, dihydrofuranyl, dihydropyranyl, dihydrothienyl, dihydropyridyl, dihydropyrimidinyl, dihydropyrazinyl, dihydropyridazinyl, phenyl, naphthyl, furyl, thienyl, imidazolyl, pyrazolyl, pyrimidinyl , pyridyl, pyrrolyl, pyrazinyl, pyridazinyl, thiazolyl, tetrazolyl, triazolyl, isoxazolyl, isothiazolyl, oxadiazolyl or oxazolyl, and is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, -CHF2, -CH2F, -CH2CF3, difluoromethoxy, -C(=O)-OCH3, -C(=O)-OCH2CH3, -C(=O)-OCH(CH3)2, -C(=O)-OCH2CH2CH3,-C(=O)-O(CH2)3CH3, -C(=O)-OCH2CH(CH3)2, -C(=O)-NHCH3, -C(=O)-N(CH3)2, -C(=O)-CH3, -C(=O)-CH2CH3, -S(=O)2-CH, 3、 -S(=O)2-CH2CH3, -S(=O)2-CH2CH2CH3, -S(=O)2-NHCH3, -S(=O)2-N(CH3)2, -CH=CH2, -CH2CH=CH2, -CH=CHCH3, -C≡CH, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydropyrrolyl, tetrahydrofuranyl, Tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydropyrazinyl, tetrahydropyridazinyl, dihydropyrrolyl, dihydrofuranyl, dihydropyranyl, dihydrothienyl, dihydropyridyl, dihydropyrimidinyl, dihydropyrazinyl, dihydropyridazinyl, phenyl, naphthyl, furyl, thienyl, imidazolyl, pyrazolyl, pyrimidinyl, pyridyl, pyrrolyl, pyrazinyl, pyri Each of dazinyl, thiazolyl, tetrazolyl, triazolyl, isoxazolyl, isothiazolyl, oxadiazolyl and oxazolyl is independently unsubstituted or substituted with deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -C(=O)NH2, -S(=O)2NH2, -SH, -OH, -NH2, =O, -C(=O)-CH3, -C(=O)-CH2CH3, -C(=O)-OCH3, -C(=O)-OCH2CH3, -C(=O)-OC Substituted by 1, 2 or 3 substituents selected from H(CH3)2, -C(=O)-OCH2CH2CH3, -C(=O)-O(CH2)3CH3, -C(=O)-OCH2CH(CH3)2, -C(=O)-CH3, -C(=O)-CH2CH3, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, -CF3, -CHF2, -CH2CF3, trifluoromethoxy or difluoromethoxy.

[0135] In some embodiments, R 4are H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, -C(=O)-C 1~4 Alkoxy, -C(=O)-C 1~4 Alkyl, -C(=O)-C 1~4 Alkylamino, -C(=O)NH2, -S(=O)2-C 1~4 Alkyl, -S(=O)2-C 1~4 Alkylamino, C 1~4 Alkylamino, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, Hydroxy C 1~4 Alkyl, Amino C 1~4 Alkyl, Carboxy C 1~4 Alkyl or cyano C 1~4 Alkyl, C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, -C(=O)-C 1~4 Alkoxy, -C(=O)-C 1~4 Alkyl, -C(=O)-C 1~4 Alkylamino, -C(=O)NH2, -S(=O)2-C 1~4 Alkyl, -S(=O)2-C 1~4 Alkylamino, C 1~4 Alkylamino, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, Hydroxy C 1~4 Alkyl, Amino C 1~4 Alkyl, Carboxy C 1~4 Alkyl or cyano C 1~4 Each alkyl is independently unsubstituted or substituted with deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, C 1~6 Alkyl, C 2~6 Alkenyl or C 2~6 alkynyl is substituted with 1, 2 or 3 substituents selected from alkynyl.

[0136] In some embodiments, R 4 are H, deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, methyl, ethyl, n-propyl, isopropyl, -CH=CH2, -CH2CH=CH2, -CH=CHCH3, -C≡CH, -C(=O)-OCH3, -C(=O)-OCH2CH3, -C(=O)-OCH(CH3)2, -C(=O)-OCH2CH2CH3, -C(=O)-O(CH2)3CH3, -C(=O)-OCH2CH(CH3)2, -C(=O)-C H3, -C(=O)-CH2CH3, -C(=O)-NHCH3, -C(=O)-N(CH3)2, -C(=O)NH2, -S(=O)2-CH3, -S(=O)2-CH2CH3, -S(=O)2-NHCH3, methylamino, ethylamino, methoxy, ethoxy, -CF3, -CHF2, -CH2F, -CH2CF3, -CH2CHF2, trifluoromethoxy, difluoromethoxy, hydroxymethyl, aminomethyl, carboxymethyl or cyanomethyl. , methyl, ethyl, n-propyl, isopropyl, -CH=CH2, -CH2CH=CH2, -CH=CHCH3, -C≡CH, -C(=O)-OCH3, -C(=O)-OCH2CH3, -C(=O)-OCH(CH3)2, -C(=O)-OCH2CH2CH3, -C(=O)-O(CH2)3CH3, -C(=O)-OCH2CH(CH3)2, -C(=O)-CH3, -C(=O)-CH2CH3, -C(=O)-NHCH3, -C(=O)-N(CH3)2 , -C(=O)NH2, S(=O)2-CH3, -S(=O)2-CH2CH3, -S(=O)2-NHCH3, methylamino, ethylamino, methoxy, ethoxy, -CHF2, -CH2F, -CH2CF3, -CH2CHF2, difluoromethoxy, hydroxymethyl, aminomethyl, carboxymethyl and cyanomethyl are each independently unsubstituted or substituted with deuterium, F, Cl, Br, I, -CN, -NO2, -COOH, -OH, -NH2, -SH, C 1~6 Alkyl, C 2~6 Alkenyl or C 2~6 alkynyl is substituted with 1, 2 or 3 substituents selected from alkynyl.

[0137] In some embodiments, R 5 H, deuterium, C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 3~6 Cycloalkyl, 5-6 membered heterocyclyl, C 6~10 It is aryl or 5- to 6-membered heteroaryl.

[0138] In some embodiments, R 5 is H, deuterium, methyl, ethyl, n-propyl, isopropyl, tert-butyl, -CH=CH2, -CH2CH=CH2, -CH=CHCH3, -C≡CH, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 5- to 6-membered heterocyclyl, phenyl, naphthyl, or 5- to 6-membered heteroaryl.

[0139] In another aspect, the invention relates to one of the following structures, or a stereoisomer, geometric isomer, tautomer, N-oxide, solvate, metabolite, pharma- ceutically acceptable salt, or prodrug thereof:

[0140] [ka]

[0141] [ka]

[0142] [ka]

[0143] [ka]

[0144] [ka]

[0145] In another aspect, provided herein are pharmaceutical compositions comprising the compounds disclosed herein.

[0146] In some embodiments, the pharmaceutical compositions disclosed herein optionally further comprise any one or combination of a pharma- ceutically acceptable carrier, excipient, adjuvant, vehicle.

[0147] In another aspect, the invention relates to the use of a compound of the invention or a pharmaceutical composition of the invention in the manufacture of a medicament for agonizing a thyroid hormone receptor or for preventing, treating or ameliorating a disease mediated by agonist thyroid hormone in a subject.

[0148] In another aspect, provided herein is a method for agonizing thyroid hormone receptors or preventing, treating or alleviating diseases mediated by thyroid hormone receptors, comprising administering to a subject in need thereof a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein. Furthermore, the compounds provided by the present invention or pharmaceutical compositions thereof may be co-administered with other treatments or therapeutic agents. The mode of administration may be simultaneous, sequential or at a specific time interval.

[0149] In another aspect, the invention relates to a compound or pharmaceutical composition of the invention for use in agonizing the thyroid hormone receptor or for preventing, treating or ameliorating a disease mediated by the thyroid hormone receptor.

[0150] In some embodiments, the thyroid receptor mediated disease of the present invention is a disease mediated by an agonist thyroid receptor.

[0151] In some embodiments, the thyroid hormone receptor of the present invention is a thyroid hormone beta receptor.

[0152] In some embodiments, the disease mediated by the thyroid hormone receptor of the present invention is non-alcoholic fatty liver disease, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes, metabolic disorders, glycogen storage disease type 1A, hypothyroidism, or thyroid cancer.

[0153] In some embodiments, the non-alcoholic fatty liver disease of the present invention is non-alcoholic simple fatty liver, non-alcoholic steatohepatitis, cryptogenic cirrhosis or primary liver cancer.

[0154] In some embodiments, the metabolic disorder according to the present invention comprises a lipid metabolism disorder or a glucose metabolism disorder.

[0155] The dosage of the compound or pharmaceutical composition required to effect the treatment, prevention or delay generally depends on the specific compound administered, the patient, the specific disease or condition and its severity, the route and frequency of administration, etc., and must be determined by the attending physician based on the specific situation. For example, when the compound or pharmaceutical composition provided by the present invention is administered by intravenous route, it may be administered once a week, or even at longer intervals.

[0156] In some embodiments, salts refer to pharma- ceutically acceptable salts. The phrase "pharma- ceutically acceptable" means that a substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or with the mammal being treated therewith.

[0157] The compounds of the present invention also include other salts of such compounds, which are not necessarily pharma-ceutically acceptable salts, and which may be used to prepare and / or purify the compounds of the present invention and / or to isolate enantiomeric intermediates of the compounds of the present invention.

[0158] Furthermore, the compounds of the present invention, including their salts, may be obtained in the form of their hydrates or include other solvents used for their crystallization. The compounds of the present invention may inherently or by design form solvates with pharma-ceutically acceptable solvents, including water. Thus, the present invention is intended to encompass both solvated and unsolvated forms.

[0159] Pharmaceutical Compositions and Preparation and Administration of Compounds of the Invention The present invention relates to a pharmaceutical composition comprising a compound of the present invention or a compound of the structure shown in the Examples, or a stereoisomer, geometric isomer, tautomer, N-oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof. The pharmaceutical composition further comprises at least one or a combination of a pharmaceutically acceptable carrier, excipient, adjuvant, vehicle, and optionally other therapeutic and / or prophylactic ingredients. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of the present invention and at least one pharmaceutically acceptable carrier, excipient, adjuvant, or vehicle. The amount of the compound in the pharmaceutical composition of the present invention is effective to detectably activate thyroid hormone beta receptor in a biological sample or a patient.

[0160] Pharmaceutically acceptable carriers may contain inactive ingredients that do not excessively inhibit the biological activity of the compound. Pharmaceutically acceptable carriers should be biocompatible, e.g., non-toxic, non-inflammatory, non-immunogenic, or have no other adverse reactions or side effects after administration to patients. Standard pharmaceutical techniques may be used.

[0161] As noted above, the pharmaceutical or pharma- ceutically acceptable compositions of the present invention further comprise a pharma- ceutically acceptable carrier, excipient, adjuvant or vehicle, which as used herein includes any solvent, diluent, liquid excipient, dispersing agent, suspending agent, surfactant, isotonicity agent, thickening agent, emulsifying agent, preservative, solid binder, lubricant, and the like, appropriate for the particular dosage form desired. Remington: The Science and Practice of Pharmacy, 21st ed., 2005, Lippincott Williams & Wilkins, Philadelphia, and Swarbrick et al., Encyclopedia of Pharmaceutical Technology, eds., 1988-1999, Marcel Dekker, New York, both of which are incorporated herein by reference in their entireties, disclose various carriers used in formulating pharma- ceutically acceptable compositions and known techniques for their preparation. Except insofar as any conventional carrier medium is incompatible with the compounds disclosed herein, such as by producing undesirable biological effects or otherwise interacting in a deleterious manner with any other components of the pharma-ceutically acceptable compositions, its use is contemplated within the scope of the present invention.

[0162] Some examples of materials that can function as pharma- ceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as Tween 80, phosphoric acid, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, salts or electrolytes such as water, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, methylcellulose, hydroxypropylmethylcellulose, wool fat, sugars such as lactose, glucose, and sucrose, starches such as corn starch and potato starch, cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate, powdered tragacanth, wheat Excipients such as sprouts, gelatin, talc, cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar, buffers such as magnesium hydroxide and aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate; and further, coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants may also be present in the composition according to the judgment of the formulator.

[0163] The pharmaceutical composition of the present invention may be administered directly or in the form of a pharmaceutical composition or drug product with suitable carriers or excipients known in the art. The treatment method of the present invention may include administering the effective compound of the present invention to an individual in need. In some embodiments, the individual is a mammalian individual, and in other embodiments, the individual is a human individual.

[0164] The effective amount of the compound, pharmaceutical composition or drug of the present invention can be easily determined by routine testing, and the most effective and convenient administration route and the most suitable formulation can also be determined by routine testing.

[0165] The compounds or compositions of the present invention may be administered by any suitable means, and the above-mentioned compounds and pharma- ceutical acceptable compositions may be administered to humans or other animals orally, rectally, parenterally, intravesically, intravaginally, intraperitoneally, topically (as a powder, ointment or drops), or by nasal spray, etc., depending on the severity of the disease.

[0166] Liquid dosage forms for oral administration include, but are not limited to, pharma- ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. Liquid dosage forms may contain, in addition to the active ingredient, inert diluents commonly used in the art, such as water or other solvents, solubilizing and emulsifying agents, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed, peanut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, and mixtures thereof. In addition to inert diluents, oral compositions may also contain adjuvants, such as wetting agents, emulsifying and suspending agents, sweeteners, flavoring agents, and perfumes.

[0167] Injectable preparations can be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents, such as sterile injectable water or oil suspensions. Sterile injectable preparations can also be sterile injectable solutions, suspensions or emulsions in non-toxic parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally used as solvents or suspending media. For this purpose, any non-irritating fixed oil can be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectable preparations.

[0168] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water, or other sterile injectable medium prior to use.

[0169] In order to prolong the effect of the compounds or compositions described herein, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This can be accomplished by using a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of a drug will in turn depend on its rate of dissolution, which may in turn depend on crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolic acid. Depending on the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

[0170] Compositions for rectal or vaginal administration are particularly suppositories which can be prepared by mixing a compound described herein with a suitable non-irritating excipient or carrier such as cocoa butter, polyethylene glycol or a suppository wax which is solid at room temperature but liquid at body temperature and therefore melts in the rectum or vaginal cavity to release the active compound.

[0171] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one pharma- ceutically acceptable inert excipient or carrier, such as sodium citrate or dicalcium phosphate, and / or (a) fillers or swelling agents, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) adhesives, such as carboxymethylcellulose, alginates, gelatin, polyethylene pyrrol ketone, sucrose, and gum arabic; (c) humectants, such as glycerol; (d) disintegrants, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (e) blocking solutions, such as paraffin; (f) absorption enhancers, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glycerol monostearate; (h) absorbents, such as kaolin and bentonite; (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents.

[0172] Solid compositions of a similar type can also be utilized as fillers in soft and hard-filled gelatin capsules, using such excipients as lactose or milk sugar and high molecular weight polyethylene glycols. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical compounding art. These can optionally contain opacifying agents, and can optionally be of such composition that they release the active ingredient solely or preferentially in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0173] The active compound may also be in the form of a microseal using one or more of the above-mentioned excipients. In such solid dosage forms, the active compound may be mixed with at least one inert diluent, such as sucrose, lactose, or starch. In general, this dosage form may also contain additional substances in addition to the inert diluent, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. They may optionally contain opacifying agents, and may also be of such composition that they release the active ingredient singly or preferentially in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0174] Dosage forms for topical or transdermal administration of the compounds of the present invention include ointments, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The active ingredient is mixed under sterile conditions with a pharma- ceutically acceptable carrier and any needed preservatives or buffers, as appropriate. Ophthalmic formulations, ear drops, and eye drops are also contemplated within the scope of the present invention. In addition, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of the compound to the body. Such dosage forms may be made by dissolving or dispensing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound into the skin. The rate can be controlled by providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel.

[0175] The compositions described herein can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, vaginally, or via an implanted reservoir. As used herein, the term "parenteral" includes, but is not limited to, subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. In particular, the compositions are administered orally, intraperitoneally, or intravenously.

[0176] Sterile injectable forms of the compositions described herein may be aqueous or oily suspensions. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable vehicles and solvents that may be used include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally used as solvents or suspending media. For this purpose, any non-irritating fixed oil may be used, including synthetic mono- or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectable preparations, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, in particular in their polyoxyethylated form. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as carboxymethylcellulose or similar dispersants, that are commonly used in the formulation of pharmaceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifiers, or bioavailability enhancers commonly used in the manufacture of pharma- ceutically acceptable solid, liquid, or other dosage forms, can also be used for formulation purposes.

[0177] The pharmaceutical compositions described herein can be orally administered in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions or liquids.For tablets for oral use, commonly used carriers include but are not limited to lactose and corn starch.Lubricants such as magnesium stearate are also typically added.For oral administration in capsule form, useful diluents include lactose and dried corn starch.When aqueous suspension is required for oral use, active ingredient is combined with emulsifying and suspending agents.If desired, certain sweeteners, flavors or colorants can also be added.

[0178] Alternatively, the pharmaceutical compositions described herein can be administered in the form of suppositories for rectal administration. These can be prepared by mixing the drug with a suitable non-irritating excipient. Such materials include cocoa butter, beeswax, and polyethylene glycol.

[0179] The pharmaceutical compositions described herein can be administered topically, particularly when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[0180] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topical transdermal patches can also be employed.

[0181] For topical application, the pharmaceutical composition can be formulated into a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers.Carrier compounds for topical administration of the present invention include, but are not limited to, mineral oil, petrolatum oil, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax, and water.Alternatively, the pharmaceutical composition can be formulated into a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more pharma- ceutically acceptable carriers.Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.

[0182] For ophthalmic use, the pharmaceutical composition may be formulated as a micronized suspension in isotonic, pH-adjusted, sterile saline, or in particular as a solution in isotonic, pH-adjusted, sterile saline, with or without a preservative, such as benzylalkonium chloride. Alternatively, for ophthalmic use, the pharmaceutical composition may be formulated in an ointment, such as petrolatum.

[0183] Pharmaceutical compositions may also be administered by nasal aerosol or inhalation.Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as a solution in saline employing benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons and / or other conventional solubilizing or dispersing agents.

[0184] Uses of the Compounds and Pharmaceutical Compositions The compounds or pharmaceutical compositions provided by the present invention may be used in the manufacture of a medicament for agonizing the thyroid hormone receptor or for preventing, treating or ameliorating a disease modulated by the thyroid hormone receptor.

[0185] The compounds or pharmaceutical compositions provided by the present invention may be used to agonize the thyroid hormone receptor or to prevent, treat or ameliorate diseases modulated by the thyroid hormone receptor.

[0186] The present invention provides a method for agonizing thyroid hormone receptors or preventing, treating or alleviating diseases modulated by thyroid hormone receptors, comprising administering to a subject in need thereof a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein. Furthermore, the compounds provided by the present invention or pharmaceutical compositions thereof may be co-administered with other treatments or therapeutic agents. The mode of administration may be simultaneous, sequential or at a specific time interval.

[0187] A thyroid hormone receptor modulated disease of the present invention is a disease mediated by an agonist thyroid hormone receptor.

[0188] The thyroid hormone receptor of the present invention is a thyroid hormone β receptor.

[0189] The diseases of the present invention are non-alcoholic fatty liver disease, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes, metabolic disorders, glycogen storage disease type 1A, hypothyroidism, or thyroid cancer, and the non-alcoholic fatty liver disease is non-alcoholic simple fatty liver, non-alcoholic steatohepatitis, cryptogenic liver cirrhosis, or primary liver cancer, and the metabolic disorder includes lipid metabolism disorder or glucose metabolism disorder.

[0190] In addition to being useful for human treatment, these compounds are also useful for veterinary treatment of animals, such as companion animals, exotic animals and livestock animals, including mammals, rodents, etc. In other embodiments, animals disclosed herein include horses, dogs and cats. As used herein, the compounds disclosed herein include pharmaceutically acceptable derivatives thereof.

[0191] An "effective amount" or "effective dose" of a compound or pharma- ceutically acceptable composition is an amount effective to treat or lessen the severity of one or more of the disorders mentioned above. The compounds and pharma- ceutical acceptable compositions are effectively administered over a fairly wide dose range. For example, the daily dose is about 0.1 mg to 1000 mg per person, and the compound or pharma- ceutical acceptable composition can be administered in a single dose or multiple divided doses per day. The compounds and compositions may be administered in any amount and using any route of administration effective to treat or lessen the severity or severity of a disorder or disease according to the methods disclosed herein. The exact amount required will vary from subject to subject depending on the species, age, and general condition of the subject, the severity of the infection, the particular drug, its mode of administration, and the like. The compounds or compositions may be administered with one or more other therapeutic agents as discussed above.

[0192] General synthesis and determination methods To illustrate the present invention, the following examples are given, but it should be understood that the present invention is not limited to these embodiments, which merely provide a method for practicing the present invention.

[0193] In the present invention, when the chemical name of a compound does not correspond to the corresponding structure, the compound is characterized by the corresponding structure.

[0194] In general, the compounds disclosed herein can be prepared by the methods described herein, and alternatives are as defined herein unless further stated. The following non-limiting schemes and examples are presented to further illustrate the present invention.

[0195] Those skilled in the art will recognize that the chemical reactions described can be easily adapted to prepare some other compounds disclosed herein, and alternative methods for preparing the compounds disclosed herein are considered to be within the scope disclosed herein. For example, the synthesis of unexemplified compounds according to the present invention can be successfully carried out by modifications that are obvious to those skilled in the art, such as by appropriately protecting interfering groups, utilizing other suitable reagents known in the art other than those described, and / or by making routine modifications to reaction conditions. Alternatively, it will be recognized that other reactions disclosed herein or known in the art have applicability for preparing other compounds disclosed herein.

[0196] The structure of a compound can be determined by nuclear magnetic resonance (e.g. 1 H-NMR, 13 C-NMR and / or 19 The identity was determined by F-NMR. 1 H-NMR, 13 C-NMR and 19F-NMR chemical shifts (δ) are expressed in ppm (10 -6 ) was recorded. 1 H-NMR, 13 C-NMR and 19F-NMR measurements were performed on a Bruker Ultrashield-400 and a Bruker Avance III HD 600 nuclear magnetic resonance spectrometer, respectively, using deuterated chloroform (CDCl3), deuterated methanol (CD3OD and MeOH-d4), or deuterated DMSO (DMSO-d6) as solvents. TMS (0 ppm) or chloroform (7.25 ppm) were the reference standards. When reporting peak multiplicities, the following abbreviations were used: s (singlet), d (doublet), t (triplet), m (multiplet), br (broad), dd (doublet of doublets), dt (doublet of triplets), td (triplet of doublets), brs (broad singlet). When given, coupling constants J were reported in Hertz (Hz).

[0197] A Novasep Pump 250 high performance liquid chromatograph is typically used for the preparation, purification or separation.

[0198] LC-MS spectra were determined on an Agilen-6120 quadrupole LC / MS mass spectrometer.

[0199] The silica gel used in column chromatography was generally 300-400 mesh silica gel from Qingdao Ocean Chemical Factory.

[0200] The starting materials of the present invention are known or can be purchased from Shanghai Accela, Energy, J&K, Alfa, etc., or prepared by conventional synthetic methods in the prior art.

[0201] The term "nitrogen atmosphere" refers to an atmosphere in which the reaction flask is equipped with a balloon or a stainless steel autoclave filled with approximately 1 L of nitrogen.

[0202] The term "hydrogen atmosphere" refers to an atmosphere in which the reaction flask is equipped with a balloon or a stainless steel autoclave filled with approximately 1 L of hydrogen.

[0203] Unless otherwise stated, the solutions used in the examples disclosed herein were aqueous solutions.

[0204] Unless otherwise stated, reaction temperature was room temperature.

[0205] Room temperature was 20°C to 40°C unless otherwise stated.

[0206] The reaction process in the examples was monitored by thin layer chromatography (TLC). The solvent system for developing the TLC plate included dichloromethane and methanol, dichloromethane and ethyl acetate, petroleum ether and ethyl acetate. The volume ratio of the solvents in the solvent system was adjusted according to the polarity of the compounds.

[0207] The elution system of the column chromatography included A: petroleum ether and ethyl acetate, B: dichloromethane and ethyl acetate, C: dichloromethane and methanol. The volume ratio of the solvents in the elution system was adjusted according to the polarity of the compounds, and in some cases was also adjusted by adding a basic agent such as aqueous ammonia or an acidic agent such as acetic acid.

[0208] HPLC refers to high performance liquid chromatography.

[0209] HPLC was determined on an Agilent 1260 high performance liquid chromatography analyzer (chromatographic column: Agilent ZORBAX Eclipse Plus C18 4.6 mm × 150 mm, 3.5 μm);

[0210] HPLC test conditions: run time was 25 minutes (min); column temperature was 35°C; detection was performed at wavelengths of 210 nm and 245 nm using a PDA detector;

[0211] Mobile phase: Phase A: 0.05% phosphoric acid solution; Phase B: acetonitrile; Flow rate: 1.0 ml / min;

[0212] The mobile phase gradient is shown in Table A.

[0213] [Table 1]

[0214] The LC / MS / MS system used for the bioanalytical studies included an Agilent 1200 series vacuum degassing furnace, a binary pump, a well-plate autosampler, a thermostated column compartment, and an Agilent G6430 triple quadrupole mass spectrometer equipped with an electrospray ionization (ESI) source. Quantitative analysis was performed using MRM mode. The parameters of the MRM transitions are given in Table B (Table 2).

[0215] [Table 2]

[0216] An Agilent XDB-C18, 2.1×30 mm, 3.5 μM column was used for the analysis. 5 μL of sample was injected. Analytical conditions: the mobile phase was 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B). The flow rate was 0.4 mL / min. The gradient of the mobile phase is shown in Table C.

[0217] [Table 3]

[0218] Low-resolution mass spectral (MS) data were determined on an Agilent 6120 quadrupole HPLC-MS analyzer equipped with an Agilent Zorbax SB-C18 (2.1 × 30 mm, 3.5 μm). The flow rate was 0.6 mL / min; the mobile phase consisted of a combination of A (0.1% formic acid in CH3CN) and B (0.1% formic acid in HO) in gradient mode (5%–95%), using ESI mode, and HPLC peaks were recorded at 210 nm / 254 nm with UV-Vis detection.

[0219] [Table 4]

[0220] General synthetic procedure Exemplary synthetic steps for preparing the disclosed compounds of the present invention are shown in the following synthetic scheme: Unless otherwise specified, X is F, Cl, Br or I, and each of L, E1, E2, E3, R 3a , R 3d and R 1 has the definition as described in the present invention. Synthetic Scheme 1:

[0221] [ka]

[0222] Compounds having formula (IA) are those having the formula R 4a is -CN or -CF3, the compound (Ia) can be prepared by the general synthesis method described in the synthesis scheme 1. First, compound (Ia) is reacted with compound (Ib) under alkaline conditions (potassium carbonate, etc.) to obtain compound (Ic), compound (Ic) is subjected to nitro reduction reaction to obtain compound (Id), compound (Id) is subjected to aminodiazotization reaction, and then reacted with compound (Ie) to obtain compound (If), and compound (If) is ring-closed under alkaline conditions (potassium acetate, etc.) to obtain the target compound (IA). Synthetic Scheme 2:

[0223] [ka]

[0224] The intermediate having the formula (Id) can also be prepared by the general synthesis method described in the synthesis scheme 2, in which each PG1 and PG2 are independently an amino protecting group, or PG1 and PG2 are bonded to the N atom to form a 5-10 membered heterocyclyl or a 5-10 membered heteroaryl together, the 5-10 membered heterocyclyl or the 5-10 membered heteroaryl can protect the amino group, and LG is a leaving group. First, compound (Ig) is reacted with compound (Ib) under alkaline conditions (such as potassium carbonate) to obtain compound (Ih), compound (Ih) is subjected to a nitro reduction reaction to obtain compound (Ii), compound (Ii) is protected by an amino group to obtain compound (Ij), compound (Ij) is reacted with compound (Ik) to obtain compound (Il), and compound (Il) is deprotected from the amino group to obtain the intermediate having the formula (Id). Synthetic Scheme 3:

[0225] [ka]

[0226] The intermediate having formula (Id) can also be prepared by the general synthetic method described in Synthesis Scheme 3, where LG is a leaving group. First, compound (Im) is reacted with compound (Ik) to obtain compound (In), which can then be deprotected from the amino group to obtain the intermediate having formula (Id). Synthetic Scheme 4:

[0227] [ka]

[0228] The intermediate having formula (Im) can also be prepared by the general synthetic method described in synthetic scheme 4, where X is a halogen. First, compound (Io) is reacted with compound (Ib) under alkaline conditions (such as potassium carbonate) to obtain compound (Iq), which is then demethylated to obtain compound (Ih), which is then subjected to a nitro reduction reaction to obtain compound (Ii), which is then protected by an amino group to obtain compound (Im). Synthetic Scheme 5:

[0229] [ka]

[0230] The intermediate having formula (Id) can also be prepared by the general synthetic method described in Synthesis Scheme 5, where LG is a leaving group. First, compound (Ih) can be reacted with compound (Ik) to obtain compound (Ir), which can then be deprotected from the amino group to obtain the intermediate having formula (Id). Synthetic Scheme 6:

[0231] [ka]

[0232] The intermediate having formula (Ih) can also be prepared by the general synthetic method described in Synthetic Scheme 6. First, compound (Is) can be reacted with compound (Ib) under alkaline conditions (such as potassium carbonate) to give compound (It), which can then be hydrolyzed to give compound (Ih). Synthetic Scheme 7:

[0233] [ka]

[0234] Compounds having the formula (IB) are those having the formula R 0is alkoxy, -OH or -NH2, it can be prepared by the general synthetic method described in Synthesis Scheme 4. Compound (Iu) can be reacted under acidic conditions (concentrated hydrochloric acid, etc.) to obtain compound (IB). EXAMPLES

[0235] Example 1 2-[4-[(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]-3,5-dichlorophenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 1)

[0236] [ka]

[0237] Step 1) 2-Fluoro-5-(methoxymethoxy)pyridine 1b At 0° C., sodium hydride (1.1 g, 28 mmol, 60% by weight) was added to anhydrous tetrahydrofuran (10 mL), then 6-fluoropyridin-3-ol 1a (2.0 g, 18 mmol) was added, then chloromethyl methyl ether (1.6 mL, 21 mmol) was added dropwise to the mixture, and the mixture was reacted for 8 hours at 0° C. The resulting mixture was quenched with water (50 mL), extracted with ethyl acetate (100 mL), and the organic phase was washed with saturated sodium chloride solution (50 mL×3), then dried over anhydrous sodium sulfate, and concentrated by suction filtration to obtain the title compound 1b (2.3 g, 83% yield) as a colorless oil.

[0238] Step 2) 2-Benzyloxy-5-(methoxymethoxy)pyridine 1c Benzyl alcohol (0.40 mL) and 2-fluoro-5-(methoxymethoxy)pyridine 1b (0.50 g, 3.2 mmol) were added to a solution of sodium hydride (0.19 g, 4.8 mmol, 60% by mass) in N,N-dimethylformamide (8 mL), and the mixture was reacted at room temperature for 2 hours. The resulting mixture was quenched with water (10 mL), extracted with ethyl acetate (20 mL x 3), and the combined organic phase was washed with saturated sodium chloride solution (20 mL), then dried over anhydrous sodium sulfate and concentrated by suction filtration. The resulting residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume) = 9 / 1] to obtain the title compound 1c (0.55 g, 70% yield) as a colorless liquid. 1 H NMR (400 MHz, CDCl3) δ (ppm) 8.01 (d, J = 2.9 Hz, 1H), 7.49 (d, J = 7.3 Hz, 2H), 7.38 (ddt, J = 18.8, 14.5, 7.2 Hz, 4H), 6.79 (d, J = 8.9 Hz, 1H), 5.37 (s, 2H), 5.13 (s, 2H), 3.52 (s, 3H).

[0239] Step 3) 5-(methoxymethoxy)pyridin-2(1H)-one 1d 2-Benzyloxy-5-(methoxymethoxy)pyridine 1c (0.50 g, 2.0 mmol) was dissolved in methanol (10 mL) and then 10% palladium on carbon (50 mg) was added. The mixture was purged with H2 and hydrogenated for 40 min. The resulting mixture was filtered and the filtrate was concentrated to give the title compound 1d (0.31 g, 98% yield) as an off-white solid. 1 H NMR (400 MHz, CDCl3) δ (ppm) 7.36 (dd, J = 9.7, 3.1 Hz, 1H), 7.27 (t, J = 5.2 Hz, 1H), 6.55 (d, J = 9.7 Hz, 1H), 4.99 (s, 2H), 3.47 (s, 3H).

[0240] Step 4) 1-Benzyl-5-(methoxymethoxy)pyridin-2(1H)-one 1e 5-(Methoxymethoxy)pyridin-2(1H)-one 1d (0.10 g, 0.64 mmol) was added to a solution of sodium hydride (52 mg, 1.3 mmol, 60% by mass) in N,N-dimethylformamide (5 mL), then benzyl bromide (0.10 mL, 0.84 mmol) was added dropwise, and the mixture was reacted at room temperature for 3 hours. The resulting mixture was quenched with water (10 mL), extracted with ethyl acetate (20 mL x 3), and the combined organic phase was washed with saturated sodium chloride solution (20 mL), then dried over anhydrous sodium sulfate and concentrated by suction filtration. The resulting residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume) = 1 / 2] to give the title compound 1e (0.11 g, 70% yield) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ (ppm) 7.29 (dt, J = 12.3, 6.9 Hz, 5H), 7.20 (dd, J = 9.8, 1.4 Hz, 1H), 7.08 (d, J = 2.5 Hz, 1H), 6.54 (d, J = 9.8 Hz, 1H), 5.07 (s, 2H), 4.89 (d, J = 1.1 Hz, 2H), 3.39 (dd, J = 2.6, 1.3 Hz, 3H).

[0241] Step 5) 1-Benzyl-5-hydroxy-pyridin-2(1H)-one 1f Bromotrimethylsilane (0.82 mL, 6.1 mmol) was added to a solution of 1-benzyl-5-(methoxymethoxy)pyridin-2(1H)-one 1e (0.10 g, 0.41 mmol) in dichloromethane (5 mL), and the mixture was reacted at room temperature for 30 minutes. The reaction solution was concentrated to give the title compound 1f (82 mg, 100% yield) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ (ppm) 7.93-7.67 (m, 2H), 7.33 (d, J = 14.4 Hz, 5H), 7.28 (t, J = 5.0 Hz, 1H), 5.39 (d, J = 2.8 Hz, 2H).

[0242] Step 6) 1-benzyl-5-(2,6-dichloro-4-nitro-phenoxy)-pyridin-2(1H)-one 1g 1-Benzyl-5-hydroxy-pyridin-2(1H)-one 1f (1.2 g, 6.0 mmol), potassium carbonate (2.5 g, 18 mmol) and 1,3-dichloro-2-iodo-5-nitrobenzene (1.9 g, 6.0 mmol) were dissolved in N,N-dimethylformamide (15 mL), and the mixture was reacted at 120° C. for 2 hours. The reaction solution was cooled to room temperature, quenched with water (20 ml), and extracted with ethyl acetate (30 mL×3). The combined organic phase was washed with saturated sodium chloride solution (20 mL), then dried over anhydrous sodium sulfate, and concentrated by suction filtration. The obtained residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=4 / 1] to obtain the title compound 1g (1.2 g, 51% yield) as a yellow solid.

[0243] Step 7) 5-(4-nitro-2,6-dichloro-phenoxy)-1-benzyl-pyridin-2(1H)-one 1h 1-Benzyl-5-(2,6-dichloro-4-nitro-phenoxy)-pyridin-2(1H)-one 1g (64 mg, 0.16 mmol) was dissolved in acetic acid (3 mL), then iron powder (6 mg) was added, and the mixture was reacted at 70° C. for 5 hours. The reaction solution was cooled to room temperature, concentrated, water (10 mL) and ethyl acetate (10 mL) were added to the residue, and then solid sodium carbonate was added to adjust the pH to 8, and then the resulting mixture was extracted with ethyl acetate (20 mL×3). The combined organic phase was washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated by suction filtration. The resulting residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=1 / 1] to obtain the title compound 1h (30 mg, 51% yield) as a yellow solid. MS (ESI, positive ion) m / z: 361.1 [M+H] + .

[0244] Step 8) Ethyl (2-(2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)hydrazono)-2-cyanoacetyl)carbamate 1i 5-(4-nitro-2,6-dichloro-phenoxy)-1-benzyl-pyridin-2(1H)-one 1h (0.20 g, 0.6 mmol), N-cyanoacetylurethane (0.097 g, 0.6 mmol) and concentrated hydrochloric acid (0.14 mL) were added to acetic acid (3 mL), and an aqueous solution (2 mL) of sodium nitrite (0.043 g, 0.6 mmol) was added dropwise to the mixture at 3° C., and then the mixture was reacted for 6 hours. Water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (50 mL×2), and the combined organic phase was dried over anhydrous sodium sulfate and concentrated by suction filtration to obtain a dark red solid, which was used directly in the next reaction. MS (ESI, positive ion) m / z: 529.2 [M+H] + .

[0245] Step 9) 2-[4-[(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]-3,5-dichlorophenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 1 The dark red solid obtained from the previous step was dissolved in N,N-dimethylacetamide (2 mL), then potassium acetate (0.22 g, 2.2 mmol) was added, and the mixture was reacted at 120° C. for 24 hours. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [49% ACN / 51% HO (0.1% TFA), Phenomenex ACE specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to obtain the title compound 1 (11 mg, yield 4%, HPLC purity: 92.89%) as a white solid. MS (ESI, negative ion) m / z: 481.8 [MH] - ; 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 7.77 (s, 2H), 7.58 (d, J = 3.3 Hz, 1H), 7.46 (dd, J = 9.9, 3.3 Hz, 1H), 7.31 (d, J = 7.5 Hz, 2H), 7.27 (d, J = 7.2 Hz, 1H), 7.22-7.19 (m, 2H), 6.48 (d, J = 9.9 Hz, 1H), 5.32 (s, 1H), 5.04 (s, 2H).

[0246] Example 2 2-[4-(1-benzyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy-3,5-dichlorophenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 2)

[0247] [ka]

[0248] Step 1) 3,5-Dichloro-4-(6-chloropyridazin-3-yl)oxy-aniline 2b Cesium carbonate (3.75 g, 11.5 mmol) and 3,6-dichloropyridazine (1.49 g, 10.0 mmol) were added to a solution of 4-amino-2,6-dichloro-phenol 2a (1.82 g, 10.2 mmol) in N,N-dimethylacetamide (10 mL), and the mixture was reacted at 110° C. for 6 hours. The reaction solution was cooled to room temperature, and then ethyl acetate (20 mL) was added, and the resulting mixture was filtered through diatomaceous earth and rinsed with ethyl acetate (20 mL). The filtrate was washed with saturated sodium chloride solution (10 mL×3), dried over anhydrous sodium sulfate, and concentrated by suction filtration. The residue was purified by silica gel column chromatography [ethyl acetate / petroleum ether (volume / volume)=1 / 2] to give the title compound 2b (1.47 g, 51% yield) as a brown solid. MS (ESI, positive ion) m / z: 291.9 [M+H] + .

[0249] Step 2) 5-Bromo-2-(3,5-dichloro-4-((6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)isoindoline-1,3-dione 2c 3,5-Dichloro-4-(6-chloropyridazin-3-yl)oxy-aniline 2b (0.2 g, 0.69 mmol) and 4-bromophthalic anhydride (0.20 g, 0.69 mmol) were dissolved in acetic acid (2 mL), the mixture was reacted at 120° C. for 3 hours, and then sodium acetate (0.23 g, 2.8 mmol) was added. The mixture was reacted at 120° C. for 16 hours. The reaction solution was cooled to room temperature, and then saturated sodium carbonate solution (50 mL) was added. The mixture was stirred for 15 minutes, filtered, and the filter cake was collected and dried to give the title compound 2c (0.20 g, 60% yield) as a white solid. MS (ESI, positive ion) m / z: 481.8 [M+H] + ; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 12.35 (s, 1H), 8.21 (d, J = 1.3 Hz, 1H), 8.13 (dd, J = 7.9, 1.5 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.77 (s, 2H), 7.67 (d, J = 9.9 Hz, 1H), 7.11 (d, J = 9.9 Hz, 1H).

[0250] Step 3) 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-5-bromoisoindoline-1,3-dione 2d 5-Bromo-2-(3,5-dichloro-4-((6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)isoindoline-1,3-dione 2c (0.10 g, 0.21 mmol), potassium carbonate (0.058 g, 0.42 mmol), potassium iodide (0.003 g, 0.02 mmol) and benzyl bromide (0.036 g, 0.21 mmol) were dissolved in N,N-dimethylacetamide (1 mL). The mixture was reacted at room temperature for 13 hours. The resulting mixture was quenched with water (10 mL) and extracted with ethyl acetate (5 mL x 2). The combined organic phase was dried over anhydrous sodium sulfate and concentrated by suction filtration. The residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume) = 1 / 1] to give the title compound 2d (50 mg, 42% yield) as a yellow solid. 1 H NMR (600 MHz, CDCl3) δ (ppm) 8.15 (s, 1H), 7.99 (dd, J = 7.9, 1.5 Hz, 1H), 7.87 (d, J = 7.9 Hz, 1H), 7.61 (s, 2H), 7.31-7.27 (m, 3H), 7.24 (d, J = 6.4 Hz, 3H), 7.06 (d, J = 9.7 Hz, 1H), 5.04 (s, 2H).

[0251] Step 4) 6-(4-amino-2,6-dichlorophenoxy)-2-benzylpyridazin-3(2H)-one 2e 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)-5-bromoisoindoline-1,3-dione 2d (50 mg, 0.09 mmol) was dissolved in ethanol (2 mL), and then 35% hydrazine hydrate aqueous solution (0.08 mL) was added. The mixture was reacted at room temperature for 2 hours. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=3 / 1] to give the title compound 2e (10 mg, 32% yield) as a white solid. MS (ESI, positive ion) m / z: 362.1 [M+H] + .

[0252] Step 5) Ethyl (2-(2-(4-((1-benzyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)hydrazono)-2-cyanoacetyl)carbamate 2f 6-(4-amino-2,6-dichlorophenoxy)-2-benzylpyridazin-3(2H)-one 2e (0.10 g, 0.28 mmol), N-cyanoacetylurethane (0.048 g, 0.30 mmol) and concentrated hydrochloric acid (0.07 mL) were added to acetic acid (3 mL), and an aqueous solution (2 mL) of sodium nitrite (0.021 g, 0.30 mmol) was added dropwise at 3° C., and then the mixture was reacted for 4 hours. Water (20 mL) was added to the reaction solution, and then the mixture was extracted with ethyl acetate (20 mL×2), and the combined organic phase was dried over anhydrous sodium sulfate and then concentrated by suction filtration to obtain the title compound 2f (0.15 g, 100% yield), which was used directly in the next reaction. MS (ESI, negative ion) m / z: 529.1 [MH] - .

[0253] Step 6) 2-[4-(1-benzyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy-3,5-dichlorophenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 2 Potassium acetate (0.11 g, 1.06 mmol) was added to a solution of ethyl (2-(2-(4-((1-benzyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)-3,5-dichlorophenyl)hydrazono)-2-cyanoacetyl)carbamate 2f in N,N-dimethylacetamide (2 mL), and the mixture was reacted at 120° C. for 3 hours. The reaction solution was cooled to room temperature, filtered, the filtrate was concentrated, and the residue was purified by a preparative chromatography column [50% ACN / 50% HO (0.1% TFA), Phenomenex ACE specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to obtain the title compound 2 (10 mg, yield 7.8%, HPLC purity: 98.92%) as a white solid. MS (ESI, negative ion) m / z: 482.9 [MH] - . 1 H NMR (400 MHz, DMSO-d6), δ (ppm) 7.79 (s, 2H), 7.68 (d, J = 9.8 Hz, 1H), 7.27-7.23 (m, 3H), 7.19 (d, J = 9.8 Hz, 1H), 7.06 (dd, J = 7.0, 1.9 Hz, 2H), 4.92 (s, 2H).

[0254] Example 3 2-[3,5-dichloro-4-[(1-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (compound 3)

[0255] [ka]

[0256] Step 1) N-(3,5-dichloro-4-((6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)benzamide 3b 3,5-Dichloro-4-((6-chloropyridazin-3-yl)oxy)aniline 3a (2.29 g, 7.88 mmol) and benzoic anhydride (2.06 g, 7.88 mmol) were dissolved in acetic acid (3 mL), and the mixture was reacted at 110° C. for 3 hours. Sodium acetate (2.63 g, 31.5 mmol) was added to the mixture, and the mixture was reacted for 24 hours. The reaction solution was poured into saturated sodium carbonate solution (50 mL), and the resulting mixture was stirred for 15 minutes, filtered, and the filter cake was collected and dried in vacuum to obtain the title compound 3b (2.50 g, 84% yield) as a pale white solid.

[0257] Step 2) 6-(4-amino-2,6-dichlorophenoxy)pyridazin-3(2H)-one 3c N-(3,5-dichloro-4-((6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)benzamide 3b (2.50 g, 6.65 mmol) and potassium hydroxide (4.39 g, 66.5 mmol) were dissolved in 50% aqueous ethanol (18 mL), and the mixture was reacted at 95° C. for 7 hours. The reaction solution was cooled to room temperature and extracted with dichloromethane (10 mL×2), and the combined organic phase was dried over anhydrous sodium sulfate and concentrated by suction filtration to obtain the title compound 3c (1.17 g, 65% yield) as a gray solid. MS (ESI, positive ion) m / z: 272.0 [M+H] + .

[0258] Step 3) 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridazin-3(2H)-one 3d 6-(4-amino-2,6-dichlorophenoxy)pyridazin-3(2H)-one 3c (0.67 g, 2.5 mmol), p-toluenesulfonic acid (0.045 g, 0.25 mmol) and 2,5-hexanedione (0.29 g, 2.5 mmol) were dissolved in toluene (3 mL), and the mixture was reacted at 110° C. for 1.5 hours. The reaction solution was cooled to room temperature, and then saturated sodium carbonate solution (50 mL) was added, and the resulting mixture was stirred for 10 minutes and extracted with ethyl acetate (10 mL×2). The combined organic phase was dried over anhydrous sodium sulfate and concentrated by suction filtration to give the title compound 3d (0.85 g, 99% yield) as a dark solid. MS (ESI, positive ion) m / z: 409.6 [M+H] + .

[0259] Step 4) 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-isopropylpyridazin-3(2H)-one 3e 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridazin-3(2H)-one 3d (0.85 g, 2.4 mmol), cuprous iodide (49 mg, 0.24 mmol), potassium carbonate (0.68 g, 4.9 mmol) and isopropyl iodide (0.41 g, 2.4 mmol) were dissolved in N,N-dimethylformamide (10 mL), and the mixture was reacted at 85° C. for 18 hours. The reaction solution was cooled to room temperature, and then water (20 mL) was added, and the resulting mixture was stirred for 10 minutes, and then filtered with suction, and the filter cake was collected and dried in vacuum to obtain the title compound 3e (0.70 g, 74% yield) as a gray solid. MS (ESI, positive ion) m / z: 392.0 [M+H] + .

[0260] Step 5) 6-(4-amino-2,6-dichlorophenoxy)-2-isopropylpyridazin-3(2H)-one 3f 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-isopropylpyridazin-3(2H)-one 3e (0.20 g, 0.51 mmol), hydroxylamine hydrochloride (0.37 g, 5.1 mmol) and triethylamine (0.14 mL) were dissolved in ethanol (10 mL), and the mixture was reacted at 80° C. for 7 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added. The resulting mixture was stirred for 10 minutes, suction filtered, and the filter cake was collected and purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=1 / 1] to obtain the title compound 3f (30 mg, 19% yield) as a pale solid. MS (ESI, positive ion) m / z: 314.0 [M+H] + ; 1 H NMR (400 MHz, CDCl3), δ (ppm) 7.15 (d, J = 9.7 Hz, 1H), 6.98 (d, J = 9.7 Hz, 1H), 6.67 (s, 2H), 5.10 (dt, J = 13.2, 6.6 Hz, 1H), 3.76 (s, 2H), 1.10 (d, J = 6.6 Hz, 6H).

[0261] Step 6) Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 3g 6-(4-amino-2,6-dichlorophenoxy)-2-isopropylpyridazin-3(2H)-one 3f (30 mg, 0.095 mmol), N-cyanoacetylurethane (16 mg, 0.105 mmol) and concentrated hydrochloric acid (0.4 mL) were dissolved in acetic acid (1 mL), and an aqueous solution (1 mL) of sodium nitrite (7 mg, 0.286 mmol) was added dropwise at 3° C., and then the mixture was reacted for 10 minutes. Water (20 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes and filtered with suction. The filter cake was collected and dried in vacuum to give the title compound 3g (45 mg, 98% yield) as a pale yellow solid. MS (ESI, positive ion) m / z: 481.0 [M+H] + .

[0262] Step 7) 2-[3,5-dichloro-4-[(1-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 3 Potassium acetate (27 mg, 0.28 mmol) was added to a solution of ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 3g (45 mg, 0.093 mmol) in N,N-dimethylacetamide (3 mL), and the mixture was reacted at 120° C. for 1 hour. The reaction solution was cooled to room temperature and filtered, and the filtrate was purified by a preparative chromatography column [43% ACN / 57% HO (0.1% TFA), Kromasil specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to obtain the title compound 3 (30 mg, yield 74%, HPLC purity: 98.16%) as a white solid. MS (ESI, negative ion) m / z: 432.9 [MH] - ; 1 H NMR (400 MHz, CDCl3) δ (ppm) 7.69 (s, 2H), 7.34 (d, J = 9.7 Hz, 1H), 7.28 (d, J = 9.7 Hz, 1H), 5.13 (dt, J = 13.1, 6.6 Hz, 1H), 1.10 (d, J = 6.6Hz, 6H).

[0263] Example 4 2-[3,5-dichloro-4-[(1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (compound 4)

[0264] [ka]

[0265] Step 1) 5-(2,6-dichloro-4-nitrophenoxy)-2-methoxypyridine 4b Potassium carbonate (0.56 g, 4.0 mmol) was added to a solution of 6-methoxypyridin-3-ol 4a (0.20 g, 1.6 mmol) and 1,3-dichloro-2-iodo-5-nitrobenzene (0.51 g, 1.6 mmol) in N,N-dimethylacetamide (2 mL), and the mixture was reacted at 120° C. for 1 h. The reaction solution was cooled to room temperature, water (20 mL) was added, and the resulting mixture was stirred for 5 min, then filtered, and the filter cake was collected and dried in vacuum to give the title compound 4b (0.30 g, 60% yield) as a yellow solid. MS (ESI, positive ion) m / z: 315.0 [M+H] + .

[0266] Step 2) 5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 4c p-Toluenesulfonic acid (0.86 g, 4.7 mmol) and lithium chloride (0.20 g, 4.7 mmol) were added to a solution of 5-(2,6-dichloro-4-nitrophenoxy)-2-methoxypyridine 4b (0.35 g, 1.1 mmol) in N,N-dimethylformamide (2 mL), and the mixture was reacted at 120° C. for 30 minutes. The reaction solution was cooled to room temperature, saturated sodium carbonate solution (50 mL) was added, and the mixture was extracted with ethyl acetate (20 mL×2), and the combined organic phase was washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and then concentrated by suction filtration to give the title compound 4c (0.30 g, 90% yield) as a pale yellow solid. MS (ESI, positive ion) m / z: 301.1 [M+H] + ; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 11.25 (s, 1H), 8.50 (s, 2H), 7.40 (dd, J = 9.6, 3.3 Hz, 1H), 7.24 (d, J = 2.6 Hz, 1H), 6.46 (d, J = 9.6 Hz, 1H).

[0267] Step 3) 5-(2,6-dichloro-4-nitrophenoxy)-1-isopropylpyridin-2(1H)-one 4d Potassium carbonate (0.28 g, 2.0 mmol) and isopropyl iodide (0.19 g, 1.1 mmol) were added to a solution of 5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 4c (0.30 g, 1.0 mmol) in N,N-dimethylformamide (2 mL), and the mixture was reacted at 85° C. for 16 hours. The reaction solution was cooled to room temperature, then water (30 mL) was added, the mixture was stirred for 10 minutes, then filtered, the filter cake was collected and dried in vacuum to give the title compound 4d (0.34 g, 99% yield) as a gray solid. MS (ESI, positive ion) m / z: 343.0 [M+H] + .

[0268] Step 4) 5-(4-amino-2,6-dichlorophenoxy)-1-isopropylpyridin-2(1H)-one 4e 5-(2,6-dichloro-4-nitrophenoxy)-1-isopropylpyridin-2(1H)-one 4d (0.34 g, 0.99 mmol) and sodium sulfide (0.39 g, 5.00 mmol) were dissolved in ethanol (3 mL), and the mixture was reacted at 80° C. for 40 minutes. The reaction solution was cooled to room temperature, and then water (30 mL) was added, and the mixture was stirred for 15 minutes, and then filtered, and the filter cake was collected and dried in vacuum to obtain the title compound 4e (0.17 g, 55% yield) as a brown solid. MS (ESI, positive ion) m / z: 313.3 [M+H] + .

[0269] Step 5) Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 4f 5-(4-amino-2,6-dichlorophenoxy)-1-isopropylpyridin-2(1H)-one 4e (0.17 g, 0.54 mmol), N-cyanoacetylurethane (0.095 g, 0.59 mmol) and concentrated hydrochloric acid (0.18 mL) were added to acetic acid (3 mL), and a solution of sodium nitrite (0.041 g, 0.59 mmol) in water (2 mL) was added dropwise at 3° C., and the mixture was reacted for 4 hours. Water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (5 mL×2), and the combined organic phase was dried over anhydrous sodium sulfate and then concentrated by suction filtration to obtain the title compound 4f (0.26 g, 100% yield) as a deep red solid. MS (ESI, positive ion) m / z: 480.0 [M+H] + .

[0270] Step 6) 2-[3,5-dichloro-4-[(1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 4 Potassium acetate (0.21 g, 2.2 mmol) was added to a solution of ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 4f (0.26 g, 0.54 mmol) in N,N-dimethylacetamide (2 mL), and the mixture was reacted at 120° C. for 2 hours. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [60% ACN / 40% HO (0.1% TFA), Phenomenex ACE specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to give the title compound 4 (7 mg, yield 2.8%, HPLC purity: 92.99%) as a white solid. MS (ESI, positive ion) m / z: 434.5 [M+H] + ; 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 8.30 (s, 1H), 7.90 (s, 1H), 7.76 (s, 2H), 7.54 (d, J = 8.8 Hz, 1H), 7.27 (d, J = 8.6 Hz, 1H), 5.35-5.29 (m, 1H), 1.46 (d, J = 10.2 Hz, 6H).

[0271] Example 5 2-[3,5-dichloro-4-(1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy-phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (compound 5)

[0272] [ka]

[0273] Step 1: 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-ethylpyridazin-3(2H)-one 5d 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridazin-3(2H)-one 3d (1.20 g, 3.43 mmol), cuprous iodide (68 mg, 0.34 mmol), potassium carbonate (0.95 g, 6.85 mmol) and ethyl iodide (0.53 g, 3.43 mmol) were dissolved in N,N-dimethylformamide (2 mL), and the mixture was reacted at 70° C. for 1 hour. The reaction solution was cooled to room temperature, and then water (20 mL) was added, and the mixture was stirred for 10 minutes, and then filtered, and the filter cake was collected and dried in vacuum to give the title compound 5d (1.20 g, 92.6% yield) as a gray solid. MS (ESI, positive ion) m / z: 378.0 [M+H] + .

[0274] Step 2 6-(4-amino-2,6-dichlorophenoxy)-2-ethylpyridazin-3(2H)-one 5e 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-ethylpyridazin-3(2H)-one 5d (1.20 g, 3.17 mmol), hydroxylamine hydrochloride (2.32 g, 31.7 mmol) and triethylamine (0.89 mL) were dissolved in ethanol (10 mL), and the mixture was reacted at 80° C. for 24 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added, and the mixture was stirred for 10 minutes, and then filtered, and the filter cake was collected and dried in vacuum to obtain the title compound 5e (0.40 g, 42% yield) as a black solid. MS (ESI, positive ion) m / z: 300.0 [M+H] + .

[0275] Step 3 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 5f 6-(4-amino-2,6-dichlorophenoxy)-2-ethylpyridazin-3(2H)-one 5e (0.40 g, 1.00 mmol), N-cyanoacetylurethane (0.20 g, 1.00 mmol) and concentrated hydrochloric acid (0.30 mL) were dissolved in acetic acid (2 mL), and an aqueous solution (0.5 mL) of sodium nitrite (0.10 g, 1.00 mmol) was added dropwise at 3° C., and the mixture was then reacted for 10 minutes. Water (20 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, then filtered, and the filter cake was collected and dried in vacuum to give the title compound 5f (0.60 g, 100% yield) as a pale yellow solid. MS (ESI, positive ion) m / z: 467.6 [M+H] + .

[0276] Step 4 2-[3,5-dichloro-4-(1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy-phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 5 Potassium acetate (0.38 g, 3.90 mmol) was added to a solution of ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 5f (0.60 g, 1.30 mmol) in N,N-dimethylacetamide (3 mL), and the mixture was reacted at 120° C. for 4.5 hours. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [40% ACN / 60% HO (0.1% TFA), Kromasil specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to obtain the title compound 5 (50 mg, yield 9%, HPLC purity: 97.78%) as a white solid. MS (ESI, negative ion) m / z: 419.5 [MH] - ; 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 8.31 (s, 1H), 7.82 (s, 2H), 7.67 (d, J = 9.8 Hz, 1H), 7.18 (d, J = 9.8 Hz, 1H), 2.04-1.95 (m, 2H), 1.05 (t, J = 7.1 Hz, 3H).

[0277] Example 6 2-[3,5-Dichloro-4-(1-cyclopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy-phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 6)

[0278] [ka]

[0279] Step 1: 2-Cyclopropyl-6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridazin-3(2H)-one 6a 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridazin-3(2H)-one 3d (0.85 g, 2.4 mmol), cuprous iodide (29 mg, 0.24 mmol) and potassium carbonate (0.68 g, 4.9 mmol) were dissolved in N,N-dimethylformamide (4 mL), and the mixture was reacted at 130° C. for 40 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added, and the mixture was stirred for 10 minutes, and then filtered, and the filter cake was collected and dried in vacuum. The crude product was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=2 / 1] to obtain the title compound 6a (0.10 g, 11% yield) as a pale yellow solid. MS (ESI, positive ion) m / z: 390.1 [M+H] + .

[0280] Step 2: 6-(4-amino-2,6-dichlorophenoxy)-2-cyclopropylpyridazin-3(2H)-one 6b 2-Cyclopropyl-6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridazin-3(2H)-one 6a (0.10 g, 0.26 mmol), hydroxylamine hydrochloride (0.19 g, 2.60 mmol) and triethylamine (0.07 mL) were dissolved in ethanol (3 mL), and the mixture was reacted at 80° C. for 15 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added, and the mixture was stirred for 10 minutes, and then filtered, and the filter cake was collected and dried in vacuum to give the title compound 6b (50 mg, 60% yield) as a black solid. MS (ESI, positive ion) m / z: 314.1 [M+H] + .

[0281] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 6c 6-(4-amino-2,6-dichlorophenoxy)-2-cyclopropylpyridazin-3(2H)-one 6b (0.05 g, 0.20 mmol), N-cyanoacetylurethane (0.03 g, 0.20 mmol) and concentrated hydrochloric acid (0.04 mL) were dissolved in acetic acid (2 mL), and a solution of sodium nitrite (0.010 g, 0.20 mmol) in water (0.5 mL) was added dropwise at 3° C., and the mixture was reacted for 10 minutes. Water (20 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, and then filtered, and the filter cake was collected and dried in vacuum to give the title compound 6c (80 mg, 99% yield) as a black solid. MS (ESI, positive ion) m / z: 479.0 [M+H] + .

[0282] Step 4 2-[3,5-Dichloro-4-(1-cyclopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy-phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 6 Potassium acetate (0.046 g, 0.50 mmol) was added to a solution of ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-cyclopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 6c (0.08 g, 0.17 mmol) in N,N-dimethylacetamide (2 mL), and the mixture was reacted at 120° C. for 4 hours. The reaction solution was cooled to room temperature and filtered, and the filtrate was purified by a preparative chromatography column [45% ACN / 55% HO (0.1% TFA), Kromasil specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to give the title compound 6 (8 mg, 10% yield, HPLC purity: 95.4%) as a pale solid. MS (ESI, positive ion) m / z: 433.1 [M+H] + ; 1H NMR (400 MHz, CDCl3) δ (ppm) 7.65 (s, 2H), 7.30 (d, J = 9.8 Hz, 1H), 7.16 (d, J = 9.8 Hz, 1H), 5.88-5.74 (m, 1H), 5.13 (dd, J = 21.6, 13.3 Hz, 2H), 4.50 (d, J = 5.8 Hz, 2H).

[0283] Example 7 2-[3,5-Dichloro-4-(6-oxo-1-phenyl-1,6-dihydropyridazin-3-yl)oxy-phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 21)

[0284] [ka]

[0285] Step 1 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-phenylpyridazin-3(2H)-one 21a 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridazin-3(2H)-one 3d (0.50 g, 1.4 mmol), cuprous iodide (29 mg, 0.14 mmol) and potassium carbonate (0.40 g, 2.9 mmol) were dissolved in iodobenzene (3 mL), and the mixture was reacted at 160° C. for 2 hours. The reaction solution was cooled to room temperature, and then water (20 mL) was added, and the mixture was stirred for 10 minutes, and then filtered, and the filter cake was collected and dried in vacuum to give the title compound 21a (0.50 g, 82% yield) as a gray solid. MS (ESI, positive ion) m / z: 426.1 [M+H] + .

[0286] Step 2 6-(4-amino-2,6-dichlorophenoxy)-2-phenylpyridazin-3(2H)-one 21b 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-phenylpyridazin-3(2H)-one 21a (0.50 g, 1.2 mmol), hydroxylamine hydrochloride (0.86 g, 12 mmol) and triethylamine (0.33 mL) were dissolved in ethanol (10 mL), and the mixture was reacted at 80° C. for 22 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added, and a solid was precipitated. The solid was filtered by suction, and the filter cake was dried in vacuum and purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=1 / 1] to obtain the title compound 21b (212 mg, 52% yield) as a black solid. MS (ESI, positive ion) m / z: 348.0 [M+H] + .

[0287] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 21c 6-(4-amino-2,6-dichlorophenoxy)-2-phenylpyridazin-3(2H)-one 21b (0.21 g, 0.61 mmol), N-cyanoacetylurethane (0.11 g, 0.67 mmol) and concentrated hydrochloric acid (0.15 mL) were dissolved in acetic acid (2 mL), and a solution of sodium nitrite (0.05 g, 0.67 mmol) in water (2 mL) was added dropwise at 3° C., and the mixture was then reacted for 10 minutes. Water (20 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, then filtered, and the filter cake was collected and dried in vacuum to give the title compound 21c (0.30 g, 96% yield) as a black solid. MS (ESI, negative ion) m / z: 515.0 [MH] - .

[0288] Step 4 2-[3,5-Dichloro-4-(6-oxo-1-phenyl-1,6-dihydropyridazin-3-yl)oxy-phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 21 Potassium acetate (0.17 g, 0.17 mmol) was added to a solution of ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-phenyl-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 21c (0.30 g, 0.58 mmol) in N,N-dimethylacetamide (3 mL), and the mixture was reacted at 120° C. for 1 h. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [48% ACN / 52% HO (0.1% TFA), Kromasil specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to give the title compound 21 (4 mg, yield 1.2%, HPLC purity: 81.9%) as a dark solid. MS (ESI, positive ion) m / z: 468.9 [M+H] + ; 1 H NMR (600 MHz, CDCl3) δ (ppm) 7.65 (d, J = 5.3 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.37 (t, J = 8.6 Hz, 3H), 7.31-7.28 (m, 1H), 7.20 (d, J = 9.8 Hz, 1H).

[0289] Example 8 2-[3,5-Dichloro-4-[1-(4-fluorophenyl)-6-oxo-1,6-dihydropyridazin-3-yl]oxy-phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 27

[0290] [ka]

[0291] Step 1: 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-(4-fluorophenyl)pyridazin-3(2H)-one 27a 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridazin-3(2H)-one 3d (0.50 g, 1.4 mmol), cuprous iodide (29 mg, 0.14 mmol), potassium carbonate (0.40 g, 2.9 mmol) and p-fluoroiodobenzene (0.33 g, 1.4 mmol) were dissolved in N,N-dimethylformamide (2 mL), and the mixture was reacted at 160° C. for 22 hours. The reaction solution was cooled to room temperature, and then water (10 mL) was added, and the mixture was stirred for 10 minutes, and then filtered, and the filter cake was collected and dried in vacuum to give the title compound 27a (0.60 g, 95% yield) as a gray solid. MS (ESI, positive ion) m / z: 444.6 [M+H] + .

[0292] Step 2: 6-(4-amino-2,6-dichlorophenoxy)-2-(4-fluorophenyl)pyridazin-3(2H)-one 27b 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-(4-fluorophenyl)pyridazin-3(2H)-one 27a (0.60 g, 1.4 mmol), hydroxylamine hydrochloride (0.99 g, 14 mmol) and triethylamine (0.38 mL) were dissolved in ethanol (10 mL), and the mixture was reacted at 80° C. for 18 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added, and the mixture was stirred for 10 minutes, and then filtered, and the filter cake was collected and purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=1 / 1] to obtain the title compound 27b (380 mg, 77% yield) as a black solid. MS (ESI, positive ion) m / z: 365.9.0 [M+H] + .

[0293] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(4-fluorophenyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 27c 6-(4-amino-2,6-dichlorophenoxy)-2-(4-fluorophenyl)pyridazin-3(2H)-one 27b (0.38 g, 1.0 mmol), N-cyanoacetylurethane (0.18 g, 1.1 mmol) and concentrated hydrochloric acid (0.3 mL) were dissolved in acetic acid (2 mL), and a solution of sodium nitrite (0.26 g, 3.1 mmol) in water (1 mL) was added dropwise at 3° C., and the mixture was then reacted for 10 minutes. Water (20 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, then filtered, and the filter cake was collected and dried in vacuum to give the title compound 27c (0.55 g, 99% yield) as a black solid. MS (ESI, negative ion) m / z: 531.0 [MH] - .

[0294] Step 4 2-[3,5-dichloro-4-[1-(4-fluorophenyl)-6-oxo-1,6-dihydropyridazin-3-yl]oxy-phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 27 Potassium acetate (0.31 g, 3.1 mmol) was added to a solution of ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(4-fluorophenyl)-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 27c (0.55 g, 1.0 mmol) in N,N-dimethylacetamide (3 mL), and the mixture was reacted at 120° C. for 16 hours. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [50% ACN / 50% HO (0.1% TFA), Kromasil specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to give the title compound 27 (48 mg, yield 74%, HPLC purity: 86.92%) as a yellow solid. MS (ESI, positive ion) m / z: 487.0 [M+H] + ; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 7.81 (s, 1H), 7.79 (s, 2H), 7.41 (dd, J = 9.1, 5.0 Hz, 2H), 7.32 (d, J = 9.8 Hz, 1H), 7.26 (t, J = 8.7 Hz, 2H).

[0295] Example 9 2-[3,5-Dichloro-4-[[6-oxo-1-(1-phenethyl)-1,6-dihydropyridazin-3-yl]oxyl]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 37)

[0296] [ka]

[0297] Step 1: 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-(1-phenylethyl)pyridazin-3(2H)-one 37a 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridazin-3(2H)-one 3d (1.20 g, 3.43 mmol), cuprous iodide (68 mg, 0.34 mmol), potassium carbonate (0.95 g, 6.85 mmol) and 1-bromoethylbenzene (0.53 g, 3.43 mmol) were dissolved in N,N-dimethylformamide (2 mL), and the mixture was reacted at 70° C. for 1 hour. The reaction solution was cooled to room temperature, and then water (20 mL) was added, and the mixture was stirred for 10 minutes, and then filtered, and the filter cake was collected and dried in vacuum to give the title compound 37a (1.40 g, 89.9% yield) as a gray solid. MS (ESI, positive ion) m / z: 454.0 [M+H] + .

[0298] Step 2: 6-(4-amino-2,6-dichlorophenoxy)-2-(1-phenylethyl)pyridazin-3(2H)-one 37b 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-(1-phenylethyl)pyridazin-3(2H)-one 37a (1.40 g, 3.08 mmol), hydroxylamine hydrochloride (2.25 g, 30.8 mmol) and triethylamine (0.86 mL) were dissolved in ethanol (10 mL), and the mixture was reacted at 80° C. for 24 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added, and the mixture was stirred for 10 minutes, and then filtered, and the filter cake was collected and dried in vacuum to give the title compound 37b (0.50 g, 43% yield) as a black solid. MS (ESI, positive ion) m / z: 376.0 [M+H] + .

[0299] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-(1-phenylethyl)-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 37c 6-(4-amino-2,6-dichlorophenoxy)-2-(1-phenylethyl)pyridazin-3(2H)-one 37b (0.50 g, 1.30 mmol), N-cyanoacetylurethane (0.23 g, 1.50 mmol) and concentrated hydrochloric acid (0.34 mL) were dissolved in acetic acid (3 mL), and an aqueous solution (0.5 mL) of sodium nitrite (0.10 g, 1.50 mmol) was added dropwise at 3° C., and the mixture was then reacted for 30 minutes. Water (20 mL) was added to the reaction solution, and the mixture was then stirred for 10 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 37c (0.70 g, 100% yield) as a pale yellow solid. MS (ESI, positive ion) m / z: 543.6 [M+H] + .

[0300] Step 4: 2-[3,5-Dichloro-4-[[6-oxo-1-(1-phenethyl)-1,6-dihydropyridazin-3-yl]oxyl]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 37 Potassium acetate (0.39 g, 4.00 mmol) was added to a solution of ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-(1-phenylethyl)-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 37c (0.72 g, 1.30 mmol) in N,N-dimethylacetamide (3 mL), and the mixture was reacted at 120° C. for 5 hours. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [40% ACN / 60% HO (0.1% TFA), Kromasil specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to give the title compound 36 (100 mg, 15% yield, HPLC purity: 97.91%) as a red solid. MS (ESI, negative ion) m / z: 495.0 [MH] - ; 1 H NMR (400 MHz, CDCl3) δ (ppm) 7.61 (s, 2H), 7.20 (s, 5H), 7.11 (s, 2H), 4.13 (dd, J = 14.2, 7.1 Hz, 1H), 1.47 (d, J = 6.1 Hz, 3H).

[0301] Example 10 2-[4-(1-benzyl-2-oxo-1,2-dihydropyrimidin-5-yl)oxy-3,5-dichlorophenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (compound 38)

[0302] [ka]

[0303] Step 1 2-Chloro-5-(2,6-dichloro-4-nitrophenoxy)pyrimidine 38b 1,2,3-Trichloro-5-nitrobenzene (5.72 g, 25.3 mmol) and potassium carbonate (6.42 g, 46.0 mmol) were added to a solution of 2-chloropyrimidin-5-ol 38a (3.00 g, 23.0 mmol) in N,N-dimethylformamide (25 mL), and the mixture was reacted at 120° C. for 7 h. The reaction solution was cooled to room temperature, then water (75 mL) was added dropwise, the mixture was stirred for 15 min, then filtered, the filter cake was collected and dried in vacuum to give the title compound 38b (6.50 g, 88.2% yield) as an orange solid. 1 H NMR (400 MHz, CDCl3) δ (ppm) 8.38 (s, 2H), 8.28 (s, 2H).

[0304] Step 2: 5-(2,6-dichloro-4-nitrophenoxy)pyrimidin-2(1H)-one 38c 2-Chloro-5-(2,6-dichloro-4-nitrophenoxy)pyrimidine 38b (1.43 g, 4.46 mmol), potassium carbonate (1.25 g, 8.95 mmol) and triethylenediamine (0.255 g, 2.23 mmol) were dissolved in 1,4-dioxane (20 mL) and water (20 mL), and the mixture was reacted at 70° C. for 6 h. The reaction solution was cooled to room temperature and concentrated in vacuum. The resulting residue was filtered, and the filter cake was washed with water (10 mL×3), collected and recrystallized (petroleum ether / ethyl acetate (v / v)=5 / 1, 50 mL) to give the title compound 38c (1.12 g, 83.1% yield) as a yellow solid. MS (ESI, positive ion) m / z: 302.1 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 11.75 (s, 1H), 8.71 (s, 1H), 8.60 (s, 1H), 8.52 (s, 1H), 8.26 (s, 1H).

[0305] Step 3 1-Benzyl-5-(2,6-dichloro-4-nitrophenoxy)pyrimidin-2(1H)-one 38d 5-(2,6-dichloro-4-nitrophenoxy)pyrimidin-2(1H)-one 38c (0.60 g, 1.99 mmol) and benzyl bromide (0.37 mL, 2.98 mmol) were dissolved in dichloromethane (10 mL), then triethylamine (0.57 mL, 4.0 mmol) was added, and the mixture was reacted at room temperature for 7 hours. The reaction solution was quenched with water (10 mL), extracted with ethyl acetate (10 mL x 3), and the combined organic phase was washed with saturated sodium chloride solution (15 mL x 3), dried over anhydrous sodium sulfate, and then concentrated by suction filtration. The obtained residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume) = 1 / 2] to give the title compound 38d (0.68 g, 87% yield) as a yellow solid. MS (ESI, positive ion) m / z: 392.5 [M+H] + .

[0306] Step 4 5-(4-amino-2,6-dichlorophenoxy)-1-benzylpyrimidin-2(1H)-one 38e 1-Benzyl-5-(2,6-dichloro-4-nitrophenoxy)pyrimidin-2(1H)-one 38d (0.68 g, 1.7 mmol) was dissolved in acetic acid (15 mL), and then iron powder (0.40 g, 7.0 mmol) was added, and the mixture was reacted at 90° C. for 2.5 hours. After the reaction solution was cooled to room temperature, the iron powder was removed by suction filtration, and the filtrate was concentrated to give the title compound 38e (0.55 g, 88%) as a yellow solid. MS (ESI, positive ion) m / z: 362.0 [M+H] + .

[0307] Step 5 Ethyl (2-(2-(4-((1-benzyl-2-oxo-1,2-dihydropyrimidin-5-yl)oxy)-3,5-dichlorophenyl)hydrazono)-2-cyanoacetyl)carbamate 38f 5-(4-amino-2,6-dichlorophenoxy)-1-benzylpyrimidin-2(1H)-one 38e (0.30 g, 0.83 mmol) and N-(2-cyanoacetyl)ethyl carbamate (0.155 g, 0.99 mmol) were dissolved in acetic acid (4 mL), then an aqueous solution (1 mL) of sodium nitrite (0.087 g, 1.2 mmol) was added dropwise at 0° C., and the mixture was reacted for 2 h. The reaction solution was added directly to the next reaction.

[0308] Step 6 2-[4-(1-benzyl-2-oxo-1,2-dihydropyrimidin-5-yl)oxy-3,5-dichlorophenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 38 Sodium acetate (0.343 g, 4.14 mmol) was added to the reaction solution obtained from the previous step and reacted at 120° C. for 4 hours. The resulting solution was cooled to room temperature and concentrated under vacuum to remove acetic acid, then water (15 mL) was added. The mixture was extracted with ethyl acetate (15 mL×3), and the combined organic phase was dried over anhydrous sodium sulfate and then concentrated by suction filtration. The obtained crude product was purified by preparative chromatography column [37% ACN / 63% H2O (0.1% TFA), Philomon ACE specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to obtain the title compound 38 (0.18 g, yield 45.0%, HPLC purity: 98.37%) as a yellow solid. MS (ESI, negative ion) m / z: 481.1 [MH] - , 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 13.27 (s, 1H), 8.80 (d, J = 3.8 Hz, 1H), 8.29 (d, J = 3.8 Hz, 1H), 7.80 (s, 2H), 7.36 (t, J = 7.1 Hz, 2H), 7.30 (d, J = 7.0 Hz, 1H), 7.26 (d, J = 7.9 Hz, 2H), 5.02 (s, 2H).

[0309] Example 11 2-[3,5-Dichloro-4-[[1-(3,4-difluorobenzyl)-6-oxo-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 39)

[0310] [ka]

[0311] Step 1: 5-(4-amino-2,6-dichlorophenoxy)pyridin-2(1H)-one 39a 5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 4c (5.00 g, 1.6 mmol) was dissolved in acetic acid (10 mL), then iron powder (2.79 g, 49.8 mmol) was added, and the mixture was reacted at 75° C. for 3 hours. The reaction solution was cooled to room temperature, then water (100 mL) was added, the mixture was stirred for 15 minutes, then filtered, the filter cake was collected, and dried in vacuum to give the title compound 39a (2.00 g, 44.4% yield) as a pale yellow solid. MS (ESI, positive ion) m / z: 271.0 [M+H] + .

[0312] Step 2: 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridin-2(1H)-one 39b 5-(4-amino-2,6-dichlorophenoxy)pyridin-2(1H)-one 39a (1.60 g, 5.9 mmol), p-toluenesulfonic acid (0.11 g, 0.59 mmol) and 2,5-hexanedione (0.69 g, 5.9 mmol) were dissolved in toluene (5 mL), and the mixture was reacted at 110° C. for 2 hours. The reaction solution was cooled to room temperature, then quenched with saturated sodium carbonate solution (50 mL) and extracted with ethyl acetate (10 mL×2). The combined organic phase was dried over anhydrous sodium sulfate and then concentrated by suction filtration to give the title compound 39b (1.90 g, 92% yield) as a gray solid. MS (ESI, positive ion) m / z: 349.0 [M+H] + .

[0313] Step 3: 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(3,4-difluorobenzyl)pyridin-2(1H)-one 39c 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridin-2(1H)-one 39b (0.30 g, 0.85 mmol) and 3,4-difluorobenzyl bromide (0.18 g, 0.86 mmol) were dissolved in N,N-dimethylacetamide (8 mL), and then potassium carbonate (0.30 g, 2.1 mmol) was added, and the mixture was reacted at room temperature for 24 hours. Water (30 mL) was added to the reaction solution, and then the mixture was stirred for 10 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 39c (0.30 g, 73% yield) as a red solid. MS (ESI, positive ion) m / z: 475.1 [M+H] + .

[0314] Step 4: 5-(4-amino-2,6-dichlorophenoxy)-1-(3,4-difluorobenzyl)pyridin-2(1H)-one 39d 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(3,4-difluorobenzyl)pyridin-2(1H)-one 39c (0.30 g, 0.63 mmol), hydroxylamine hydrochloride (0.58 g, 6.3 mmol) and triethylamine (0.89 mL) were dissolved in ethanol (10 mL), and the mixture was reacted at 80° C. for 16 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added, and the mixture was stirred for 15 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 39d (0.20 g, 80% yield) as a black solid. MS (ESI, positive ion) m / z: 399.0 [M+H] + .

[0315] Step 5. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(3,4-difluorobenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 39e 5-(4-amino-2,6-dichlorophenoxy)-1-(3,4-difluorobenzyl)pyridin-2(1H)-one 39d (0.20 g, 0.50 mmol), N-cyanoacetylurethane (0.088 g, 0.55 mmol) and concentrated hydrochloric acid (0.13 mL) were added to acetic acid (3 mL), a solution of sodium nitrite (38 mg, 0.55 mmol) in water (2 mL) was added dropwise at 3° C., and the mixture was then reacted for 15 minutes. Water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (10 mL×2). The combined organic phase was dried over anhydrous sodium sulfate and then concentrated by suction filtration to give the title compound 39e (0.28 g, 99% yield) as a deep red solid. MS (ESI, positive ion) m / z: 564.0 [M+H] + .

[0316] Step 6: 2-[3,5-Dichloro-4-[[1-(3,4-difluorobenzyl)-6-oxo-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 39 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(3,4-difluorobenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 39e (0.28 g, 0.50 mmol) was dissolved in N,N-dimethylacetamide (3 mL), and then potassium acetate (0.20 g, 2.00 mmol) was added, and the mixture was reacted at 120° C. for 18 hours. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [48% ACN / 52% HO (0.1% TFA), Phenomenex ACE specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to give the title compound 39 (25 mg, yield 8.6%, HPLC purity: 88.95%) as a red solid. MS (ESI, negative ion) m / z: 516.5 [MH] - ; 1 H NMR (400 MHz, CDCl3) δ (ppm) 7.64 (s, 2H), 7.39 (dd, J = 9.8, 3.1 Hz, 1H), 7.35 (s, 1H), 7.18-7.13 (m, 1H), 7.12-7.08 (m, 1H), 6.99 (d, J = 3.1 Hz, 1H), 6.94 (d, J = 9.8 Hz, 1H), 5.12 (s, 2H).

[0317] Example 12 2-[3,5-Dichloro-4[[6-oxo-1-[4-(trifluoromethoxy)benzyl]-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 40)

[0318] [ka]

[0319] Step 1: 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(4-(trifluoromethoxy)benzyl)pyridin-2(1H)-one 40a 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridin-2(1H)-one 39b (0.23 g, 0.66 mmol), potassium carbonate (0.23 g, 1.65 mmol) and 4-trifluoromethoxybenzyl bromide (0.17 g, 0.86 mmol) were dissolved in N,N-dimethylacetamide (4 mL), and the mixture was reacted at room temperature for 24 hours. Water (30 mL) was added to the reaction solution, and then the mixture was stirred for 10 minutes and suction filtered to obtain the title compound 40a (0.30 g, 87% yield) as a red solid. MS (ESI, positive ion) m / z: 523.0 [M+H] + .

[0320] Step 2: 5-(4-amino-2,6-dichlorophenoxy)-1-(4-(trifluoromethoxy)benzyl)pyridin-2(1H)-one 40b 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(4-(trifluoromethoxy)benzyl)pyridin-2(1H)-one 40a (0.30 g, 0.63 mmol) and hydroxylamine hydrochloride (0.58 g, 6.3 mmol) were dissolved in ethanol (10 mL), then triethylamine (0.89 mL) was added, and the mixture was reacted at 80° C. for 16 hours. The reaction solution was cooled to room temperature, then water (30 mL) was added, the mixture was stirred for 15 minutes, filtered, the filter cake was collected, and dried in vacuum to give the title compound 40b (0.24 g, 94% yield) as a black solid. MS (ESI, positive ion) m / z: 445.0 [M+H] + .

[0321] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-(4-(trifluoromethoxy)benzyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 40c 5-(4-amino-2,6-dichlorophenoxy)-1-(4-(trifluoromethoxy)benzyl)pyridin-2(1H)-one 40b (0.24 g, 0.54 mmol), N-cyanoacetylurethane (0.11 g, 0.59 mmol) were dissolved in acetic acid (3 mL) and concentrated hydrochloric acid (0.18 mL), then an aqueous solution (2 mL) of sodium nitrite (0.05 g, 0.59 mmol) was added dropwise at 3° C., and the mixture was reacted for 30 minutes. The reaction was quenched with water (20 mL), extracted with ethyl acetate (5 mL×2), and the combined organic phase was dried over anhydrous sodium sulfate, suction filtered, and concentrated to give the title compound 40c (0.33 g, 100% yield) as a deep red solid. MS (ESI, negative ion) m / z: 610.0 [MH] - .

[0322] Step 4 2-[3,5-dichloro-4[[6-oxo-1-[4-(trifluoromethoxy)benzyl]-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 40 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-(4-(trifluoromethoxy)benzyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 40c (0.33 g, 0.54 mmol) was dissolved in N,N-dimethylformamide (3 mL), then potassium acetate (0.21 g, 2.20 mmol) was added, and the mixture was reacted at 120° C. for 2 h. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [52% ACN / 48% HO (0.1% TFA), Phenomenex ACE specifications: C18 10 μm × 50 mm × 250 mm, flow rate: 100 mL / min] to give the title compound 40 (7.0 mg, yield 2.0%, purity: 82.25%) as a yellow solid. MS (ESI, negative ion) m / z: 564.0 [MH] - ; 1 H NMR (600 MHz, CDCl3) δ (ppm) 10.02 (s, 1H), 7.64 (s, 2H), 7.39 (d, J = 8.5 Hz, 1H), 7.31 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 8.3 Hz, 1H), 7.21 (d, J = 7.6 Hz, 2H), 6.61 (s, 1H), 4.33 (s, 2H).

[0323] Example 13 2-[3,5-Dichloro-4-[[1-(4-fluorobenzyl)-6-oxo-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 41)

[0324] [ka]

[0325] Step 1: 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(4-fluorobenzyl)pyridin-2(1H)-one 41a 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridin-2(1H)-one 39b (0.30 g, 1.0 mmol) and p-fluorobenzyl bromide (0.17 g, 0.86 mmol) were dissolved in N,N-dimethylformamide (8 mL), then potassium carbonate (0.30 g, 2.7 mmol) was added, and the mixture was reacted at room temperature for 16 hours. Water (30 mL) was added to the reaction solution, then the mixture was stirred for 10 minutes, filtered, the filter cake was collected, and dried in vacuum to obtain the title compound 41a (0.37 g, 94% yield) as a pink solid. MS (ESI, positive ion) m / z: 457.5 [M+H] + .

[0326] Step 2. 5-(4-amino-2,6-dichlorophenoxy)-1-(4-fluorobenzyl)pyridin-2(1H)-one 41b 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(4-fluorobenzyl)pyridin-2(1H)-one 41a (0.37 g, 0.81 mmol), hydroxylamine hydrochloride (0.59 g, 8.1 mmol) and triethylamine (0.24 mL) were dissolved in ethanol (10 mL), and the mixture was reacted at 80° C. for 24 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added, and the mixture was stirred for 15 minutes, and then filtered, and the filter cake was collected and dried in vacuum to obtain the title compound 41b (0.28 g, 91% yield) as a black solid. MS (ESI, positive ion) m / z: 381.4 [M+H] + .

[0327] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(4-fluorobenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 41c 5-(4-amino-2,6-dichlorophenoxy)-1-(4-fluorobenzyl)pyridin-2(1H)-one 41b (0.28 g, 0.73 mmol), N-cyanoacetylurethane (0.13 g, 0.81 mmol) and concentrated hydrochloric acid (0.13 mL) were added to acetic acid (3 mL), and a solution of sodium nitrite (0.056 g, 0.81 mmol) in water (2 mL) was added dropwise at 3° C., and then the mixture was reacted for 1 hour. Water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (5 mL×2), and the combined organic phase was dried over anhydrous sodium sulfate and then concentrated by suction filtration to obtain the title compound 41c (0.40 g, 99% yield) as a deep red solid. MS (ESI, positive ion) m / z: 546.0 [M+H] + .

[0328] Step 4 2-[3,5-dichloro-4-[[1-(4-fluorobenzyl)-6-oxo-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 41 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(4-fluorobenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 41c (0.40 g, 0.73 mmol) was dissolved in N,N-dimethylacetamide (3 mL), and then potassium acetate (0.29 g, 2.9 mmol) was added, and the mixture was reacted at 120° C. for 4 hours. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [48% ACN / 52% HO (0.1% TFA), Phenomenex ACE specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to obtain the title compound 41 (94 mg, yield 24%, HPLC purity: 98.27%) as a red solid. MS (ESI, positive ion) m / z: 500.0 [M+H] + ; 1 H NMR (600 MHz, DMSO-d6) δ (ppm) 13.28 (s, 1H), 7.77 (s, 2H), 7.62 (d, J = 3.3 Hz, 1H), 7.45 (dd, J = 9.9, 3.3 Hz, 1H), 7.30 (dd, J = 8.4, 5.6 Hz, 2H), 7.16 (t, J = 8.8 Hz, 2H), 6.47 (d, J = 9.9 Hz, 1H), 5.02 (s, 2H).

[0329] Example 14 2-[3,5-Dichloro-4-[[6-oxo-1-[3-(trifluoromethyl)benzyl]-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 42)

[0330] [ka]

[0331] Step 1: 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(3-(trifluoromethyl)benzyl)pyridin-2(1H)-one 42a 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridin-2(1H)-one 39b (0.30 g, 1.0 mmol) and m-trifluoromethylbenzyl bromide (0.21 g, 0.86 mmol) were dissolved in N,N-dimethylformamide (8 mL), and then potassium carbonate (0.30 g, 2.7 mmol) was added, and the mixture was reacted at room temperature for 24 hours. Water (30 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, then filtered, and the filter cake was collected and dried in vacuum to give the title compound 42a (0.40 g, 94% yield) as a gray solid. MS (ESI, positive ion) m / z: 507.0 [M+H]+ .

[0332] Step 2: 5-(4-amino-2,6-dichlorophenoxy)-1-(3-(trifluoromethyl)benzyl)pyridin-2(1H)-one 42b 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(3-(trifluoromethyl)benzyl)pyridin-2(1H)-one 42a (0.40 g, 0.79 mmol), hydroxylamine hydrochloride (0.58 g, 8.1 mmol) and triethylamine (0.89 mL) were dissolved in ethanol (10 mL), and the mixture was reacted at 80° C. for 16 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added, and the mixture was stirred for 15 minutes, and then filtered, and the filter cake was collected and dried in vacuum to give the title compound 42b (0.34 g, 91% yield) as a black solid. MS (ESI, positive ion) m / z: 429.0 [M+H] + .

[0333] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-(3-(trifluoromethyl)benzyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 42c 5-(4-amino-2,6-dichlorophenoxy)-1-(3-(trifluoromethyl)benzyl)pyridin-2(1H)-one 42b (0.34 g, 0.79 mmol), N-cyanoacetylurethane (0.14 g, 0.87 mmol) and concentrated hydrochloric acid (0.18 mL) were added to acetic acid (3 mL), a solution of sodium nitrite (56 mg, 0.81 mmol) in water (2 mL) was added dropwise at 3° C., and the mixture was then reacted for 6 hours. Water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (5 mL×2), and the combined organic phase was dried over anhydrous sodium sulfate and then concentrated by suction filtration to give the title compound 42c (0.47 g, 99% yield) as a deep red solid. MS (ESI, positive ion) m / z: 596.0 [M+H] + .

[0334] Step 4 2-[3,5-Dichloro-4-[[6-oxo-1-[3-(trifluoromethyl)benzyl]-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 42 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-(3-(trifluoromethyl)benzyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 42c (0.47 g, 0.79 mmol) was dissolved in N,N-dimethylacetamide (3 mL), and then potassium acetate (0.31 g, 3.2 mmol) was added, and the mixture was reacted at 120° C. for 3 hours. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [50% ACN / 50% HO (0.1% TFA), Phenomenex ACE specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to obtain the title compound 42 (38 mg, yield 8.7%, HPLC purity: 98.74%) as a red solid. MS (ESI, negative ion) m / z: 548.0 [MH] - ; 1 H NMR (400 MHz, CDCl3) δ (ppm) 7.63 (s, 2H), 7.57 (d, J = 7.9 Hz, 1H), 7.46 (t, J = 6.9 Hz, 3H), 7.32-7.28 (m, 1H), 6.88 (d, J = 3.0 Hz, 1H), 6.71 (d, J = 9.8 Hz, 1H), 5.15 (s, 2H).

[0335] Example 15 2-(3,5-dichloro-4-((6-isopropoxypyridin-3-yl)oxy)phenyl)-3,5-dioxo-1,2,4-triazine-6-carbonitrile (compound 43)

[0336] [ka]

[0337] Step 1 5-(2,6-dichloro-4-nitrophenoxy)-2-isopropoxypyridine 43a 5-(2,6-dichloro-4-nitro-phenoxy)-pyridin-2(1H)-one 4c (0.30 g, 1.0 mmol) was dissolved in N,N-dimethylformamide (2 mL), then potassium carbonate (0.28 g, 2.0 mmol) and isopropyl iodide (0.19 g, 1.1 mmol) were added, and the mixture was reacted at 85° C. for 16 hours. Water (30 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, then filtered, and the filter cake was collected and dried in vacuum to give the title compound 43a (0.34 g, 94% yield) as a gray solid. MS (ESI, positive ion) m / z: 343.0 [M+H] + .

[0338] Step 2: 3,5-Dichloro-4-((6-isopropoxypyridin-3-yl)oxy)aniline 43b 5-(2,6-Dichloro-4-nitrophenoxy)-2-isopropoxypyridine 43a (0.34 g, 0.99 mmol) and sodium sulfide (0.39 g, 5.00 mmol) were dissolved in ethanol (3 mL), and the mixture was reacted at 80° C. for 40 minutes. The reaction solution was cooled to room temperature, and then water (30 mL) was added, and the mixture was stirred for 15 minutes, and then filtered, and the filter cake was collected and dried in vacuum to obtain the title compound 43b (0.28 g, 91% yield) as a brown solid. MS (ESI, positive ion) m / z: 313.3 [M+H] + .

[0339] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-isopropoxypyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 43c 3,5-Dichloro-4-((6-isopropoxypyridin-3-yl)oxy)aniline 43b (0.17 g, 0.54 mmol), N-cyanoacetylurethane (0.095 g, 0.59 mmol) and concentrated hydrochloric acid (0.18 mL) were added to acetic acid (3 mL), a solution of sodium nitrite (0.041 g, 0.59 mmol) in water (2 mL) was added dropwise at 3° C., and the mixture was reacted for 4 hours. Water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (5 mL×2), and the combined organic phase was dried over anhydrous sodium sulfate and then concentrated by suction filtration to give the title compound 43c (0.26 g, 100% yield) as a deep red solid. MS (ESI, positive ion) m / z: 480.0 [M+H] + .

[0340] Step 4 2-(3,5-dichloro-4-((6-isopropoxypyridin-3-yl)oxy)phenyl)-3,5-dioxo-1,2,4-triazine-6-carbonitrile 43 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-isopropoxypyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 43c (0.26 g, 0.54 mmol) was dissolved in N,N-dimethylacetamide (2 mL), then potassium acetate (0.21 g, 2.2 mmol) was added, and the mixture was reacted at 120° C. for 2 hours. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [60% ACN / 40% HO (0.1% TFA), Phenomenex ACE specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to obtain the title compound 43 (15 mg, yield 6.3%, HPLC purity: 99.15%) as a yellow solid. MS (ESI, positive ion) m / z: 434.5 [M+H] + ; 1H NMR (400 MHz, DMSO-d6), δ (ppm) 7.79 (d, J = 2.8 Hz, 1H), 7.66 (s, 2H), 7.30 (d, J = 2.5 Hz, 1H), 6.73 (d, J = 9.0 Hz, 1H), 5.14 (dt, J = 11.8, 5.9 Hz, 1H), 1.35 (d, J = 6.1 Hz, 6H).

[0341] (Example 16) Methyl 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate (Compound 45)

[0342] [ka]

[0343] 2-[4-[(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy]-3,5-dichlorophenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 1 (0.30 g, 0.60 mmol) was dissolved in a solution of hydrogen chloride in methanol (2 mL, 4.5 mol / L), and the mixture was reacted at 70° C. for 16 hours. The reaction solution was cooled to room temperature and concentrated, and the residue was purified by silica gel column chromatography [100% ethyl acetate] to obtain the title compound 45 (27 mg, yield 51%, HPLC purity: 96.10%) as a yellow solid. MS (ESI, positive ion) m / z: 515.0 [M+H] + ; 1 H NMR (400 MHz, CDCl3) δ (ppm) 10.10 (s, 1H), 7.67 (s, 2H), 7.44-7.27 (m, 6H), 6.91 (d, J = 2.9 Hz, 1H), 6.71 (d, J = 9.9 Hz, 1H), 5.14 (s, 2H), 4.01 (s, 3H).

[0344] (Example 16) Ethyl 2-[5-[2,6-dichloro-4-(6-cyano-3,5-dioxo-1,2,4-triazin-2-yl)phenoxy]-2-oxy-pyridin-1(2H)-yl]acetate (Compound 48)

[0345] [ka]

[0346] Step 1. Ethyl 2-(5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-oxopyridin-1(2H)-yl)acetate 48a 5-[2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy]pyridin-2(1H)-one 39b (1.00 g, 2.86 mmol), potassium carbonate (1.00 g, 7.16 mmol) and ethyl bromoacetate (0.49 g, 2.86 mmol) were dissolved in N,N-dimethylacetamide (5 mL), and the mixture was reacted at room temperature for 16 hours. Water (50 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, then filtered, and the filter cake was collected and dried in vacuum to give the title compound 48a (0.75 g, 60% yield) as a red solid. MS (ESI, positive ion) m / z: 435.1 [M+H] + .

[0347] Step 2. Ethyl 2-(5-(4-amino-2,6-dichlorophenoxy)-2-oxopyridin-1(2H)-yl)acetate 48b Ethyl 2-(5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-oxopyridin-1(2H)-yl)acetate 48a (0.75 g, 1.70 mmol), hydroxylamine hydrochloride (1.40 g, 17.00 mmol) and triethylamine (0.39 mL) were dissolved in ethanol (10 mL), and the mixture was reacted at 80° C. for 5 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added, and the mixture was stirred for 15 minutes, and then filtered, and the filter cake was collected and dried in vacuum to give the title compound 48b (0.46 g, 75% yield) as a black solid. MS (ESI, positive ion) m / z: 357.0 [M+H] + .

[0348] Step 3. Ethyl 2-(5-(2,6-dichloro-4-(2-(1-cyano-2-((ethoxycarbonyl)amino)-2-oxoethylidene)hydrazinyl)phenoxy)-2-oxopyridin-1(2H)-yl)acetate 48c Ethyl 2-(5-(4-amino-2,6-dichlorophenoxy)-2-oxopyridin-1(2H)-yl)acetate 48b (0.46 g, 1.29 mmol), N-cyanoacetylurethane (0.23 g, 1.42 mmol) and concentrated hydrochloric acid (0.18 mL) were added to acetic acid (3 mL), and an aqueous solution (2 mL) of sodium nitrite (0.10 g, 1.42 mmol) was added dropwise at 3° C., and then the mixture was reacted for 1 hour. Water (50 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, then filtered, and the filter cake was collected and dried in vacuum to give the title compound 48c (0.46 g, 68% yield) as a deep red solid. MS (ESI, positive ion) m / z: 524.0 [M+H] + .

[0349] Step 4 Ethyl 2-[5-[2,6-dichloro-4-(6-cyano-3,5-dioxo-1,2,4-triazin-2-yl)phenoxy]-2-oxy-pyridin-1(2H)-yl]acetate 48 Ethyl 2-(5-(2,6-dichloro-4-(2-(1-cyano-2-((ethoxycarbonyl)amino)-2-oxoethylidene)hydrazinyl)phenoxy)-2-oxopyridin-1(2H)-yl)acetate 48c (0.46 g, 0.88 mmol) was dissolved in N,N-dimethylformamide (3 mL), then potassium acetate (0.13 g, 1.30 mmol) was added, and the mixture was reacted at 120° C. for 6 h. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [58% ACN / 42% HO (0.1% TFA), Phenomenex ACE specifications: C18 10 μm × 50 mm × 250 mm, flow rate: 100 mL / min] to give the title compound 48 (55 mg, yield 12%, HPLC purity: 93.99%) as a yellow solid. MS (ESI, positive ion) m / z: 478.0 [M+H] + ; 1 H NMR (400 MHz, CDCl3) δ (ppm) 7.66 (s, 2H), 7.43 (d, J = 9.8 Hz, 1H), 6.86 (d, J = 9.6 Hz, 2H), 4.65 (s, 2H), 4.27-4.21 (m, 2H), 1.30 (s, 3H).

[0350] (Example 18) 2-[3,5-Dichloro-4-[[1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 49)

[0351] [ka]

[0352] Step 1 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(2-methoxyethyl)pyridin-2(1H)-one 49a 5-[2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy]pyridin-2(1H)-one 39b (2.0 g, 5.7 mmol) was dissolved in N,N-dimethylformamide (20 mL), then potassium carbonate (1.6 g, 11 mmol) and 2-bromoethyl methyl ether (0.66 mL, 6.9 mmol) were added, and the mixture was reacted at 70 °C for 5 hours. The reaction solution was cooled to room temperature, then water (20 mL) was added, and the mixture was extracted with ethyl acetate (80 mL × 3). The combined organic phase was washed with saturated sodium chloride solution (40 mL), then dried over anhydrous sodium sulfate, and concentrated by suction filtration. The obtained residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume) = 1 / 1] to obtain the title compound 49a (1.2 g, 51% yield) as a reddish brown oil.

[0353] Step 2. 5-(4-amino-2,6-dichlorophenoxy)-1-(2-methoxyethyl)pyridin-2(1H)-one 49b 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(2-methoxyethyl)pyridin-2(1H)-one 49a (0.50 g, 1.2 mmol) and hydroxylamine hydrochloride (1.3 g, 19 mmol) were dissolved in ethanol (4 mL), then triethylamine (0.51 mL, 3.7 mmol) was added, and the mixture was reacted at 85° C. for 16 hours. The reaction solution was cooled to room temperature, and then ethyl acetate (20 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filtrate was concentrated. The resulting residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=2 / 3] to give the title compound 49b (0.20 g, 49% yield) as a yellow solid.

[0354] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 49c 5-(4-amino-2,6-dichlorophenoxy)-1-(2-methoxyethyl)pyridin-2(1H)-one 49b (0.20 g, 0.61 mmol), N-cyanoacetylurethane (0.11 g, 0.69 mmol) were dissolved in acetic acid (4 mL), and an aqueous solution (2 mL) of sodium nitrite (85 mg, 1.2 mmol) was added dropwise at 0° C., and then the mixture was reacted for 2 hours. Water (10 mL) was added to the reaction solution. The resulting mixture was stirred for 10 minutes, filtered, and the filter cake was washed with water (2 mL), collected, and dried in vacuum to give the title compound 49c (0.30 g, 99% yield) as a red solid.

[0355] Step 4 2-[3,5-dichloro-4-[[1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 49 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 49c (0.30 g, 0.60 mmol) was dissolved in N,N-dimethylacetamide (3 mL), then sodium acetate (53 mg, 0.65 mmol) was added, and the mixture was reacted at 120° C. for 5 hours. The reaction solution was cooled to room temperature, then water (20 mL) was added, the mixture was extracted with ethyl acetate (20 mL×3), and the combined organic phase was washed with saturated sodium chloride solution (10 mL×3), dried over anhydrous sodium sulfate, then filtered and concentrated. The obtained residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume) = 1 / 3], and the obtained yellow solid was recrystallized at 85 °C using ethanol / ethyl acetate / petroleum ether (0.3 / 5 / 8, 13.3 mL) to give the title compound 49 (0.10 g, yield 37%, HPLC purity: 98.02%) as a white solid. MS (ESI, negative ion) m / z: 448.0 [MH] - . 1H NMR (400 MHz, DMSO-d6) δ (ppm) 13.27 (s, 1H), 7.78 (s, 2H), 7.44 (dd, J = 9.9, 3.3 Hz, 1H), 7.32 (d, J = 3.2 Hz, 1H), 6.43 (d, J = 9.9 Hz, 1H), 4.01 (t, J = 5.2 Hz, 2H), 3.51 (t, J = 5.2 Hz, 2H), 3.20 (s, 3H).

[0356] (Example 19) Ethyl 2-[3-[2,6-dichloro-4-(6-cyano-3,5-dioxo-1,2,4-triazin-2-yl)phenoxy]-6-oxy-pyridazin-1(6H)-yl]acetate (Compound 52)

[0357] [ka]

[0358] Step 1. Ethyl 2-(3-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-6-oxopyridazin-1(6H)-yl)acetate 52a 6-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridazin-3(2H)-one 3d (1.00 g, 2.86 mmol), potassium carbonate (0.80 g, 5.70 mmol) and ethyl bromoacetate (0.49 g, 2.86 mmol) were dissolved in N,N-dimethylacetamide (2 mL), and the mixture was reacted at 70° C. for 24 hours. Water (20 mL) was added to the reaction solution, and the resulting mixture was stirred for 10 minutes, then filtered, and the filter cake was collected and dried in vacuum to give the title compound 52a (1.05 g, 84% yield) as a gray solid.

[0359] Step 2. Ethyl 2-(3-(4-amino-2,6-dichlorophenoxy)-6-oxopyridazin-1(6H)-yl)acetate 52b Ethyl 2-(3-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-6-oxopyridazin-1(6H)-yl)acetate 52a (1.05 g, 2.41 mmol), hydroxylamine hydrochloride (1.76 g, 24.10 mmol) and triethylamine (0.67 mL) were dissolved in ethanol (10 mL), and the mixture was reacted at 80° C. for 15 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added. The resulting mixture was stirred for 15 minutes, filtered, and the filtrate was concentrated. The resulting residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=1 / 1] to obtain the title compound 52b (0.15 g, 17% yield) as a red solid. MS (ESI, positive ion) m / z: 357.9 [M+H] + .

[0360] Step 3. Ethyl 2-(3-(2,6-dichloro-4-(2-(1-cyano-2-((ethoxycarbonyl)amino)-2-oxoethylidene)hydrazinyl)phenoxy)-6-oxopyridazin-1(6H)-yl)acetate 52c Ethyl 2-(3-(4-amino-2,6-dichlorophenoxy)-6-oxopyridazin-1(6H)-yl)acetate 52b (0.15 g, 0.42 mmol), N-cyanoacetylurethane (0.07 g, 0.42 mmol) and concentrated hydrochloric acid (0.11 mL) were dissolved in acetic acid (3 mL), and an aqueous solution (2 mL) of sodium nitrite (0.03 g, 0.46 mmol) was added dropwise at 3° C., and the mixture was then reacted for 50 minutes. Water (50 mL) was added to the reaction solution, and the resulting mixture was stirred for 5 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 52c (156 mg, 71% yield) as a deep red solid. MS (ESI, positive ion) m / z: 525.0 [M+H] + .

[0361] Step 4 Ethyl 2-[3-[2,6-dichloro-4-(6-cyano-3,5-dioxo-1,2,4-triazin-2-yl)phenoxy]-6-oxy-pyridazin-1(6H)-yl]acetate 52 Ethyl 2-(3-(2,6-dichloro-4-(2-(1-cyano-2-((ethoxycarbonyl)amino)-2-oxoethylidene)hydrazinyl)phenoxy)-6-oxopyridazin-1(6H)-yl)acetate 52c (0.156 g, 0.30 mmol) was dissolved in N,N-dimethylformamide (3 mL), then potassium acetate (0.05 g, 0.50 mmol) was added and the mixture was reacted at 120° C. for 6 h. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [40% ACN / 60% HO (0.1% TFA), Phenomenex ACE specifications: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to give the title compound 52 (70.0 mg, yield 48%, HPLC purity: 98.24%) as a white solid. MS (ESI, positive ion) m / z: 476.8 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 7.79 (s, 2H), 7.74 (d, J = 9.9 Hz, 1H), 7.25 (d, J = 9.9 Hz, 1H), 4.56 (s, 2H), 4.07 (q, J = 7.1 Hz, 2H), 1.14 (t, J = 7.1 Hz, 3H).

[0362] (Example 20) 2-[3,5-Dichloro-4-[1-(4-fluorobenzyl)-2-oxo-1,2-dihydropyrimidin-5-yl]oxy-phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 50)

[0363] [ka]

[0364] Step 1. 5-(2,6-dichloro-4-nitrophenoxy)-1-(4-fluorobenzyl)pyrimidin-2(1H)-one 50a 5-(2,6-Dichloro-4-nitro-phenoxy)-pyrimidin-2(1H)-one 38c (1.15 g, 3.81 mmol) and 1-(bromomethyl)-4-fluorobenzene (0.54 mL, 4.20 mmol) were dissolved in dichloromethane (25 mL), then triethylamine (1.10 mL, 7.68 mmol) was added dropwise, and the mixture was reacted at room temperature for 4.5 h. The mixture was quenched with water (30 mL) and extracted with ethyl acetate (30 mL x 3). The combined organic phase was washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, and concentrated by suction filtration. The residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume) = 1 / 2] to give the title compound 50a (1.25 g, 80% yield) as a yellow solid. MS (ESI, positive ion) m / z: 410.0 [M+H] + .

[0365] Step 2. 5-(4-amino-2,6-dichlorophenoxy)-1-(4-fluorobenzyl)pyrimidin-2(1H)-one 50b 5-(2,6-Dichloro-4-nitrophenoxy)-1-(4-fluorobenzyl)pyrimidin-2(1H)-one 50a (0.51 g, 1.24 mmol) was dissolved in acetic acid (20 mL), then iron powder (0.28 g, 4.97 mmol) was added, and the mixture was reacted for 2 hours at 90° C. The reaction solution was cooled to room temperature, the iron powder was removed, and concentrated in vacuo to give the title compound 50b (1.16 g, 94% yield) as a yellow solid. MS (ESI, positive ion) m / z: 380.0 [M+H] + .

[0366] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(4-fluorobenzyl)-2-oxo-1,2-dihydropyrimidin-5-yl)oxy)phenyl)hydrazono)acetyl)carbamate 50c 5-(4-amino-2,6-dichlorophenoxy)-1-(4-fluorobenzyl)pyrimidin-2(1H)-one 50b (6, 0.53 g, 1.39 mmol) and N-cyanoacetylurethane (0.198 g, 1.34 mmol) were dissolved in acetic acid (5 mL), and an aqueous solution (1.5 mL) of sodium nitrite (0.119 g, 1.69 mmol) was added dropwise at 0° C., and the mixture was allowed to react for 2 hours. Water (20 mL) was added to the reaction solution. The resulting mixture was stirred for 30 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 50c (0.58 g, 76% yield) as a yellow solid.

[0367] Step 4 2-[3,5-dichloro-4-[1-(4-fluorobenzyl)-2-oxo-1,2-dihydropyrimidin-5-yl]oxy-phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 50 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(4-fluorobenzyl)-2-oxo-1,2-dihydropyrimidin-5-yl)oxy)phenyl)hydrazono)acetyl)carbamate 50c (0.31 g, 0.56 mmol) was dissolved in acetic acid (4 mL), and then sodium acetate (0.23 g, 2.81 mmol) was added, and the mixture was reacted at 120° C. for 4 hours. The reaction solution was cooled to room temperature, suction filtered, and concentrated. The obtained residue was purified by a preparative chromatography column [37% ACN / 63% H2O (0.1% TFA), Phenomenex ACE specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to obtain the title compound 50 (70 mg, yield 25%, HPLC purity: 96.63%) as a white solid. MS (ESI, negative ion) m / z: 498.9 [MH] - . 1H NMR (400 MHz, DMSO-d6) δ (ppm) 13.31 (s, 1H), 8.79 (d, J = 3.6 Hz, 1H), 8.30 (d, J = 3.5 Hz, 1H), 7.80 (s, 2H), 7.37-7.33 (m, 1H), 7.19 (t, J = 8.4 Hz, 1H), 7.13 (s, 1H), 7.00 (s, 1H), 4.99 (s, 2H).

[0368] Example 21 2-[3,5-Dichloro-4-[[6-oxo-1-(4-pyridylmethyl)-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 46)

[0369] [ka]

[0370] Step 1: 5-(2,6-dichloro-4-nitrophenoxy)-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 46a 5-(2,6-dichloro-4-nitro-phenoxy)-pyridin-2(1H)-one 4c (1.0 g, 3.3 mmol) and cesium carbonate (2.7 g, 8.2 mmol) were dissolved in acetonitrile (10 mL), then 4-(bromomethyl)pyridine hydrobromide (1.0 g, 4.0 mmol) was added, and the mixture was reacted at room temperature for 12 hours. The reaction solution was cooled to room temperature, then filtered, the filtrate was concentrated, and the obtained residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=1 / 4] to obtain the title compound 46a (0.83 g, 64% yield) as a yellow solid.

[0371] Step 2. 5-(4-Amino-2,6-dichlorophenoxy)-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 46b 5-(2,6-dichloro-4-nitrophenoxy)-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 46a (0.63 g, 1.6 mmol) was dissolved in acetic acid (6 mL), then iron powder (0.22 g, 3.9 mmol) was added, and the mixture was reacted at 60° C. for 2.5 hours. The reaction solution was cooled to room temperature, then iron powder was removed, and water (10 mL) was added. The resulting mixture was stirred for 10 minutes, extracted with ethyl acetate (50 mL×3), and the combined organic phase was washed with saturated sodium chloride (10 mL×2), then dried over anhydrous sodium sulfate, and concentrated by suction filtration to give the title compound 46b (0.58 g, 100% yield) as a brown solid.

[0372] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-(pyridin-4-ylmethyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 46c 5-(4-amino-2,6-dichlorophenoxy)-1-(pyridin-4-ylmethyl)pyridin-2(1H)-one 46b (0.58 g, 1.6 mmol) and N-cyanoacetylurethane (0.31 g, 1.9 mmol) were dissolved in acetic acid (12 mL), and a solution of sodium nitrite (0.22 g, 3.2 mmol) in water (5.8 mL) was added at 0° C., and the mixture was reacted at 0° C. for 3 hours. At 0° C., water (25 mL) was added to the reaction solution. The resulting mixture was stirred for 15 minutes, filtered, and the filter cake was washed with water (10 mL×2), collected, and dried in vacuum to give the title compound 46c (0.85 g, 99% yield) as a yellow solid.

[0373] Step 4 2-[3,5-Dichloro-4-[[6-oxo-1-(4-pyridylmethyl)-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 46 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-(pyridin-4-ylmethyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 46c (0.85 g, 1.6 mmol) was dissolved in N,N-dimethylformamide (8.5 mL), then sodium acetate (0.14 g, 1.7 mmol) was added, and the mixture was reacted at 120° C. for 6 hours. The reaction solution was cooled to room temperature and then concentrated. The obtained residue was purified by silica gel column chromatography (dichloromethane / methanol=4 / 1). The obtained solid was recrystallized at 85° C. (ethanol / ethyl acetate / petroleum ether=1 / 3 / 2, 30 mL) to give the title compound 46 (0.37 g, 48% yield, HPLC purity: 99.24%) as a yellow solid. MS (ESI, negative ion) m / z: 480.0 [MH] - ; 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 8.51 (d, J = 4.7 Hz, 2H), 7.79 (s, 2H), 7.63-7.44 (m, 2H), 7.11 (d, J = 5.2 Hz, 2H), 6.53 (d, J = 9.8 Hz, 1H), 5.09 (s, 2H).

[0374] Example 22 2-[3,5-Dichloro-4-[[1-[(3-methoxyphenyl)methyl]-6-oxopyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 55)

[0375] [ka]

[0376] Step 1. 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(3-methoxybenzyl)pyridin-2(1H)-one 55a 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridin-2(1H)-one 39b (1.00 g, 2.86 mmol), potassium carbonate (0.80 g, 5.73 mmol) and 3-methoxybenzyl chloride (0.46 g, 2.86 mmol) were dissolved in N,N-dimethylacetamide (4 mL), and the mixture was reacted at room temperature for 24 hours. Water (10 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, filtered, and the solid was collected and dried to give the title compound 55a (1.00 g, 74% yield) as a gray solid. MS (ESI, positive ion) m / z: 469.0 [M+H] + .

[0377] Step 2. 5-(4-amino-2,6-dichlorophenoxy)-1-(3-methoxybenzyl)pyridin-2(1H)-one 55b 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(3-methoxybenzyl)pyridin-2(1H)-one 55a (1.00 g, 2.13 mmol) was dissolved in ethanol (10 mL), then hydrochloric acid (4 mol / L, 4 mL) was added, and the mixture was reacted at 100° C. for 1.5 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added. The resulting mixture was stirred for 15 minutes, filtered, and the filter cake was collected and dried in vacuum. The solid was purified by silica gel column chromatography [petroleum ether / ethyl acetate=1 / 1] to give the title compound 55b (0.37 g, 44% yield) as a black solid. MS (ESI, positive ion) m / z: 391.0 [M+H] + .

[0378] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(3-methoxybenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 55c 5-(4-amino-2,6-dichlorophenoxy)-1-(3-methoxybenzyl)pyridin-2(1H)-one 55b (0.37 g, 0.95 mmol) and N-cyanoacetylurethane (0.16 g, 1.04 mmol) were dissolved in acetic acid (3 mL), and an aqueous solution (2 mL) of sodium nitrite (0.07 g, 1.04 mmol) was added dropwise at 3° C., and the mixture was then reacted for 4 hours. Water (20 mL) was added to the reaction solution. The resulting mixture was stirred for 5 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 55c (0.42 g, 80% yield) as an orange solid. MS (ESI, positive ion) m / z: 558.1 [M+H] + .

[0379] Step 4 2-[3,5-dichloro-4-[[1-[(3-methoxyphenyl)methyl]-6-oxopyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 55 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(3-methoxybenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 55c (0.42 g, 0.76 mmol) was dissolved in N,N-dimethylformamide (3 mL), then sodium acetate (0.09 g, 1.13 mmol) was added, and the mixture was reacted at 120° C. for 7 hours. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [45% ACN / 55% HO (0.1% TFA), Phenomenex ACE specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to give the title compound 55 (15 mg, yield 3.6%, HPLC purity: 93.79%) as a white solid. MS (ESI, positive ion) m / z: 514.0 [M+H] + . 1H NMR (400 MHz, CDCl3) δ (ppm) 7.63 (s, 2H), 7.34-7.28 (m, 2H), 6.97 (s, 1H), 6.87-6.77 (m, 4H), 5.13 (s, 2H), 3.78 (s, 3H).

[0380] Example 23 2-[3,5-Dichloro-4-[[1-(4-methylbenzyl)-6-oxo-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (Compound 56)

[0381] [ka]

[0382] Step 1: 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(4-methylbenzyl)pyridin-2(1H)-one 56a 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridin-2(1H)-one 39b (1.00 g, 2.86 mmol), potassium carbonate (0.80 g, 5.73 mmol) and 4-methylbenzyl chloride (0.41 g, 2.86 mmol) were dissolved in N,N-dimethylacetamide (4 mL), and the mixture was reacted at room temperature for 26 hours. Water (10 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, then filtered, and the solid was collected and dried. The obtained solid was purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 1) to obtain the title compound 56a (0.70 g, 54% yield) as a white solid.

[0383] Step 2. 5-(4-Amino-2,6-dichlorophenoxy)-1-(4-methylbenzyl)pyridin-2(1H)-one 56b 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(4-methylbenzyl)pyridin-2(1H)-one 56a (0.70 g, 1.50 mmol), hydroxylamine hydrochloride (1.70 g, 23.0 mmol) and triethylamine (1.10 mL) were dissolved in ethanol (10 mL) and the mixture was reacted at 90° C. for 18 hours. The reaction solution was cooled to room temperature and then ethyl acetate (20 mL) was added. The resulting mixture was stirred for 15 minutes, filtered and the filtrate was concentrated to give the title compound 56b (0.53 g, 91% yield) as a white solid.

[0384] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(4-methylbenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 56c 5-(4-amino-2,6-dichlorophenoxy)-1-(4-methylbenzyl)pyridin-2(1H)-one 56b (0.53 g, 1.41 mmol) and N-cyanoacetylurethane (0.24 g, 1.55 mmol) were dissolved in acetic acid (3 mL), and an aqueous solution (2 mL) of sodium nitrite (0.11 g, 1.55 mmol) was added dropwise at 3° C., and the mixture was then reacted for 2 hours. Water (20 mL) was added to the reaction solution, and the mixture was stirred for 5 minutes, filtered, and the filter cake was dried to give the title compound 56c (0.70 g, 91% yield) as an orange solid. MS (ESI, positive ion) m / z: 542.1 [M+H] + .

[0385] Step 4 2-[3,5-Dichloro-4-[[1-(4-methylbenzyl)-6-oxo-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 56 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(4-methylbenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 56c (0.70 g, 1.30 mmol) was dissolved in N,N-dimethylformamide (3 mL), then sodium acetate (0.16 g, 1.90 mmol) was added, and the mixture was reacted at 120° C. for 5 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filter cake was collected and dried. The obtained solid was purified by silica gel column chromatography [petroleum ether / ethyl acetate=1 / 1] to give the title compound 56 (77 mg, 11% yield, HPLC purity: 87.52%) as a white solid. MS (ESI, positive ion) m / z: 496.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 8.30 (s, 1H), 7.77 (s, 2H), 7.56 (d, J = 3.2 Hz, 1H), 7.43 (dd, J = 9.9, 3.3 Hz, 1H), 7.12 (s, 4H), 6.46 (d, J = 9.9 Hz, 1H), 4.99 (s, 2H), 2.25 (s, 3H).

[0386] (Example 24) Ethyl 2-(5-(2,6-dichloro-4-(6-cyano-3,5-dioxo-1,2,4-triazin-2-yl)phenoxy)-2-oxypyridin-1(2H)-yl)propionate (Compound 57)

[0387] [ka]

[0388] Step 1. Ethyl 2-(5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-oxopyridin-1(2H)-yl)propanoate 57a 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridin-2(1H)-one 39b (0.83 g, 2.40 mmol), potassium carbonate (0.66 g, 4.80 mmol) and ethyl 2-bromopropionate (0.44 g, 2.40 mmol) were dissolved in N,N-dimethylacetamide (4 mL), and the mixture was reacted at 60° C. for 21 hours. Water (50 mL) was added to the reaction solution, and then the mixture was stirred for 10 minutes, filtered, and the filter cake was collected and purified by silica gel column chromatography [petroleum ether / ethyl acetate=3 / 1] to obtain the title compound 57a (0.34 g, 32% yield) as a yellow oil.

[0389] Step 2. Ethyl 2-(5-(4-amino-2,6-dichlorophenoxy)-2-oxopyridin-1(2H)-yl)propanoate 57b Ethyl 2-(5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-2-oxopyridin-1(2H)-yl)propanoate 57a (0.34 g, 0.76 mmol), hydroxylamine hydrochloride (0.86 g, 11.00 mmol) and triethylamine (0.55 mL) were dissolved in ethanol (10 mL), and the mixture was reacted at 90° C. for 21 hours. The reaction solution was cooled to room temperature, and then ethyl acetate (20 mL) was added. The resulting mixture was stirred at −10° C. for 15 minutes, filtered, and the filtrate was concentrated to give the title compound 57b (0.28 g, 100% yield) as a white solid.

[0390] Step 3. Ethyl 2-(5-(2,6-dichloro-4-(2-(1-cyano-2-((ethoxycarbonyl)amino)-2-oxoethylidene)hydrazinyl)phenoxy)-2-oxopyridin-1(2H)-yl)propanoate 57c Ethyl 2-(5-(4-amino-2,6-dichlorophenoxy)-2-oxopyridin-1(2H)-yl)propanoate 57b (0.28 g, 0.75 mmol) and N-cyanoacetylurethane (0.14 g, 0.83 mmol) were dissolved in acetic acid (3 mL), and an aqueous solution (2 mL) of sodium nitrite (0.06 g, 0.83 mmol) was added dropwise at 3° C., and then the mixture was reacted for 1 hour. Water (20 mL) was added to the reaction solution, and the mixture was stirred for 5 minutes, filtered, and the filter cake was dried to give the title compound 57c (0.23 g, 57% yield) as an orange solid. MS (ESI, positive ion) m / z: 538.1 [M+H] + .

[0391] Step 4. Ethyl 2-(5-(2,6-dichloro-4-(6-cyano-3,5-dioxo-1,2,4-triazin-2-yl)phenoxy)-2-oxypyridin-1(2H)-yl)propionate 57 Ethyl 2-(5-(2,6-dichloro-4-(2-(1-cyano-2-((ethoxycarbonyl)amino)-2-oxoethylidene)hydrazinyl)phenoxy)-2-oxopyridin-1(2H)-yl)propanoate 57c (0.23 g, 0.43 mmol) was dissolved in N,N-dimethylformamide (3 mL), then sodium acetate (0.06 g, 0.64 mmol) was added, and the mixture was reacted at 120° C. for 6 hours. The reaction solution was cooled to room temperature, and then water (30 mL) was added. The resulting mixture was stirred for 15 minutes, filtered, and the filter cake was collected and purified by silica gel column chromatography [petroleum ether / ethyl acetate=2 / 1] to give the title compound 57 (44.0 mg, yield 19%, HPLC purity: 91.31%) as a red solid. MS (ESI, positive ion) m / z: 492.0 [M+H] + . 1H NMR (400 MHz, CDCl3) δ (ppm) 7.65 (s, 2H), 7.23 (d, J = 2.6 Hz, 1H), 7.02 (d, J = 2.8 Hz, 1H), 6.67 (d, J = 9.7 Hz, 1H), 5.56 (d, J = 7.4 Hz, 1H), 4.20 (dd, J = 7.1, 2.4 Hz, 2H), 1.61 (d, J = 7.2 Hz, 3H), 1.28-1.25 (m, 3H).

[0392] (Example 25) 2-[3,5-Dichloro-4-[[6-oxo-1-((tetrahydropyran-4-yl)methyl)-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile (compound 58)

[0393] [ka]

[0394] Step 1. 5-(2,6-Dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-((tetrahydro-2H-pyran-4-yl)methyl)pyridin-2(1H)-one 58a 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridin-2(1H)-one 39b (2.0 g, 5.7 mmol) was dissolved in N,N-dimethylformamide (15 mL), then potassium carbonate (1.6 g, 11 mmol) and 4-(bromomethyl)tetrahydropyran (0.90 mL, 6.8 mmol) were added, and the mixture was reacted at 70 ° C for 6 hours. The reaction solution was cooled to room temperature, then water (50 mL) was added, and the mixture was extracted with ethyl acetate (80 mL × 2). The combined organic phase was washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, concentrated by suction filtration, and the residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate = 1 / 1] to obtain the title compound 58a (0.79 g, yield 31%) as a yellow solid.

[0395] Step 2. 5-(4-Amino-2,6-dichlorophenoxy)-1-((tetrahydro-2H-pyran-4-yl)methyl)pyridin-2(1H)-one 58b 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-((tetrahydro-2H-pyran-4-yl)methyl)pyridin-2(1H)-one 58a (89 g, 2.0 mmol) and hydroxylamine hydrochloride (2.1 g, 30 mmol) were dissolved in ethanol (10 mL), then triethylamine (1.4 mL, 10 mmol) was added, and the mixture was reacted at 85° C. for 17 hours. The reaction solution was cooled to room temperature, and then ethyl acetate (20 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate=2 / 3] to give the title compound 58b (0.54 g, 74% yield) as a yellow solid.

[0396] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 58c 5-(4-amino-2,6-dichlorophenoxy)-1-((tetrahydro-2H-pyran-4-yl)methyl)pyridin-2(1H)-one 58b (0.54 g, 1.5 mmol), N-cyanoacetylurethane (0.26 g, 1.6 mmol) were dissolved in acetic acid (8 mL), then an aqueous solution (4 mL) of sodium nitrite (0.20 g, 2.9 mmol) was added dropwise at 0° C., and then the mixture was reacted for 2 hours. Water (20 mL) was added to the reaction solution, then the mixture was stirred for 10 minutes, filtered, the filter cake was washed with water (4 mL), collected and dried to give the title compound 58c (0.78 g, 99% yield) as a red solid.

[0397] Step 4. 2-[3,5-Dichloro-4-[[6-oxo-1-((tetrahydropyran-4-yl)methyl)-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 58 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((6-oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 58c (0.78 g, 1.5 mmol) was dissolved in N,N-dimethylacetamide (6 mL), then sodium acetate (0.13 g, 1.6 mmol) was added, and the mixture was reacted at 120 °C for 5 hours. The reaction solution was cooled to room temperature, then water (20 mL) was added, and extracted with ethyl acetate (20 mL x 3). The combined organic phase was washed with saturated sodium chloride solution (10 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated. The obtained residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=2 / 1), and the obtained brown solid was recrystallized at 85° C. (petroleum ether / ethyl acetate=1 / 4, 5 mL) to give the title compound 58 (0.38 g, yield 53%, HPLC purity: 97.44%) as a yellow solid. MS (ESI, positive ion) m / z: 490.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 13.28 (s, 1H), 7.79 (s, 2H), 7.49-7.39 (m, 2H), 6.44 (d, J = 9.4 Hz, 1H), 3.81 (d, J = 9.1 Hz, 2H), 3.75 (d, J = 7.3 Hz, 2H), 3.21 (t, J = 10.9 Hz, 2H), 1.98 (dd, J = 7.9, 4.1 Hz, 1H), 1.37 (d, J = 11.5 Hz, 2H), 1.21 (dt, J = 7.2, 5.9 Hz, 2H).

[0398] (Example 26) Methyl 2-[3,5-dichloro-4-[[6-oxo-1-((tetrahydropyran-4-yl)methyl)-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carboxylate (Compound 59)

[0399] [ka]

[0400] 2-[3,5-Dichloro-4-[[6-oxo-1-((tetrahydropyran-4-yl)methyl)-1,6-dihydropyridin-3-yl]oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile 58 (0.10 g, 0.20 mmol) was dissolved in a solution of hydrogen chloride in methanol (3 mol / L, 3 mL), and the mixture was reacted at 65° C. for 48 hours. The reaction solution was concentrated, slurried with ethyl acetate (5 mL), and then filtered, and the filter cake was collected and dried to give the title compound 59 (17.0 mg, 14% yield, HPLC purity: 85.59%) as a white solid. MS (ESI, positive ion) m / z: 525.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 12.76 (s, 1H), 7.83-7.77 (m, 2H), 7.42 (d, J = 8.3 Hz, 2H), 6.43 (d, J = 10.4 Hz, 1H), 3.84 (s, 3H), 3.82-3.78 (m, 2H), 3.74 (d, J = 7.4 Hz, 2H), 3.22 (d, J = 10.9 Hz, 2H), 1.98 (dd, J = 13.2, 6.8 Hz, 1H), 1.36 (d, J = 12.3 Hz, 2H), 1.22 (dd, J = 12.7, 8.8 Hz, 2H).

[0401] Example 27 Ethyl 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-1,2,4-triazine-6-carboxylate (Compound 60)

[0402] [ka]

[0403] A solution of hydrogen chloride in ethyl acetate (3 mL, 4 mol / L) was added to a solution of 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 1 (0.15 g, 0.31 mmol) in ethanol (3 mL), and the mixture was reacted at 70° C. for 19 hours. The reaction solution was cooled to room temperature, then concentrated and recrystallized at 85° C. (petroleum ether / ethyl acetate=1 / 1, 20 mL) to give the title compound 60 (0.13 g, 81% yield, HPLC purity: 92.31%) as a yellow solid. MS (ESI, positive ion) m / z: 531.0 [M+H] + . 1 H NMR (400 MHz, CDCl3) δ (ppm) 12.76 (s, 1H), 7.80 (s, 2H), 7.60 (d, J = 3.3 Hz, 1H), 7.44-7.37 (m, 1H), 7.32 (d, J = 7.5 Hz, 2H), 7.22 (d, J = 7.1 Hz, 2H), 7.17-7.10 (m, 1H), 6.48 (d, J = 9.9 Hz, 1H), 5.06 (s, 2H), 4.32 (q, J = 7.1 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H).

[0404] (Example 28) 2-Hydroxyethyl 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate (Compound 61)

[0405] [ka]

[0406] A solution of hydrogen chloride in 1,4-dioxane (4 mL, 16 mmol, 4 mol / L) was added to a solution of 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 1 (0.20 g, 0.41 mmol) in ethylene glycol (4 mL), and the mixture was reacted at 70° C. for 16 hours. The reaction solution was cooled to room temperature and concentrated. The resulting residue was purified by silica gel column chromatography (100% ethyl acetate). The resulting yellow liquid was recrystallized at 85° C. (ethanol / ethyl acetate / petroleum ether=1 / 2 / 4, 17.5 mL) to give the title compound 61 (40 mg, 18% yield, HPLC: 95.88%) as a white solid. MS (ESI, negative ion) m / z: 543.1 [MH] - ; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 12.77 (s, 1H), 7.81 (s, 2H), 7.60 (d, J = 3.2 Hz, 1H), 7.46 (dd, J = 9.9, 3.3 Hz, 1H), 7.33 (t, J = 7.2 Hz, 2H), 7.27 (d, J = 7.1 Hz, 1H), 7.22 (d, J = 7.2 Hz, 2H), 6.48 (d, J = 9.9 Hz, 1H), 5.06 (s, 2H), 4.91 (t, J = 5.3 Hz, 1H), 4.34-4.25 (m, 2H), 3.65 (dd, J = 10.0, 5.1Hz, 2H).

[0407] (Example 29) 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-1,2,4-triazine-3,5-dione (Compound 62)

[0408] [ka]

[0409] Step 1 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-1,2,4-triazine-6-carboxylic acid 62a Concentrated hydrochloric acid (1 mL) was added to a solution of 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 1 (0.10 g, 0.21 mmol) in acetic acid (2 mL), and the mixture was reacted at 120° C. for 24 hours. The reaction solution was cooled to room temperature, and then water (10 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 62a (90 mg, 87% yield) as a yellow solid.

[0410] Step 2 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-1,2,4-triazine-3,5-dione 62 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-1,2,4-triazine-6-carboxylic acid 62a (90 mg, 0.18 mmol) was dissolved in thioglycolic acid (2 mL), and the mixture was reacted at 160° C. for 24 hours. The reaction solution was cooled to room temperature, water (10 mL) was added to quench the reaction, and extracted with ethyl acetate (20 mL×3). The combined organic phase was washed with saturated sodium chloride (20 mL), dried over anhydrous sodium sulfate, and concentrated by suction filtration. The obtained residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 3), and the obtained yellow solid was recrystallized at 85° C. (petroleum ether / ethyl acetate=1 / 2, 9 mL) to give the title compound 62 (82 mg, 100% yield, HPLC: 96.90%) as an off-white solid. MS (ESI, negative ion) m / z: 457.9 [MH] - ; 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 12.49 (s, 1H), 7.80 (s, 2H), 7.70 (s, 1H), 7.56 (d, J = 3.2 Hz, 1H), 7.43 (dd, J = 9.9, 3.3 Hz, 1H), 7.32 (t, J = 7.2 Hz, 2H), 7.27 (d, J = 7.0 Hz, 1H), 7.22 (t, J = 7.7 Hz, 2H), 6.48 (d, J = 9.9 Hz, 1H), 5.05 (s, 2H).

[0411] (Example 30) 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (compound 63)

[0412] [ka]

[0413] 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 1 (0.30 g, 0.62 mmol) was dissolved in a solution of hydrogen chloride in 1,4-dioxane (10 mL, 4.0 mol / L), and the mixture was reacted at 60° C. for 7 hours. Ethyl acetate (10 mL) was added to the reaction solution, and the mixture was slurried for 2 hours, then filtered, and the solid was collected and dried to give the title compound 63 (0.29 g, 93% yield, HPLC purity: 89.87%) as a white solid. MS (ESI, positive ion) m / z: 500.0 [M+H] + ; 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 12.78 (s, 1H), 8.08 (s, 1H), 7.94 (s, 1H), 7.86 (s, 2H), 7.59 (d, J = 3.2 Hz, 1H), 7.45 (dd, J = 9.9, 3.2 Hz, 1H), 7.33 (t, J = 7.2 Hz, 2H), 7.27 (d, J = 7.0 Hz, 1H), 7.23 (t, J = 6.3 Hz, 2H), 6.48 (d, J = 9.9 Hz, 1H), 5.06 (s, 2H).

[0414] (Example 31) 2-(3,5-dichloro-4-((1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (Compound 64)

[0415] [ka]

[0416] Step 1 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(4-methoxybenzyl)pyridin-2(1H)-one 64a 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridin-2(1H)-one 39b (2.00 g, 5.73 mmol), potassium carbonate (1.60 g, 11.50 mmol) and 4-methoxybenzyl chloride (0.92 g, 5.73 mmol) were dissolved in N,N-dimethylacetamide (4 mL), and the mixture was reacted at room temperature for 18 hours. Water (10 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 64a (2.00 g, 74% yield) as a gray solid. MS (ESI, positive ion) m / z: 469.1 [M+H] + .

[0417] Step 2 5-(4-amino-2,6-dichlorophenoxy)-1-(4-methoxybenzyl)pyridin-2(1H)-one 64b 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)-1-(4-methoxybenzyl)pyridin-2(1H)-one 64a (2.00 g, 4.26 mmol), hydroxylamine hydrochloride (2.88 g, 42.6 mmol) and triethylamine (1.10 mL) were dissolved in ethanol (20 mL) and the mixture was reacted at 80° C. for 16 hours. The reaction solution was cooled to room temperature and then water (30 mL) was added. The resulting mixture was stirred for 15 minutes, filtered, and the filter cake was collected and dried. The solid was purified by silica gel column chromatography [petroleum ether / ethyl acetate=1 / 1] to give the title compound 64b (0.19 g, 11% yield) as a black solid. MS (ESI, positive ion) m / z: 391.0 [M+H] + .

[0418] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 64c 5-(4-amino-2,6-dichlorophenoxy)-1-(4-methoxybenzyl)pyridin-2(1H)-one 64b (0.19 g, 0.48 mmol) and N-cyanoacetylurethane (0.09 g, 0.53 mmol) were dissolved in acetic acid (3 mL), and an aqueous solution (2 mL) of sodium nitrite (0.04 g, 0.53 mmol) was added dropwise at 3° C., and the mixture was then reacted for 30 minutes. Water (20 mL) was added to the reaction solution. The resulting mixture was stirred for 5 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 64c (0.14 g, 52% yield) as an orange solid. MS (ESI, negative ion) m / z: 560.1 [MH] - .

[0419] Step 4 2-(3,5-dichloro-4-((1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 64 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 64c (0.14 g, 0.25 mmol) was dissolved in N,N-dimethylformamide (3 mL), then sodium acetate (0.03 g, 0.38 mmol) was added, and the mixture was reacted at 120° C. for 4 hours. The reaction solution was cooled to room temperature, filtered, and the filtrate was purified by a preparative chromatography column [45% CAN / 55% HO (0.1% formic acid), Phenomenex ACE specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to give the title compound 64 (15 mg, 10% yield, HPLC purity: 90.73%) as a yellow solid. MS (ESI, negative ion) m / z: 510.0 [MH] -. 1 H NMR (400 MHz, CDCl3) δ (ppm) 7.61 (s, 2H), 7.21 (d, J = 4.6 Hz, 4H), 6.86 (d, J = 8.5 Hz, 3H), 5.04 (s, 2H), 3.79 (s, 3H).

[0420] Example 32 2-(3,5-dichloro-4-((1-(2-hydroxyethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (Compound 65)

[0421] [ka]

[0422] Step 1: 1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridin-2(1H)-one 65a 5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridin-2(1H)-one 39b (1.50 g, 4.30 mmol) was dissolved in N,N-dimethylformamide (15 mL), then potassium carbonate (1.2 g, 8.6 mmol) and 2-bromoethoxy-tert-butyl-dimethyl-silane (1.11 g, 4.64 mmol) were added, and the mixture was reacted at 40° C. for 23 hours. The reaction solution was cooled to room temperature, then water (20 mL) was added, and extracted with ethyl acetate (30 mL×2). The combined organic phase was washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, concentrated by suction filtration, and the residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate=3 / 1] to give the title compound 65a (1.1 g, 50% yield) as a yellow oil.

[0423] Step 2: 5-(4-amino-2,6-dichlorophenoxy)-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)pyridin-2(1H)-one 65b 1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-(2,6-dichloro-4-(2,5-dimethyl-1H-pyrrol-1-yl)phenoxy)pyridin-2(1H)-one 65a (0.80 g, 1.6 mmol) and hydroxylamine hydrochloride (2.7 g, 39 mmol) were dissolved in ethanol (15 mL), then triethylamine (1.0 mL, 7.2 mmol) was added, and the mixture was reacted at 85° C. for 16 hours. The reaction solution was cooled to room temperature, and then ethyl acetate (20 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 1) to give the title compound 65b (0.62 g, 92% yield) as a white solid.

[0424] Step 3. Ethyl (2-(2-(4-((1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)hydrazono)-2-cyanoacetyl)carbamate 65c 5-(4-amino-2,6-dichlorophenoxy)-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)pyridin-2(1H)-one 65b (0.51 g, 1.2 mmol) was dissolved in acetic acid (10 mL), and then a solution of sodium nitrite (0.17 g, 2.4 mmol) in water (5 mL) was added at 0° C. After 20 minutes of reaction, N-cyanoacetylurethane (0.23 g, 1.4 mmol) was added to the mixture and reacted at 0° C. At 0° C., water (10 mL) was added to the reaction solution, the mixture was stirred for 10 minutes, filtered, the filter cake was washed with water (2 mL), collected and dried in vacuum to give the title compound 65c (0.45 g, 64% yield) as a red solid.

[0425] Step 4 2-(4-((1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 65d Ethyl (2-(2-(4-((1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)hydrazono)-2-cyanoacetyl)carbamate 65c (0.45 g, 0.75 mmol) was dissolved in N,N-dimethylformamide (8 mL), then sodium acetate (93 mg, 1.13 mmol) was added, and the mixture was reacted at 120° C. for 5.5 hours. The reaction solution was cooled to room temperature, then water (20 mL) was added, and extracted with ethyl acetate (20 mL×3). The combined organic phase was washed with saturated sodium chloride solution (10 mL×3), then dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate=1 / 2] to give the title compound 65d (0.32 g, yield 77%) as a red oil.

[0426] Step 5 2-(3,5-dichloro-4-((1-(2-hydroxyethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 65 2-(4-((1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 65d (0.31 g, 0.56 mmol) was dissolved in 1,4-dioxane (5 mL), and then a solution of hydrogen chloride in 1,4-dioxane (0.60 mL, 2.4 mmol, 4 mol / L) was added at 0° C., and the mixture was reacted at room temperature for 45 minutes. The reaction solution was concentrated, and the residue was dissolved in ethanol (20 mL), decolorized with activated carbon (0.20 g) at 85° C., then filtered, and the filtrate was concentrated. The resulting residue was slurried with ethanol / petroleum ether (1 / 2, 15 mL), filtered, and the filter cake was collected to give the title compound 65 (76 mg, 31% yield, HPLC purity: 87.26%) as a yellow solid. MS (ESI, negative ion) m / z: 436.0 [MH] - . 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 13.28 (s, 1H), 7.78 (s, 2H), 7.41 (dd, J = 9.8, 3.2 Hz, 1H), 7.36 (d, J = 3.0 Hz, 1H), 6.43 (d, J = 9.8 Hz, 1H), 4.83 (s, 1H), 3.90 (t, J = 5.1 Hz, 2H), 3.62-3.55 (m, 2H).

[0427] (Example 33) 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-6-(hydroxymethyl)-1,2,4-triazine-3,5(2H,4H)-dione (Compound 66)

[0428] [ka]

[0429] At 0° C., isopropyl chloroformate (0.12 mL, 1.0 mmol) was added dropwise to a solution of 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid 62a (0.20 g, 0.40 mmol) and triethylamine (0.2 mL, 1.2 mmol) in tetrahydrofuran (6 mL), and the mixture was reacted at 0° C. for 2 hours, after which methanol (4 mL) and calcium chloride (0.26 g, 2.4 mmol) were added. The mixture was stirred for 3 minutes, and then sodium borohydride (90 mg, 0.24 mmol) was added and the mixture was reacted at room temperature for 12 hours. The reaction solution was concentrated, and the resulting residue was purified by a preparative chromatography column [38% ACN / 62% HO (0.1% TFA), Kromasil specification: C18 10 μm × 50 mm × 250 mm, flow rate: 100 mL / min] to give the title compound 66 (21 mg, yield 11%, HPLC purity: 97.67%) as a pale yellow solid. MS (ESI, positive ion) m / z: 488.0 [M+H] + ; 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 7.88 (s, 2H), 7.56 (d, J = 3.0 Hz, 1H), 7.43 (dd, J = 9.9, 3.1 Hz, 1H), 7.33 (t, J = 7.1 Hz, 2H), 7.29-7.18 (m, 3H), 6.48 (d, J = 9.9 Hz, 1H), 5.28 (s, 1H), 5.06 (s, 2H), 4.39 (s, 2H).

[0430] (Example 34) 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dimethylphenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (Compound 67)

[0431] [ka]

[0432] Step 1 5-(2,6-Dimethyl-4-nitrophenoxy)-2-methoxypyridine 67a 6-Methoxypyridin-3-ol 4a (3.0 g, 24 mmol), 2-fluoro-1,3-dimethyl-5-nitro-benzene (4.50 g, 26.6 mmol) and potassium carbonate (2.60 g, 26.2 mmol) were dissolved in N,N-dimethylformamide (25 mL), and the mixture was reacted at 80° C. for 24 hours. The reaction solution was cooled to room temperature, and water (50 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filter cake was washed with water (10 mL×2), collected and dried to give the title compound 67a (6.10 g, 93% yield) as a pale yellow solid.

[0433] Step 2 5-(2,6-Dimethyl-4-nitrophenoxy)pyridin-2(1H)-one 67b 5-(2,6-Dimethyl-4-nitrophenoxy)-2-methoxypyridine 67a (2.00 g, 7.29 mmol), p-toluenesulfonic acid (6.30 g, 36.6 mmol) and lithium chloride (1.50 g, 35.4 mmol) were dissolved in N,N-dimethylformamide (8 mL) and the mixture was reacted at 120° C. for 4 h. The hot reaction solution was poured into ice water (16 mL), then stirred for 10 min, filtered, and the filter cake was washed with water (10 mL×2), collected and dried to give the title compound 67b (1.70 g, 90% yield) as an off-white solid.

[0434] Step 3 1-Benzyl-5-(2,6-dimethyl-4-nitrophenoxy)pyridin-2(1H)-one 67c 5-(2,6-Dimethyl-4-nitrophenoxy)pyridin-2(1H)-one 67b (0.80 g, 3.1 mmol) and potassium carbonate (0.61 g, 6.2 mmol) were dissolved in acetonitrile (8 mL), then benzyl bromide (0.60 mL, 5.1 mmol) was added dropwise, and the mixture was reacted at 60° C. for 6 hours. The reaction solution was cooled to room temperature, then filtered, and the filtrate was concentrated. The resulting residue was recrystallized at 85° C. (petroleum ether / ethyl acetate=4 / 1, 12 mL), then filtered, and the filter cake was collected and dried to give the title compound 67c (0.70 g, 65% yield) as a yellow solid.

[0435] Step 4 5-(4-amino-2,6-dimethylphenoxy)-1-benzylpyridin-2(1H)-one 67d 1-Benzyl-5-(2,6-dimethyl-4-nitrophenoxy)pyridin-2(1H)-one 67c (0.70 g, 2.0 mmol) was dissolved in acetic acid (5 mL), then iron (0.33 g, 5.9 mmol) was added, and the mixture was reacted at 60° C. for 2 hours. The reaction solution was quenched with water (15 mL) and extracted with ethyl acetate (20 mL×2). The combined organic phase was washed with saturated sodium chloride solution (10 mL×2) and dried over anhydrous sodium sulfate. The residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate=1 / 2] to give the title compound 67d (0.32 g, 50% yield) as a yellow solid.

[0436] Step 5 Ethyl (2-(2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dimethylphenyl)hydrazono)-2-cyanoacetyl)carbamate 67e 5-(4-amino-2,6-dimethylphenoxy)-1-benzylpyridin-2(1H)-one 67d (0.30 g, 0.94 mmol) and N-cyanoaceturethane (0.18 g, 1.2 mmol) were dissolved in acetic acid (6 mL), then a solution of sodium nitrite (0.13 g, 1.9 mmol) in water (3 mL) was added at 0° C., and the mixture was reacted for 4 hours. Water (30 mL) was added to the reaction solution, the mixture was stirred for 10 minutes, then filtered, and the filter cake was collected and dried to obtain the title compound 67d (0.20 g, 44% yield) as a red-brown solid.

[0437] Step 6 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dimethylphenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 67 Ethyl (2-(2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dimethylphenyl)hydrazono)-2-cyanoacetyl)carbamate 67e (1.5 g, 3.1 mmol) was dissolved in N,N-dimethylformamide (15 mL), then sodium acetate (0.28 g, 3.4 mmol) was added, and the mixture was reacted at 120° C. for 6 hours. The reaction solution was cooled to room temperature, then water (20 mL) was added, and extracted with ethyl acetate (10 mL×3). The combined organic phase was washed with saturated sodium chloride solution (20 mL×3), dried over anhydrous sodium sulfate, and concentrated by suction filtration. The resulting residue was recrystallized at 85° C. using ethanol / ethyl acetate / petroleum ether (1 / 5 / 10, 16 mL), then filtered, and the filter cake was collected and dried to give the title compound 67 (0.50 g, yield 40%, HPLC purity: 99.16%) as a pale yellow solid. MS (ESI, negative ion) m / z: 440.4 [MH] - ; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 13.04 (s, 1H), 7.41-7.14 (m, 9H), 6.48 (d, J = 9.8 Hz, 1H), 5.05 (s, 2H), 2.15 (s, 6H).

[0438] (Example 35) 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dibromophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (Compound 68)

[0439] [ka]

[0440] Step 1 5-(2,6-Dibromo-4-nitrophenoxy)-2-methoxypyridine 68a 6-Methoxypyridin-3-ol 4a (0.50 g, 4.0 mmol), 1,3-dibromo-2-fluoro-5-nitrobenzene (1.20 g, 4.8 mmol) were dissolved in N,N-dimethylformamide (16 mL), then potassium carbonate (1.66 g, 12.0 mmol) was added, and the mixture was reacted at 60° C. for 13 hours. The reaction solution was cooled to room temperature, and then water (15 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 68a (1.60 g, 99% yield) as a pale red solid.

[0441] Step 2: 5-(2,6-Dibromo-4-nitrophenoxy)pyridin-2(1H)-one 68b 5-(2,6-Dibromo-4-nitrophenoxy)-2-methoxypyridine 68a (1.60 g, 3.96 mmol), p-toluenesulfonic acid monohydrate (3.80 g, 20.0 mmol) and lithium chloride (0.85 g, 20 mmol) were dissolved in N,N-dimethylformamide (6 mL), and the mixture was reacted at 120° C. for 2 h. The reaction solution was cooled to room temperature, and then water (12 mL) was added. The resulting mixture was stirred for 10 min, filtered, and the filter cake was collected and dried in vacuum to give the title compound 68b (1.54 g, 99% yield) as an off-white solid.

[0442] Step 3 1-Benzyl-5-(2,6-dibromo-4-nitrophenoxy)pyridin-2(1H)-one 68c 5-(2,6-dibromo-4-nitrophenoxy)pyridin-2(1H)-one 68b (1.54 g, 3.95 mmol) was dissolved in acetonitrile (15 mL), then cesium carbonate (2.57 g, 7.90 mmol) and benzyl bromide (0.7 mL, 5.92 mmol) were added, and the mixture was reacted at 60° C. for 5 hours. The reaction solution was cooled to room temperature and then concentrated, water (20 mL) was added to the resulting residue, and the mixture was extracted with ethyl acetate (40 mL×2). The combined organic phase was dried over anhydrous sodium sulfate and concentrated by suction filtration. The residue was purified by silica gel column chromatography (100% ethyl acetate) to give the title compound 68c (1.45 g, 76% yield) as a white solid.

[0443] Step 4 5-(4-amino-2,6-dibromophenoxy)-1-benzylpyridin-2(1H)-one 68d 1-Benzyl-5-(2,6-dibromo-4-nitrophenoxy)pyridin-2(1H)-one 68c (1.45 g, 3.02 mmol) was dissolved in acetic acid (15 mL), then iron powder (0.50 g, 9.06 mmol) was added, and the mixture was reacted at 60° C. for 6 hours. The reaction solution was cooled to room temperature, and then water (15 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filter cake was washed with water (15 mL), collected, and dried in vacuum to give the title compound 68d (1.35 g, 99% yield) as a yellow solid.

[0444] Step 5 Ethyl (2-(2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dibromophenyl)hydrazono)-2-cyanoacetyl)carbamate 68e 5-(4-amino-2,6-dibromophenoxy)-1-benzylpyridin-2(1H)-one 68d (1.35 g, 3.0 mmol) was dissolved in acetic acid (12 mL), and then N-cyanoacetylurethane (0.58 g, 3.6 mmol) was added at 0° C. The resulting mixture was stirred for 5 minutes, and then a solution of sodium nitrite (0.41 g, 6.0 mmol) in water (10 mL) was added, and then the mixture was reacted at 0° C. for 1 hour. Water (5 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, and then filtered, and the filter cake was collected and dried in vacuum to give the title compound 68e (1.80 g, 95% yield) as a red-brown solid.

[0445] Step 6 2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dibromophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 68 Ethyl (2-(2-(4-((1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dibromophenyl)hydrazono)-2-cyanoacetyl)carbamate 68e (1.80 g, 2.84 mmol) was dissolved in N,N-dimethylformamide (15 mL), then sodium acetate (0.29 g, 3.5 mmol) was added, and the mixture was reacted at 120° C. for 18 hours. The reaction solution was cooled to room temperature, and then water (15 mL) was added. The resulting mixture was stirred for 10 minutes, then filtered, and the filter cake was collected and dried in vacuum. The crude product was purified by silica gel column chromatography [100% ethyl acetate] to give the title compound 68 (0.31 g, 19% yield, HPLC purity: 95.24%) as a white solid. MS (ESI, positive ion) m / z: 570.0 [M+H] + ; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 13.27 (s, 1H), 7.93 (s, 2H), 7.53-7.41 (m, 2H), 7.37-7.19 (m, 5H), 6.50 (d, J = 10.0 Hz, 1H), 5.06 (s, 2H).

[0446] (Example 36) 2-(3,5-dichloro-4-((1-(4-fluorobenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione (Compound 69)

[0447] [ka]

[0448] Step 1 2-(3,5-dichloro-4-((1-(4-fluorobenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid 69a 2-(3,5-dichloro-4-((1-(4-fluorobenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 41 (0.50 g, 1.0 mmol) was dissolved in acetic acid (6 mL), then concentrated hydrochloric acid (3 mL) was added, and the mixture was reacted at 120° C. for 11 hours. The reaction solution was cooled to room temperature, and then saturated brine (30 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 69a (0.51 g, 99% yield) as a yellow solid.

[0449] Step 2: 2-(3,5-dichloro-4-((1-(4-fluorobenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione 69 2-(3,5-dichloro-4-((1-(4-fluorobenzyl)-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid 69a (0.51 g, 0.99 mmol) was dissolved in thioglycolic acid (3 mL), and the mixture was reacted at 160° C. for 24 hours. The reaction solution was cooled to room temperature, then quenched with water (20 mL) and extracted with ethyl acetate (20 mL×3). The combined organic phase was washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, concentrated by suction filtration, and the residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate=1 / 2] to give the title compound 69 (0.15 g, 32% yield, HPLC purity: 99.10%) as a white solid. MS (ESI, negative ion) m / z: 473.0 [MH] - ; 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 12.49 (s, 1H), 7.81 (s, 2H), 7.61 (d, J = 16.6 Hz, 2H), 7.42 (s, 1H), 7.23 (d, J = 56.0 Hz, 4H), 6.59-6.34 (m, 1H), 5.03 (s, 2H).

[0450] (Example 37) 2-(4-((1-benzyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (Compound 70)

[0451] [ka]

[0452] Step 1 5-(2,6-dichloro-4-nitrophenoxy)-2-fluoro-3-methylpyridine 70b 6-Fluoro-5-methylpyridin-3-ol 70a (0.70 g, 5.5 mmol) and 1,2,3-trichloro-5-nitrobenzene (1.50 g, 6.62 mmol) were dissolved in N,N-dimethylformamide (10 mL), then potassium carbonate (1.83 g, 13.2 mmol) was added, and the mixture was reacted at 60° C. for 5 hours. The reaction solution was cooled to room temperature, and then water (10 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 70b (1.74 g, 95% yield) as a gray solid.

[0453] Step 2 5-(2,6-dichloro-4-nitrophenoxy)-3-methylpyridin-2(1H)-one 70c 5-(2,6-dichloro-4-nitrophenoxy)-2-fluoro-3-methylpyridine 70b (1.74 g, 5.23 mmol) was dissolved in acetic acid (16 mL) and water (8 mL), and the mixture was reacted at 120° C. for 24 hours. The reaction solution was cooled to room temperature, then water (20 mL) was added, and saturated sodium carbonate solution was added to adjust the pH to 7, and then the mixture was extracted with ethyl acetate (50 mL×2). The combined organic phase was washed with saturated sodium chloride (20 mL), dried over anhydrous sodium sulfate, and concentrated by suction filtration. The obtained residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate (volume / volume)=1 / 1) to obtain the title compound 70c (0.75 g, 45% yield) as a white solid.

[0454] Step 3 1-Benzyl-5-(2,6-dichloro-4-nitrophenoxy)-3-methylpyridin-2(1H)-one 70d 5-(2,6-dichloro-4-nitrophenoxy)-3-methylpyridin-2(1H)-one 70c (0.75 g, 2.4 mmol) was dissolved in acetonitrile (10 mL), then cesium carbonate (1.56 g, 4.8 mmol) and benzyl bromide (0.43 mL, 3.6 mmol) were added, and the mixture was reacted at 60° C. for 4.5 hours. The reaction solution was cooled to room temperature, then water (20 mL) was added, and the mixture was extracted with ethyl acetate (50 mL×2). The combined organic phase was washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and then concentrated by suction filtration. The residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=1 / 1] to obtain the title compound 70d (0.80 g, 83% yield) as a yellow liquid.

[0455] Step 4 5-(4-amino-2,6-dichlorophenoxy)-1-benzyl-3-methylpyridin-2(1H)-one 70e 1-Benzyl-5-(2,6-dichloro-4-nitrophenoxy)-3-methylpyridin-2(1H)-one 70d (0.80 g, 2.0 mmol) was dissolved in acetic acid (10 mL), then iron powder (0.34 g, 6.0 mmol) was added, and the mixture was reacted at 60° C. for 6 hours. The reaction solution was cooled to room temperature, and then water (10 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 70e (0.73 g, 99% yield) as a yellow solid.

[0456] Step 5 Ethyl (2-(2-(4-((1-benzyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)hydrazono)-2-cyanoacetyl)carbamate 70f 5-(4-amino-2,6-dichlorophenoxy)-1-benzyl-3-methylpyridin-2(1H)-one 70e (0.45 g, 1.20 mmol) was dissolved in acetic acid (12 mL), then N-cyanoacetylurethane (0.23 g, 1.44 mmol) was added, and the mixture was reacted at 0° C. for 5 minutes. Then, a solution of sodium nitrite (0.17 g, 2.40 mmol) in water (4 mL) was added to the mixture, and the reaction was continued for 1 hour. Water (5 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, then filtered, and the filter cake was collected and dried in vacuum to give the title compound 70f (0.50 g, 77% yield) as a red-brown solid.

[0457] Step 6 2-(4-((1-benzyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 70 Ethyl (2-(2-(4-((1-benzyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)hydrazono)-2-cyanoacetyl)carbamate 70f (0.50 g, 0.92 mmol) was dissolved in N,N-dimethylformamide (8 mL), then sodium acetate (0.15 g, 1.8 mmol) was added, and the mixture was reacted at 120° C. for 5 hours. The reaction solution was cooled to room temperature, then water (5 mL) was added, and the resulting mixture was stirred for 10 minutes, then filtered, the filter cake was collected, and dried in vacuum. The crude product was purified by preparative chromatography column [47% ACN / 53% HO (0.1% TFA), Kromasil specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to give the title compound 70 (0.19 g, yield 42%, HPLC purity: 99.40%) as a white solid. MS (ESI, positive ion) m / z: 496.0 [M+H] + ; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 13.29 (s, 1H), 7.77 (s, 2H), 7.43-7.37 (m, 2H), 7.32 (t, J = 7.2 Hz, 1H), 7.28-7.23 (m, 1H), 7.21 (d, J = 7.2 Hz, 1H), 5.06 (s, 2H), 2.03 (s, 3H).

[0458] (Example 38) 2-(4-((1-benzyl-5-chloro-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (Compound 71)

[0459] [ka]

[0460] Step 1 3-Chloro-5-(2,6-dichloro-4-nitrophenoxy)-2-fluoropyridine 71b 5-Chloro-6-fluoropyridin-3-ol 71a (2.71 g, 12.0 mmol) was dissolved in N,N-dimethylformamide (10 mL), then potassium carbonate (2.77 g, 20.0 mmol) was added, and the mixture was reacted at 60° C. for 6 hours. The reaction solution was cooled to room temperature, and then water (10 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 71b (3.30 g, 97% yield) as a gray solid.

[0461] Step 2: 3-Chloro-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 71c 3-Chloro-5-(2,6-dichloro-4-nitrophenoxy)-2-fluoropyridine 71b (1.10 g, 3.26 mmol) was dissolved in acetic acid (10 mL) and water (5 mL), and the mixture was reacted at 120° C. for 24 hours. The reaction solution was cooled to room temperature, then water (20 mL) was added, and saturated sodium carbonate solution was added to adjust the pH to 7, and the mixture was extracted with ethyl acetate (50 mL×2). The combined organic phase was washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated by suction filtration, and the residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=1 / 1] to obtain the title compound 71c (0.40 g, 37% yield) as a white solid.

[0462] Step 3 1-Benzyl-3-chloro-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 71d 3-Chloro-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 71c (0.40 g, 1.2 mmol) was dissolved in acetonitrile (8 mL), then cesium carbonate (0.78 g, 2.4 mmol) and benzyl bromide (0.22 mL, 1.8 mmol) were added, and the mixture was reacted at 60° C. for 4.5 hours. The reaction solution was cooled to room temperature, then water (20 mL) was added, and extracted with ethyl acetate (50 mL×2). The combined organic phase was washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated by suction filtration. The residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=1 / 1] to give the title compound 71d (0.50 g, 99% yield) as a yellow liquid.

[0463] Step 4 5-(4-amino-2,6-dichlorophenoxy)-1-benzyl-3-chloropyridin-2(1H)-one 71e 1-Benzyl-3-chloro-5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 71d (0.50 g, 1.2 mmol) was dissolved in acetic acid (10 mL), then iron powder (0.20 g, 3.6 mmol) was added, and the mixture was reacted at 60° C. for 6 hours. The reaction solution was cooled to room temperature, then water (20 mL) was added, and extracted with ethyl acetate (50 mL×2). The combined organic phase was washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, concentrated by suction filtration, and the residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=1 / 1] to obtain the title compound 71e (0.32 g, 69% yield) as a white solid.

[0464] Step 5 Ethyl (2-(2-(4-((1-benzyl-5-chloro-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)hydrazono)-2-cyanoacetyl)carbamate 71f 5-(4-amino-2,6-dichlorophenoxy)-1-benzyl-3-chloropyridin-2(1H)-one 71e (0.32 g, 0.81 mmol) was dissolved in acetic acid (5 mL), then N-cyanoacetylurethane (0.15 g, 0.97 mmol) was added, and the mixture was reacted at 0° C. for 5 minutes. A solution of sodium nitrite (0.11 g, 1.62 mmol) in water (3 mL) was added to the mixture, and the mixture was reacted for 1 hour. Water (5 mL) was added to the reaction solution, and the mixture was stirred for 10 minutes, then filtered, and the filter cake was collected and dried in vacuum to give the title compound 71f (0.42 g, 99% yield) as a red-brown solid.

[0465] Step 6 2-(4-((1-benzyl-5-chloro-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 71 Ethyl (2-(2-(4-((1-benzyl-5-chloro-6-oxo-1,6-dihydropyridin-3-yl)oxy)-3,5-dichlorophenyl)hydrazono)-2-cyanoacetyl)carbamate 71f (0.42 g, 0.75 mmol) was dissolved in N,N-dimethylformamide (8 mL), then sodium acetate (73 g, 0.90 mmol) was added, and the mixture was reacted at 120° C. for 5 hours. The reaction solution was cooled to room temperature, then water (5 mL) was added, and the resulting mixture was stirred for 10 minutes, then filtered, the filter cake was collected, and dried in vacuum. The crude product was purified by preparative chromatography column [47% ACN / 53% HO (0.1% TFA), Kromasil specification: C18 10 μm×50 mm×250 mm, flow rate: 100 mL / min] to give the title compound 71 (0.13 g, yield 34%, HPLC purity: 99.16%) as a white solid. MS (ESI, negative ion) m / z: 516.0 [MH] - ; 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 13.36 (s, 1H), 7.98 (d, J = 3.2 Hz, 1H), 7.79 (s, 2H), 7.69 (d, J = 3.2 Hz, 1H), 7.34 (t, J = 7.2 Hz, 2H), 7.30-7.25 (m, 1H), 7.22 (d, J = 7.6 Hz, 2H), 5.12 (s, 2H).

[0466] (Example 39) 2-(3,5-Dichloro-4-((6-oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione (Compound 72)

[0467] [ka]

[0468] Step 1. 2-(3,5-dichloro-4-((6-oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid 72a 2-(3,5-dichloro-4-((6-oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 58 (0.15 g, 0.31 mmol) was dissolved in acetic acid (4 mL), then concentrated hydrochloric acid (1.5 mL) was added, and the mixture was reacted at 120° C. for 24 hours. The reaction solution was cooled to room temperature, and then water (20 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 72a (0.136 g, 86.2% yield) as a yellow solid.

[0469] Step 2: 2-(3,5-dichloro-4-((6-oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione 72 2-(3,5-dichloro-4-((6-oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid 72a (0.11 g, 0.22 mmol) was dissolved in thioglycolic acid (3 mL), and the mixture was reacted at 160° C. for 24 hours. The reaction solution was cooled to room temperature, quenched with water (15 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phase was washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated by suction filtration. The residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (v / v)=1 / 2] to give the title compound 72 (75 mg, yield 75%, HPLC purity: 92.35%) as a light yellow solid. MS (ESI, positive ion) m / z: 465.0 [M+H] + ; 1 H NMR (400 MHz, CDCl3) δ (ppm) 10.54 (s, 1H), 7.71 (s, 2H), 7.60 (s, 1H), 7.33 (dd, J = 9.8, 3.0 Hz, 1H), 6.79 (dd, J = 18.2, 6.3 Hz, 2H), 3.79 (d, J = 7.2 Hz, 2H), 3.73 (d, J = 7.4 Hz, 2H), 3.52 (dd, J = 10.3, 5.0 Hz, 2H), 3.35 (t, J = 11.4 Hz, 2H), 2.21 - 2.09 (m, 1H), 1.53 (d, J = 12.1 Hz, 2H).

[0470] (Example 40) 2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione (Compound 73)

[0471] [ka]

[0472] Step 1 2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid 73a 2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 4 (0.13 g, 0.29 mmol) was dissolved in acetic acid (4 mL), then concentrated hydrochloric acid (1.5 mL) was added, and the mixture was reacted at 120° C. for 24 hours. The reaction solution was cooled to room temperature, and then water (20 mL) was added. The resulting mixture was stirred for 10 minutes, filtered, and the filter cake was collected and dried in vacuum to give the title compound 73a (0.12 g, 94% yield) as a yellow solid.

[0473] Step 2: 2-(3,5-dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione 73 2-(3,5-Dichloro-4-((1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid 73a (85 mg, 0.19 mmol) was dissolved in thioglycolic acid (4 mL), and the mixture was reacted at 160° C. for 24 hours. The reaction solution was cooled to room temperature, quenched with water (10 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phase was washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated by suction filtration. The residue was purified by silica gel column chromatography [petroleum ether / ethyl acetate (volume / volume)=1 / 2] to give the title compound 73 (58 mg, 76% yield, HPLC purity: 91.57%) as a yellow solid. MS (ESI, positive ion) m / z: 409.0 [M+H] + ; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 12.49 (s, 1H), 7.81 (s, 2H), 7.71 (s, 1H), 7.53 (d, J = 3.2 Hz, 1H), 7.19 (dd, J = 9.9, 3.3 Hz, 1H), 6.38 (d, J = 9.9 Hz, 1H), 5.07-4.95 (m, 1H), 1.26 (d, J = 6.8 Hz, 6H).

[0474] (Example 41) 2-(3,5-dichloro-4-((1-isobutyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (Compound 74)

[0475] [ka]

[0476] Step 1 5-(2,6-dichloro-4-nitrophenoxy)-1-isobutylpyridin-2(1H)-one 74a 5-(2,6-dichloro-4-nitrophenoxy)pyridin-2(1H)-one 4c (1.0 g, 3.3 mmol) and potassium carbonate (0.70 g, 4.98 mmol) were dissolved in acetonitrile (60 mL), then bromoisobutane (0.54 mL, 4.98 mmol) was added, and the mixture was reacted at room temperature for 18 hours. The reaction solution was cooled to room temperature, filtered, and the filtrate was concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate (volume / volume)=1 / 1) to give the title compound 74a (0.125 g, 11% yield) as a yellow solid. MS (ESI, positive ion) m / z: 358.1 [M+H] + ; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.34-8.31 (m, 3H), 6.79 (d, J = 3.3 Hz, 1H), 6.60 (d, J = 9.9 Hz, 1H), 3.69 (d, J = 7.5 Hz, 2H), 2.15 (tt, J = 6.9 Hz, 1H), 0.94 (d, J = 6.7 Hz, 6H).

[0477] Step 2 5-(4-amino-2,6-dichlorophenoxy)-1-isobutylpyridin-2(1H)-one 74b 5-(2,6-dichloro-4-nitrophenoxy)-1-isobutylpyridin-2(1H)-one 74a (0.23 g, 0.63 mmol) was dissolved in acetic acid (6 mL), then iron powder (0.072 g, 1.3 mmol) was added, and the mixture was reacted at 50° C. for 2.5 hours. The reaction solution was cooled to room temperature, then iron powder was removed, and water (30 mL) was added. The resulting mixture was stirred for 10 minutes and extracted with ethyl acetate (50 mL×2). The combined organic phase was washed with saturated sodium chloride (50 mL), dried over anhydrous sodium sulfate, and concentrated by suction filtration to give the title compound 74b (0.11 g, 53% yield) as a yellow solid. MS (ESI, positive ion) m / z: 328.1 [M+H] + .

[0478] Step 3. Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-isobutyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 74c 5-(4-amino-2,6-dichlorophenoxy)-1-isobutylpyridin-2(1H)-one 74b (0.11 g, 0.34 mmol) and N-cyanoacetylurethane (0.058 g, 0.37 mmol) were dissolved in acetic acid (4 mL), then a solution of sodium nitrite (0.050 g, 0.72 mmol) in water (2 mL) was added at 0° C., and the mixture was reacted for 3 hours. Water (10 mL) was added to the reaction solution at 0° C. The resulting mixture was stirred for 20 minutes, filtered, and the filter cake was washed with water (5 mL), collected, and dried in vacuum to give the title compound 74c (0.14 g, 85% yield) as a yellow solid.

[0479] Step 4 2-(3,5-dichloro-4-((1-isobutyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile 74 Ethyl (2-cyano-2-(2-(3,5-dichloro-4-((1-isobutyl-6-oxo-1,6-dihydropyridin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate 74c (0.14 g, 0.29 mmol) was dissolved in N,N-dimethylformamide (4 mL), and then sodium acetate (0.05 g, 0.37 mmol) was added, and the mixture was reacted at 120° C. for 16 hours. The reaction solution was cooled to room temperature, and the reaction solution was concentrated. The obtained residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate (volume / volume)=1 / 8) to obtain the title compound 74 (62 mg, yield 48%, HPLC purity: 91.13%) as a light yellow solid. MS (ESI, negative ion) m / z: 447.0 [MH] - ; 1 H NMR (400 MHz, DMSO-d6) δ (ppm) 13.30 (s, 1H), 7.78 (s, 2H), 7.50-7.28 (m, 2H), 6.43 (d, J = 8.5 Hz, 1H), 3.66 (s, 2H), 1.99 (s, 1H), 0.81 (s, 6H).

[0480] Example of activity test 1. Detection of TRα or TRβ agonist activity of compounds of the invention in dual luciferase reporter gene experiments

[0481] Test materials: HEK293 cells, purchased from ATCC, catalog number CRL-1573; Fugene HD transfection reagent, purchased from Promega, catalog number E231A; DMEM, purchased from Gibco, catalog number 11995; FBS, purchased from Biosera, catalog number FB-1280 / 500; 0.25% trypsin-EDTA, purchased from Gibco, catalog number 25200-072; Dual luciferase reporter assay system, purchased from Promega, catalog number E1960; 96-well plates (round bottom), purchased from Corning, catalog number 3365.

[0482] Test Method: HEK293 cells were cultured in 10% FBS+DMEM total medium. pBind-TRα or pBind-TRβ (100ng / μl), pG5Luc (100ng / μl), FuGENE HD and Opti-MEM were mixed thoroughly and incubated at room temperature for 15 minutes. At the same time, HEK293 cells were digested with 0.25% trypsin-EDTA and resuspended in total medium. After calculating the cell density and adjusting the cell density to 500,000 cells / ml, the transcription mixture was added and mixed thoroughly with the cell suspension. The mixture was seeded in a 96-well plate (100μL / well) and incubated at 37℃ for 24 hours. After 24 hours, the test compounds were dissolved in DMSO and diluted three times to obtain a total of 10 concentrations, and then the compounds were diluted into a solution containing 10% DMSO with DMEM. 5μL of compound was taken into a 96-well plate. The final DMSO concentration of the compounds was 0.5%, and the compounds were re-incubated with the cells for 18 hours. After 18 hours, the firefly fluorescent signal and Renilla fluorescent signal were detected using a dual luciferase reporter assay system. The firefly fluorescent signal (F) was divided by the Renilla fluorescent signal (R) to calculate the F / R ratio, which was then graphed using Graph Pad Prism software to obtain the EC 50 The value was calculated. The test results show that the compound of the present invention has very good TRβ agonist activity. At the same time, the compound of the present invention has good selectivity for TRβ.

[0483] The test results show that the compounds of the present invention have obvious agonistic activity and selectivity for TRβ.

[0484] 2. Detection of TRα or TRβ binding activity of the compounds of the present invention in vitro

[0485] Test materials: LanthaScreen TR-FRET Thyroid Receptor Beta Coactivator Assay Kit was purchased from Invitrogen, catalog number PV4686; LanthaScreen TR-FRET Thyroid Receptor Alpha Coactivator Assay Kit was purchased from Invitrogen, catalog number PV4687;

[0486] Test Method: The method was tested using the LanthaScreen TR-FRET Thyroid Receptor Beta / Alpha Coactivator Assay Kit. Test compounds were dissolved in DMSO and diluted 3-fold to obtain a total of 10 concentrations, and then the compounds were diluted into a solution containing 2% DMSO using the TR-FRET Coregulator Buffer C in the kit. 10 μL of compound containing 2% DMSO was taken into a 384-well plate. Then, 5 μL of 4×TRα-LBD or TRβ-LBD and 5 μL of a mixture containing 0.4 μM Fluorescein-SRC2-2 and 8 nM Tb anti-GST antibody were added to each well. After thorough mixing, the compounds were incubated at room temperature in the dark for 1 hour. After 1 hour, the fluorescence values ​​(RFU) were read at 520 nm and 495 nm using a BMG LABTECH PHERAstar FSX microplate reader. The TR-FRET ratio was calculated by dividing the emission signal at 520 nm by the emission signal at 495 nm. Graphs were drawn using Graph Pad Prism 5 software to calculate EC 50 The values ​​were calculated and the results are shown in Table 1 below.

[0487] [Table 5A]

[0488] [Table 5B]

[0489] The test results show that the compounds of the present invention have strong binding affinity and selectivity for TRβ.

[0490] 3. Determining the Pharmacokinetics of the Compounds of the Invention

[0491] Test Objectives: The following methods are used to determine the pharmacokinetics of the compounds of the present invention.

[0492] Test materials: Experimental reagents and test compounds: Propranolol (internal standard), methanol, ammonium acetate, K2EDTA (potassium ethylenediaminetetraacetate), formic acid, acetonitrile, MTBE (methyl tert-butyl ether), KolliphorHS15 (polyethylene glycol 12 hydroxystearate), DMSO (dimethyl sulfoxide) were commercially available;

[0493] SD rats: male, 180-220 g, 7-8 weeks old, purchased from Hunan Slake Experimental Animal Company.

[0494] Test Method:

[0495] 1. Preparation of Test Compounds

[0496] Each prepared test compound was completely dissolved in a mixture of 5% DMSO+5% KolliphorHS15+90% saline according to its solubility.

[0497] [Table 6]

[0498] [Table 7]

[0499] 4. Solution preparation

[0500] (1) Preparation of test compound stock solution: An appropriate amount of test compound was accurately weighed, dissolved in DMSO, diluted with acetonitrile to 1 mg / mL, and shaken thoroughly to obtain a test compound stock solution, which was stored at -20°C for use.

[0501] (2) Preparation of internal standard solution: A specific amount of 1 mg / mL propranolol stock solution was accurately drawn and diluted to 100 ng / mL with water.

[0502] 5. Sample Analysis

[0503] A liquid-liquid extraction method was used to prepare the samples for chromatographic separation. Quantitative analysis was performed using multiple reactive ion monitoring (MRM) on a triple quadrupole tandem mass spectrometer, and concentrations were calculated using the instrument quantification software.

[0504] 6. Plasma sample pretreatment

[0505] A 30 μL plasma sample was accurately drawn and 250 μL of internal standard was added. The mixture was mixed thoroughly by vortexing. The mixture was extracted once with 1 mL MTBE and centrifuged at 13,000 rpm at 4° C. for 2 min, then 800 μL of the supernatant was aspirated and evaporated with a 96-well nitrogen blower. The residue was redissolved in 150 μL methanol / water (v / v=50 / 50), mixed by vortexing and injected. The injection volume was 8 μL.

[0506] 7. Preparation of Standard Samples

[0507] Appropriate amounts of compound stock solutions were accurately drawn and diluted with acetonitrile to obtain standard series solutions. Plasma samples equivalent to plasma concentrations of 3, 5, 10, 30, 100, 300, 1,000, 3,000, 5,000, and 10,000 ng / mL were prepared by accurately drawing 20 μL of each of the above standard series solutions, adding 180 μL of blank plasma, and mixing thoroughly by vortexing, all of which were treated according to "Pretreatment of Plasma Samples". Two samples were analyzed for each concentration to generate a standard curve.

[0508] 8.Analysis method

[0509] The contents of test compounds in the plasma of rats after administration of different compounds were determined by LC / MS / MS method.

[0510] 9. Data Processing

[0511] Pharmacokinetic parameters were calculated using non-compartmental methods with WinNonLin 6.1 software.

[0512] The results of pharmacokinetic studies of some example compounds of the present invention are shown in Table 2 below.

[0513] [Table 8]

[0514] The test results show that when administered by intravenous injection or oral gavage, the example compounds of the present invention (Examples 16 and 29) have excellent pharmacokinetic properties. In particular, compared with the control compound MGL3196, the example compounds of the present invention have higher blood concentration and exposure, i.e., better pharmacokinetic properties.

[0515] 4. Pharmacodynamic Evaluation of the Compounds of the Invention

[0516] Test materials: Western diet: purchased from Research diet, part number: D12079B; MCD feed: purchased from Nantong Trophy Feed Technology Co., Ltd., part number: TP3006R; ALT, AST, ALP, TG, CHO, HDL, LDL and GLU: purchased from Roche, part numbers: 20764957322, 20764949322, 03333701190, 20767107322, 03039773190, 04399803190, 03038866322 and 0440483190; 8-week-old male OB / O mice: purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.; 8-week-old male db / db mice: purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.

[0517] A. Pharmacodynamic evaluation of compounds in a Western diet-induced nonalcoholic steatohepatitis (NASH) model in OB / OB mice

[0518] OB / OB mice are leptin gene-deficient mice, and the OB / OB mouse NASH model induced by a Western diet is a commonly used NASH model for in vivo drug efficacy evaluation. Animal experiments were started after 1 week of acclimation. OB / OB mice were fed a Western diet, and the feed was replaced three times a week (Monday, Wednesday, and Friday). Drug administration to the mice began after the 5th week of feeding, and was orally administered once a day for 6 weeks. The total experimental period was 10 weeks. During the experiment, the basic condition of the animals was monitored daily, and the weight of the mice was recorded once a week. After the experiment, the rats were fasted overnight. The mice were anesthetized, and whole blood was collected from the orbit. Serum was obtained by centrifugation at 4,000 rpm at 4°C for 10 minutes and stored at -80°C. The serum was used for the detection of ALT, AST, ALP, TG, CHO, HDL, LDL, and GLU. The mice were dissected, and the liver was removed and weighed. The middle lobe of the liver was placed in an EP tube and stored at −80° C. to determine the TG and CHO contents in the liver. The left lobe of the liver was fixed with 10% formalin, then HE stained and NAS scored.

[0519] B. Pharmacodynamic evaluation of compounds in a non-alcoholic steatohepatitis (NASH) model in db / db mice induced by MCD diet

[0520] db / db mice are leptin receptor gene-deficient mice, and the db / db mouse NASH model induced by MCD diet is a commonly used NASH model for in vivo drug efficacy evaluation. Animal experiments were started after 1 week of acclimation. db / db mice were fed MCD diet, and the feed was replaced three times a week (Monday, Wednesday, and Friday). During modeling, the mice were administered drugs orally once a day for 8 weeks. The entire experimental period was 8 weeks. During the experiment, the basic condition of the animals was monitored daily, and the weight of the mice was recorded once a week. After the experiment, the rats were fasted overnight. The mice were anesthetized, and whole blood was collected from the orbit. Serum was obtained by centrifugation at 4,000 rpm at 4°C for 10 minutes and stored at -80°C. The serum was used for the detection of ALT, AST, ALP, TG, CHO, HDL, LDL, and GLU. The mice were dissected, and the liver was removed and weighed. The middle lobe of the liver was placed in an EP tube and stored at −80° C. to determine the TG and CHO contents in the liver. The left lobe of the liver was fixed with 10% formalin, then HE stained and NAS scored.

[0521] The test results show that the compounds of the present invention can effectively reduce fat accumulation in the liver, reduce inflammation, and improve liver fibrosis.

[0522] References throughout this specification to "embodiments," "some embodiments," "one embodiment," "another example," "example," "particular example," or "some examples" mean that a particular feature, structure, material, or characteristic described in connection with an embodiment or example is included in at least one embodiment or example of the disclosure. Thus, appearances of the above terms throughout this specification do not necessarily refer to the same embodiment or example of the disclosure. Furthermore, particular features, structures, materials, or characteristics may be combined in any suitable manner in one or more embodiments or examples. In addition, one skilled in the art may integrate and combine different embodiments, examples, or features thereof, as long as they are not mutually inconsistent.

[0523] While illustrative embodiments have been shown and described, the above embodiments should not be construed as limiting the present disclosure, and it will be understood by those skilled in the art that changes, substitutions and modifications may be made in the embodiments without departing from the spirit, principles and scope of the present disclosure.

Claims

1. A compound having the formula (I) or a stereoisomer, geometric isomer, tautomer, N-oxide, solvate or pharma- ceutically acceptable salt thereof. 【Chemistry 1】 (In the formula, Y is -O-; L is absent or -CR d R e - and R d and R e are independently H, deuterium, F, Cl, Br, I, -CN, -OH, -NH 2 , -SH, C 1～6 Alkyl or C 1～6 is haloalkyl, R 3a , R 3b , R 3c and R 3d are independently H, deuterium, F, Cl, Br, I, -CN, -OH, -NH 2 , -SH, C 1～6 Alkyl or C 1～6 is haloalkyl, M is -C(=O)-, E 1 is CH or CR z and R z is deuterium, F, Cl, Br, I, -CN, -NH 2 , -SH, C 1～6 Alkyl or C 1～6 is haloalkyl, E 2 is CR 2 and E 3 is CR 3 and R 2 and R 3 are independently H, deuterium, F, Cl, Br, I, -CN, -NH 2 , -SH, C 1～6 Alkyl or C 1～6 is haloalkyl, R 1 is C1-6 alkyl, C 1～6 Alkoxy, C 1～6 Haloalkyl, C 1～6 Haloalkoxy, -C(=O)-C 1～6 Alkoxy, C 3-8 cycloalkyl, 5-8 membered heterocyclyl, C 6～10 aryl or 5-8 membered heteroaryl, C 1～6 Alkyl, C 1～6 Alkoxy, C 1～6 Haloalkyl, C 1～6 Haloalkoxy, -C(=O)-C 1～6 Alkoxy, C 3-8 cycloalkyl, 5-8 membered heterocyclyl, C 6～10 Each of the aryl and 5- to 8-membered heteroaryl is independently unsubstituted or substituted with deuterium, F, Cl, Br, I, -CN, -SH, -OH, -NH 2 , =O, C1-6 alkyl, C 1～6 Alkoxy, C 1～6 Haloalkyl or C 1～6 substituted by 1, 2 or 3 substituents selected from haloalkoxy; W is 【Chemistry 2】 and R 4 are H, deuterium, F, Cl, Br, I, -CN, -OH, -NH 2 , -SH, C 1～6 Alkyl, -C(=O)-C 1～6 Alkoxy, C1-6 haloalkyl or hydroxyC 1～6 Alkyl, C 1～6 Alkyl, -C(=O)-C 1～6 Alkoxy, C1-6 haloalkyl and hydroxyC 1～6 Each alkyl is independently unsubstituted or substituted with deuterium, F, Cl, Br, I, -CN, -OH, -NH 2 , -SH or C 1～6 substituted with 1, 2 or 3 substituents selected from alkyl, R 5 is H, deuterium or C 1～6 (It is alkyl).

2. R 3a , R 3b , R 3c , and R 3d are independently H, deuterium, F, Cl, Br, I, -CN, -OH, NH 2 , -SH, methyl, ethyl, n-propyl, isopropyl, -CF 3 , -CHF 2 , -CH 2 F or -CH 2 The compound of claim 1 which is CF3.

3. R d and R e are independently H, deuterium, F, Cl, Br, I, -CN, -OH, NH 2 , -SH, methyl, ethyl, n-propyl, isopropyl, -CF 3 , -CHF 2 , -CH 2 F or -CH 2 The compound of claim 1 which is CF3.

4. R2 and R 3 are independently H, deuterium, F, Cl, Br, I, -CN, -NH 2 4. The compound according to any one of claims 1 to 3, wherein the aryl group is -SH, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, trifluoromethyl or difluoromethyl.

5. R 1 is C1-4 alkyl, C 1～4 Alkoxy, C 1～4 Haloalkyl, C 1～4 Haloalkoxy, -C(=O)-C 1～4 Alkoxy, C 3-6 cycloalkyl, 5-6 membered heterocyclyl, C 6～10 aryl or 5- to 6-membered heterocyclyl, C 1～4 Alkyl, C 1～4 Alkoxy, C 1～4 Haloalkyl, C 1～4 Haloalkoxy, -C(=O)-C 1～4 Alkoxy, C 3-6 cycloalkyl, 5-6 membered heterocyclyl, C 6～10 Each of the aryl and the 5- to 6-membered heterocyclyl is independently unsubstituted or is selected from the group consisting of deuterium, F, Cl, Br, I, -CN, -SH, -OH, -NH 2 , =O, C1-4 alkyl, C 1～4 Alkoxy, C 1～4 Haloalkyl or C 1～4 5. The compound of any one of claims 1 to 4, substituted with 1, 2 or 3 substituents selected from haloalkoxy.

6. R 1 Methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, -CF 3 , -CHF 2 , -CH 2 F, -CH 2 CF 3 , trifluoromethoxy, difluoromethoxy, -C(=O)-OCH 3 , -C(=O)-OCH 2 CH 3 , -C(=O)-OCH(CH 3 ) 2 , -C(=O)-OCH 2 CH 2 CH 3 , -C(=O)-O(CH 2 ) 3 CH 3 , -C(=O)-OCH 2 CH(CH 3 ) 2 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydropyrrolyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydropyrazinyl, tetrahydropyridazinyl, dihydropyrrolyl, dihydrofuranyl, dihydropyranyl, dihydrothienyl, dihydropyridyl, dihydro propylpyrimidinyl, dihydropyrazinyl, dihydropyridazinyl, phenyl, naphthyl, furyl, thienyl, imidazolyl, pyrazolyl, pyrimidinyl, pyridyl, pyrrolyl, pyrazinyl, pyridazinyl, thiazolyl, tetrazolyl, triazolyl, isoxazolyl, isothiazolyl, oxadiazolyl or oxazolyl; and methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, -CHF 2 , -CH 2 F, -CH 2 CF 3 , difluoromethoxy, -C(=O)-OCH 3 , -C(=O)-OCH 2 CH 3 , -C(=O)-OCH(CH 3 ) 2 , -C(=O)-OCH 2 CH 2 CH 3 , -C(=O)-O(CH 2 ) 3 CH 3 , -C(=O)-OCH 2 CH(CH 3 ) 2 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydropyrrolyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydropyrazinyl, tetrahydropyridazinyl, dihydropyrrolyl, dihydrofuranyl, dihydropyranyl, dihydropyranyl, dihydropyranyl, Each of rothienyl, dihydropyridyl, dihydropyrimidinyl, dihydropyrazinyl, dihydropyridazinyl, phenyl, naphthyl, furyl, thienyl, imidazolyl, pyrazolyl, pyrimidinyl, pyridyl, pyrrolyl, pyrazinyl, pyridazinyl, thiazolyl, tetrazolyl, triazolyl, isoxazolyl, isothiazolyl, oxadiazolyl and oxazolyl is independently unsubstituted or deuterium, F, Cl, Br, I, -CN, -SH, -OH, -NH 2 , =O, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, -CF 3 , -CHF 2 , -CH 2 CF 3 6. The compound according to any one of claims 1 to 5, substituted with 1, 2 or 3 substituents selected from: , trifluoromethoxy or difluoromethoxy.

7. R 4 H, deuterium, F, Cl, Br, I, -CN, -OH, -NH 2 , -SH, methyl, ethyl, n-propyl, isopropyl, -C(=O)-OCH 3 , -C(=O)-OCH 2 CH 3 , -C(=O)-OCH(CH 3 ) 2 , -C(=O)-OCH 2 CH 2 CH 3 , -C(=O)-O(CH 2 ) 3 CH 3 , -C(=O)-OCH 2 CH(CH 3 ) 2 , -CF 3 , -CHF 2 , -CH 2 F, -CH 2 CF 3 , -CH 2 CHF 2 or hydroxymethyl, which is methyl, ethyl, n-propyl, isopropyl, -C(=O)-OCH 3 , -C(=O)-OCH 2 CH 3 , -C(=O)-OCH(CH 3 ) 2 , -C(=O)-OCH 2 CH 2 CH 3 , -C(=O)-O(CH 2 ) 3 CH 3 , -C(=O)-OCH 2 CH(CH 3 ) 2 , -CHF 2 , -CH 2 F, -CH 2 CF 3 , -CH 2 CHF 2 and hydroxymethyl are each independently unsubstituted or selected from deuterium, F, Cl, Br, I, -CN, -OH, -NH 2 , -SH or C 1～6 7. The compound according to any one of claims 1 to 6, substituted with 1, 2 or 3 substituents selected from alkyl.

8. R 5 The compound of any one of claims 1 to 7, wherein is H, deuterium, methyl, ethyl, n-propyl, isopropyl or tert-butyl.

9. The following structure: 【Chemistry 3A】 【Chemistry 3B】 【3C】 【3D】 【Chemistry 3E】 or a stereoisomer, geometric isomer, tautomer, N-oxide, solvate, or pharma- ceutically acceptable salt thereof.

10. 10. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9, and optionally further comprising any one or combination of a pharma- ceutically acceptable carrier, excipient, adjuvant, vehicle.

11. A compound according to any one of claims 1 to 9 or a pharmaceutical composition according to claim 10 for use in the manufacture of a medicament for agonizing a thyroid hormone receptor or for preventing, treating or ameliorating a disease mediated by an agonist thyroid hormone receptor in a subject, comprising The thyroid hormone receptor is the thyroid hormone beta receptor, the disease mediated by an agonist thyroid hormone receptor is nonalcoholic fatty liver disease, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes mellitus, a metabolic disorder, glycogen storage disease type 1A, hypothyroidism, or thyroid cancer; The non-alcoholic fatty liver disease is non-alcoholic simple fatty liver, non-alcoholic steatohepatitis, cryptogenic liver cirrhosis, or primary liver cancer, The compound according to any one of claims 1 to 9 or the pharmaceutical composition according to claim 10, wherein the metabolic disorder comprises a lipid metabolism disorder or a glucose metabolism disorder.

Images